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Summary
This thesis reports the synthesis and initial evaluation of the substituted guanidine N-(l- 
Napthyl)-N'-(2-iodophenyl)-N'-methylguanidine (CNS 1261) as a potential agent to image 
N-methyl-D-aspartate (NMDA) receptor activation in vivo.
The pharmacology of unlabelled CNS 1261 was investigated in vitro using ligand binding 
assays and in vivo using autoradiographic procedures. Investigations were designed to 
examine the ability of CNS 1261 to inhibit radioligand binding to the NMDA receptor and 
to other neurotransmitter receptors. [14C]2-deoxyglucose autoradiography was used to 
measure local rates of glucose utilisation following systemic administration of CNS 1261. 
The effects of CNS 1261 on glucose utilisation were compared to those obtained in a 
previous study carried out by Kurumaji et al (1989) using MK801. Secondly, in order to 
assess the ability of [125I]CNS 1261 to measure levels of NMDA receptor activation in the 
brain, a modification of the [125I]MK801 in vivo binding technique described by 
McCulloch et al (1992) was used to investigate the uptake and retention of [125I]CNS 
1261 in the normal rat brain. The pattern of [125I]CNS 1261 uptake was compared to that 
of [125I]MK801 in parallel experiments. Finally, autoradiographic techniques were used to 
assess the utility of [125I]CNS 1261 in imaging changes in NMDA receptor activation in 
vivo. NMDA receptor activation was manipulated via proton blockade and microinjection 
of the excitatory amino acid agonist NMDA into the cortex
Pharmacology of CNS 1261
The ability of CNS 1261 to inhibit [3H]MK801 binding was investigated in crude synaptic 
rat brain membranes (Cambridge NeuroScience Inc.). CNS 1261 (lOnM) binds to the 
NMDA receptor in vitro with high affinity (Ki = 25nM for displacing [3H]MK801 
binding). The effects of unlabelled CNS 1261 (lOnM and lpM) on the binding of ligands 
to the NMDA receptor and to other neurotransmitter receptors was more extensively 
investigated by submitting the compound for commercial screening (Novascreen).
CNS 1261 (lfiM) was extremely selective showing activity (99% inhibition) only in the 
[3H]MK801 binding assay.
The effects of CNS 1261 (1, 3 and lOmg/kg) on local cerebral glucose use were 
examined in the conscious lightly restrained rat. The systemic administration of CNS 
1261 resulted in overt behavioural responses and marked alterations in glucose use 
within the central nervous system. Administration of CNS 1261 produced highly 
circumscribed changes in glucose utilisaion that could be readily visualised on 
autoradiograms. Decreases in glucose use (approximately 30%) were observed in layer 
IV of the frontal, sensory-motor and auditory cortices and in the inferior colliculus. 
Distinct, significant elevations in glucose use were observed in the hippocampus 
molecular layer, dentate gyrus, limbic system (posterior cingulate cortex, caudal 
entorhinal cortex, mamillary body, anteroventral thalamus), retrosplenial cortex and the 
myelinated fiber tract of the fornix. Correlation analysis revealed that the overall 
pharmacological effects of CNS 1261 were extremely similar to the overall effects of 
MK801, correlation coefficient, r = 0.87. Subtle differences were observed in a number 
of regions. A greater number of regions displayed extreme sensitivity to CNS 1261 than 
to MK801, such as the anteroventral thalamus, mamillary body and inferior colliculus. 
In contrast, the entorhinal cortex was much less sensitive to CNS 1261 than to MK801
[125I]CNS 1261 uptake in the normal rat brain
Radio-iodinated (*25I or *23I)CNS 1261 was synthesised at high specific activity 
(>2000Ci/mmol) and chemical purity (>97%) at the West of Scotland Radionuclide 
Dispensary, Glasgow. Investigation of the in vivo uptake and retention of [125I]CNS 
1261 was carried out in halothane anaesthetised rats. The initial uptake of [125I]CNS 
1261 reflected cerebral blood flow. At time points beyond 30 minutes the uptake of 
[125I]CNS 1261 reflected the classical pattern of NMDA receptor distribution with the 
highest levels of binding in the hippocampus and low levels in the hypothalamus and 
cerebellum. At 120 minutes, [125I]CNS 1261 uptake within hippocampal regions relative
to that in the cerebellum (a measure of non-specific binding) was 70-140% greater than 
that observed with [125I]MK801.
The mechanisms underlying the superior imaging capability of [125I]CNS 1261 was 
addressed by investigation of the lipophilicity and metabolism of this tracer.
Calculation of LogD values (the octano 1/buffer partition ratio at pH 7.4) showed that CNS 
1261 was substantially less lipophilic than iodo-MK801 (2.19 and 3.3 respectively). 
Brain/aqueous partition coefficients calculated from the non-specific binding component of 
in vitro binding experiments showed that both [125I]CNS 1261 and [125I[MK801 were 
highly lipophilic compounds however, partition ratios for [125I]CNS 1261 were 
approximately 40% lower than those for [125I]MK801 in both rat and man, suggesting a 
lower non-specific binding component with this tracer.
High performance liquid chromatography analysis of plasma samples after administration 
of [125I]CNS 1261 to halothane anaesthetised rats showed the presence of 2 species, 
identified as authentic CNS 1261 and free iodide. Almost all (95%) of the radioactivity in 
the brain at 120 minutes post-injection was authentic [125I]CNS 1261. [125I]CNS 1261 
was metabolised much more rapidly than [125I]MK801 such that five minutes after 
injection, 15% authentic [125I]CNS 1261 remained in the plasma compared to 55% for 
[125I]MK801. It is proposed that both the lower non-specific binding component observed 
with CNS 1261 and the rapid metabolism of this tracer confer significant advantage over 
MK801 as an imaging agent in the normal brain.
It was postulated that a reduction in [125I]CNS 1261 uptake by administration of 
unlabelled MK801 would confirm that enhanced uptake in areas of high receptor density 
such as the hippocampus, represents increased binding of this tracer to the NMDA receptor 
ion channel. The results presented here show displacement of [125I]CNS 1261 uptake 
from normal non-pathologic brain could not be demonstrated following administration of 
pharmacological doses of MK801. The precise mechanisms underlying this inability to 
demonstrate displacement are unknown, but it is recognised that this observation may 
impact on the future development of CNS 1261 as imaging agent in man.
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CHAPTER I 
INTRODUCTION
Imaging changes in NMDA receptor activation using [125I]CNS 1261 
The ability to image changes in NMDA receptor activation in vivo must be demonstrated 
for a tracer to be of any value in man. Varying the pH of the extracellular fluid has been 
shown to provide a mechanism of controlling the level of NMDA receptor activation 
without affecting agonist concentrations (through induction or relief of proton block of 
the ion channel). Hypercapnic acidosis was induced in halothane anaesthetised rats. 
Induction of hypercapnic acidosis (pH 6.9) caused a significant decresase in [125I]CNS 
1261 uptake within brain regions with a high density of NMDA receptors. [125I]MK801 
uptake within the same regions was not reduced by induction of hypercapnic acidosis. 
Demonstration of a reduction in [125I]CNS 1261 uptake may be attributed to the 
improved signal to noise ratio of this tracer.
The utility of [125I]CNS 1261 in measuring changes in NMDA receptor activation was 
further examined by measuring [125I]CNS 1261 uptake at different time points after 
intracortical injection of NMDA in the rat. The pattern of [125I]CNS 1261 distribution at 
the site of injection outlines a core area of reduced uptake (and hence receptor activation) 
surrounded by a narrow margin of increased uptake where isotope levels were 80% 
above contralateral values. Receptor activation was reduced within areas of decreased 
[125i]CNS 1261 uptake (as confirmed by [14C]2-deoxyglucose autoradiography). The 
increase in lesion size over time shows that [125I]CNS 1261 is capable of imaging 
dynamic processes such as the evolution of excitotoxic damage. In a separate pilot study 
[125I]CNS 1261 uptake and retention was also shown to be enhanced within the 
ischaemic caudate following permanent middle cerebral artery (MCA) occlusion in the rat. 
This regions are generally accepted to be areas of excessive NMDA receptor activation. 
[125I]CNS 1261 was also superior to [125I]MK801 in labelling non-ischaemic NMDA 
binding sites in the hippocampus.
These results suggest that CNS 1261 acts as a high affinity, selective non-competitive 
antagonist at the NMDA receptor. The relative uptake of [125I]CNS 1261 in regions with 
a high density of NMDA receptors was greater than that of [l25I]MK801 within the 
normal brain and, [125I]CNS 1261 can image subtle changes in NMDA receptor
activation in vivo in the rat. [125I]CNS 1261 uptake is determined by the activation state 
of the receptor and therefore appears to be a suitable candidate for evaluation as a SPECT 
agent to image excessive NMDA receptor activation in pathological situations in the living 
human patient.
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1.1 Excitatory amino acids as neurotransmitters in the central 
nervous system
The successful treatment of petit mal seizures using orally administered glutamate was 
reported by Price and colleagues in 1943. This report was among the first to suggest 
that glutamate may have a function in the central nervous system and stimulated 
interest in the role of glutamate in brain metabolism. However, it was not until 1960 
when a direct excitatory effect of glutamate was documented by Curtis and Watkins 
and this acidic amino acid received consideration as a neurotransmitter candidate. The 
high concentration (4-10mmol/kg wet weight) and even distribution relative to other 
transmitters (Meldrum, 1985, Greenamyre, 1986) contributed to the long delay 
between the observations of Price and Curtis and the acceptance of glutamate as a 
major neurotransmitter of several clinically important pathways, including cortical 
association fibres, corticofugal pathways such as the pyramidal tract and 
hippocampal, cerebellar and spinal cord pathways (Greenamyre, 1986). It is now 
believed that approximately 70% of fast excitatory neurotransmission within the 
central nervous system is mediated by amino acids such as glutamate, aspartate and 
possibly homocysteate (Danysz et al, 1995)
The most direct anatomical evidence that glutamate functions as a neurotransmitter 
was the demonstration of enrichment of this amino acid in nerve terminals by a 
combination of anterograde labelling of primary afferent terminals and 
immunocytochemistry (for review see Cooper et al, 1996).
Glutamate satisfies the four main criteria for the classification of a neurotransmitter, 
presynaptic localisation in specific neurons where it is stored and released from 
synaptic vesicles, Ca2+-dependent release by physiological stimuli, identity of action 
with a naturally occurring transmitter and rapid termination of transmitter actions.
1
1.2 Metabolism and release of glutamate.
Glutamate is a nonessential amino acid and is ubiquitously distributed throughout the 
central nervous system. Glutamate has an important metabolic role in carbohydrate 
and nitrogen metabolism and is the major precursor for the inhibitory neurotransmitter 
g-aminobutyric acid (GABA). In view of the many roles attributed to glutamate, the 
synthesis and metabolism of this compound are categorised in a complex way (Figure 
1, for review see Fonnum, 1984, Fleck et al, 1993). A large compartment, localised 
to neuronal structures and nerve terminals, accounts for 85-98% of the total glutamate 
pool within the brain. A smaller compartment, containing mainly glutamine has been 
assigned to astroglial cells. The two compartments can be subdivided further into the 
'transmitter' pool (20-45%) and 'precursor' glutamate for GABA synthesis. Double­
label experiments have shown that the majority of released glutamate is derived from 
glutamine (Fonnum, 1984).
The ability of glutamate to function as a neurotransmitter is intrinsically linked to two 
transport systems, uptake carriers located in neurons and glia and a specific 
transporter capable of packaging glutamate into synaptic vesicles (Cooper et al, 
1996). Glutamate transporters maintain low basal levels of extracellular glutamate 
and conserve released transmitter for reuse. The regional localisation and cellular 
distribution of different forms of these transporters may underlie the propensity of 
most diseases for specific brain areas (Torp et al, 1994). Under resting conditions 
glutamate concentrations are l|i.M, lOmM and lOOmM in the extracellular space, 
presynaptic cytoplasm and lumen of vesicles respectively.
The presence of a Na+-dependent uptake systems are common to the majority of 
transmitter amino acids such as GABA and glycine. The glutamate uptake systems 
terminate the post-synaptic action of the transmitter, recycle glutamate and maintain 
low extracellular glutamate concentrations. (Nicolls and Attwell, 1990).
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FIGURE 1 : Pathways for glutamate utilisation and metabolism
Glutamate (Glu) is released into the synaptic cleft and is recaptured by neuronal-type 
(GT(n)) and glial-type (GT(g)) Na+-coupled transporters. Glial glutamate is converted 
to glutamine (Gin) by the enzyme glutamine synthase. Gin is present in high 
concentrations in the CSF and can enter the neuron to help replenish glutamate after 
hydrolysis by mitochondrial glutaminase.
It is suggested that removal of glutamate from the synaptic cleft involves, to differing 
extents, a combination of uptake into the presynaptic neuron, uptake into glial cells 
and diffusion down the concentration gradient maintained by glial uptake (Nicolls and 
Attwell, 1990, Cooper et a l , 1996).
Three glutamate genes have been identified and cloned, 2 of glial origin, GLT1 and 
GLAST (Torp et al, 1994) and a third found in neurons, EAAC1 (Cooper et al, 
1996). These transporters display -50% sequence identity and display different 
distribution patterns within the brain (Lehre et al, 1995). The uptake systems display 
high affinity (|iM) and transport L-glutamate and D- or L-aspartate. The uptake 
process is accompanied by cotransport of 2 or 3 Na+ ions and the counter transport 
of 1 K+ ion and either the cotransport of 1 H+ ion or the counter transport of 1 OH- 
ion. Recently, Trotti and colleagues (1997) reported that glutamate uptake is 
regulated by the redox state of the reactive sulphydryl groups present on the glutamate 
transporters, with reduced or even abolished uptake capacity in their most oxidised 
form.
Naito and Ueda (1993) were among the first groups to demonstrate ATP-dependent 
uptake of glutamate into synaptic vesicles. The vesicular transporter is Na+- 
independent, has low affinity (mM) and is selective for glutamate. Calcium- 
dependent glutamate release from synaptosomes has been demonstrated by a number 
of different depolarisation methods, including electrical stimulation and high K+ 
concentrations (Zhou et al 1995, Nicolls and Attwell, 1990). Approximately 15% of 
cortical/hippocampal synaptosomal glutamate release was found to be calcium- 
dependent. This glutamate release was also dependent on the maintenance of high 
energy levels. Vesicular glutamate release was triggered by localisation of high 
concentrations of free calcium in the cytoplasm near active release zones. 
Calcium-dependent glutamate release was biphasic and shows an initial brief phase 
and a slower phase (ti/2 = 70 seconds) when the majority of the glutamate is released. 
This is thought to reflect the initial exocytosis of vesicles already docked with the
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membrane and the detachment of the remaining vesicles from cytoskeletal elements 
(Wahl etaU 1994).
Glutamate release is regulated via the action of kainate and glutamate on presynaptic 
receptors controlling chloride channels. Glutamate and quisqualate inhibit neuronal 
calcium currents (through G-protein coupled mechanisms) providing a negative 
feedback control of glutamate release. The most established regulation is the 
inhibition of glutamate release by adenosine. Release is also inhibited by the 
GABAa agonist baclofen (Burke and Nadler, 1988).
Glutamate levels in the extracellular space are markedly increased in pathological 
conditions such as focal cerebral ischaemia and epilepsy (Butcher et al, 1990). The 
increase in glutamate levels is biphasic and the majority of the glutamate released is of 
metabolic origin, originating from neurons and glia (Wahl et al, 1994). The elevation 
of extracellular glutamate has been attributed to several mechanisms, alone or in 
concert, including calcium-dependent release from neurotransmitter stores (Drejer et 
al, 1985), calcium-independent release from cytosolic stores by reversal of the 
Na+/glutamate transporter (Butcher et al, 1987) and ultimately cellular lysis.
Recent studies investigating the neuroprotective effect of the k opioid agonist eliprodil 
(CI-977) in the cat showed that pretreatment prior to middle cerebral artery occlusion 
significantly attenuated the marked increase in extracellular glutamate, aspartate and 
GABA within the focal ischaemic penumbra. Eliprodil is thought to inhibit glutamate 
release via its action on k opioid receptors specifically located on vesicular glutamate 
stores. This suggests that a proportion of the glutamate arises from calcium- 
dependent glutamate release (MacKay et al, 1996).
Under normal conditions the Na+/glutamate transporter is the primary mechanism for 
glutamate reuptake by neurons, however, during depolarisation or when Na+ is 
entering the cell, this carrier can export glutamate into the extracellular space (Graham 
et al, 1993). The resulting glutamate potentiates a positive feedback system by 
depolarising more neurons.
4
Exposure of astrocyte cultures to free radical generating systems has been shown to 
result in a marked decrease in high affinity glutamate transport. Long-lasting 
oxidation of protein sulphydryl groups has been proposed as the mechanism of 
inhibition of glutamate uptake. It is suggested therefore, that free radicals may 
induce accumulation of glutamate by reduction of glial uptake (Volterra et al, 1994). 
Regardless of the precise mechanisms involved, it is apparent that the overflow of 
excitatory amino acids into the extracellular space is an important step in genesis of 
neurotoxic damage.
1.3 Glutamate receptor subtype classification
The excitatory effects of glutamate and its congeners are mediated by several distinct 
receptor types. These receptors can be classified into two groups based on 
transduction mechanisms. Activation of ionotropic receptors leads to direct opening 
of ion channels characterised by their differing cation permeabilities. The activation 
of metabotropic receptors modifies phosphoinositide hydrolysis through a GTP- 
binding protein-dependent mechanism.
Four classes of ionotropic receptors have been defined by physiology and ligand 
binding techniques. The most common three are named according to the most 
specific agonist compound at each of these receptors, N-methyl-D-aspartate (NMDA), 
a-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) and kainate (Table 1). 
The fourth, L-2-amino-4-phosphonobutyrate (AP4) appears to represent an inhibitory 
autoreceptor.
Since the focus of this thesis is the NMDA receptor, this subclass will be discussed in 
greatest detail.
1.3.1 The NMDA receptor
The NMDA receptor is the most well characterised of all the ionotropic receptors, and 
plays a crucial role in many physiological, behavioural and pathological functions of 
the CNS including synaptic plasticity, information processing and memory. Like the 
GABAa receptor, the NMDA receptor is now recognised as having several distinct 
binding and modulatory sites (Figure 2). This complexity raises the suggestion that 
different combinations of modulatory sites may imply the existence of 
pharmacologically distinguishable receptor sites.
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TABLE 1 
Excitatory amino acid receptors
Receptor class Agonist Antagonist Radioligand
NMDA
recognition site NMDA
L-glutamate
L-aspartate
DJL(tetrazol-5-yl)glycine
D-AP5
CPP
CGS 19755
L-[3H] glutamate
channel ketamine 
TCP 
MK801 
CNS 1102
[3H]MK801
[125i]MK801
[3H]TCP
glycine site glycine 
D-serine 
D-alanine 
D-cycloserine (P)
HA-966 (P) [3r ] glycine
kynurenate
5,7-chloroky nurenate
polyamine site spermine
spermidine
argiotoxin-636
AMPA AMPA
L-glutamate
quisqualate
NBQX
CNQX
LY-293558
GYKI-52466
[3H]AMPA
[3H]quisqualate
[3H]glutamate
Kainate kainate
4-methyl glutamic acid
domoate
quisqualate
NS102
CNQX
[3H]kainate
[3H]glutamate
M etabotropic trans-ACPD
quisqualate
ibotenate
L-AP4
A summary of representative agonists, antagonists and radioligands for each of the 
excitatory amino acid receptor classes. Agents are not necessarily ranked in order of 
pharmacological potency. (P) partial agonist
AMPA : (RS)-a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, L-AP4 : S-2- 
amino-4-phosphonobutyrate, D-AP5: D(-)-2-amino-5-phosphonopentanoate, trans- 
ACPD : l-aminocyclopentane-lS,3R-dicarboxylate, CGS 19755 : 4-phosphonomethyl-2- 
piperidinecarboxylic acid, CNS 1102 : AL(l-naphthyl)-./V'-(3-ethylphenyl)-Ar'- 
methylguanidine hydrochloride, CNQX : 6-cyano-7-nitroquinoxalme-2,3-dione, C P P : 
(±)-(2-carboxypiperazine-4-yl)propyl- 1 -phosphonic acid, GYKI-53655 : l-(4- 
aminophenyl)-4-methyl-7,8-methylenedioxy-5//-(3N-methylcarbamate)-2,3- 
benzodiazepine, HA966 : (R)-3-amino-l-hydroxypyrrolid-2-one, LY-293558 : 
3S,4aR,6R,8aR-6[2(l//-tetrazol-5yl)ethyl]-decahydioisoquinoline-3-carboxylate, MK801: 
(+)-5-methyl-10,ll-dihydro-5//-dibenzo[a,d]cyclohepten-5,10-imine maleate, NMDA : N- 
methyl-D-aspartate, NBQX : 6-nitro-7-sulphamoyl-benz(f)quinoxaline-2,3-dione, NS102 :
5-nitro-6,7,8,9-tetrahydrobenzo-[Y]-inodole-2,3-dione-3-oxime, T C P : l-[l-(2- 
thienyl)cyclohexyl]-piperidine
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FIGURE 2 : Schematic illustration of the NMDA receptor
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The transmitter binding site
The transmitter binding site binds L-glutamate (and L-aspartate) with high affinity 
promoting the opening of a high conductance channel permeable to Na+ and Ca2+. 
Two schemes have been suggested to describe channel responses to 
a brief pulse of L-glutamate.
1. Channel openings may occur with a moderately high probability (~ 10ms) soon 
after agonist binding and repeatedly open and close until the agonist dissociates 
several hundred milliseconds later.
2. The majority of NMDA channels open after a considerable delay and after the initial 
burst, the likelihood of subsequent openings is reduced. Results from concentration 
jump and patch-clamp analysis support the short first latency scheme, where a 
significant number of channels exhibit long-lasting bursting (Dzubay and Jahr, 
1996).
Two distinct binding sites are associated with the transmitter binding site, one which 
preferentially binds agonists and one which preferentially binds antagonists (Foster 
and Fagg 1987, Cooper et al 1996). Autoradiographic studies by Monaghan and 
colleagues (1988) examining [3H] glutamate and [3H]3-[(±)2-carboxypiperazine-4- 
yl]propyl-l-phosphonic acid ([3H]CPP) binding suggested that these may represent 2 
distinct receptors. More recently, ligand binding studies have identified 
pharmacologically distinct receptor subtypes which display differing preferences for 
agonists and antagonists (Bresink et a l , 1995, Sucher et a l , 1996).
A number of competitive antagonists exist for the transmitter binding site. The 
'prototype' compounds are co phosphono-substituted amino acids such as D-AP5 (2- 
amino-5-phosphonopentanoic acid) and D-AP7 (2-amino-7 -phosphonopentanoic acid) 
The construction of conformationally restricted analogues of these compounds 
produced antagonists with increased affinity such as D-CPP (4-(3-phosphono- 
propyl)piperazine-2-carboxylic acid and its unsaturated analogue D-CPPene ((E)-4- 
(3-phosphono-prop-2-enyl)piperazine-2-carboxylic acid). A novel class of 
competitive antagonists have been characterised in vitro (Urwyler et al, 1996a) and in
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vivo (Urwyler et al, 1996b). Structure-activity relationship of these biphenyl 
derivatives of 2-amino-7-phosphonoheptanoic acid have shown that the a-amino, a- 
carboxylate, and co-acidic moiety are necessary for high affinity binding to the 
transmitter recognition site (Urwyler et al, 1996a).
The glycine modulatory site
The glycine recognition site has been proposed as a potentiator of NMDA evoked 
currents in a variety of preparations including cultured cortical neurons (Kemp and 
Priestly, 1991) and Xenopus oocytes (Kleckner and Dingledine, 1988). L-glutamate 
is virtually ineffective in activating NMDA receptor channels unless the glycine site is 
also occupied (Johnson and Ascher, 1987). This potentiation of glutamate responses 
is detected at glycine concentrations as low as lOnM and is not mediated by the 
inhibitory strychnine-sensitive glycine site (Johnson and Ascher, 1987). The very 
low concentration of glycine required for this effect, in relation to the concentration 
normally present in brain, suggest that glycine may serve as a constant enabling factor 
rather than a regulatory mechanism for NMDA-mediated effects.
An increasing amount of evidence suggests that the glutamate and glycine sites of the 
NMDA receptor are allosterically coupled. Patch clamp studies in hippocampal 
neurons showed that saturating concentrations of glycine prevented desensitisation of 
NMDA receptor currents and that glutamate increased the dissociation of glutamate 
from NMDA receptors (Lester et al, 1993). The interaction between glutamate and 
glycine sites had also been examined using ligand binding studies. Initial studies 
showed that glycine enhanced L-[3H] glutamate binding and inhibited binding of the 
glutamate antagonist, D-[3H]AP5 (2-amino-5-phosphonopentanoic acid) at 
concentrations consistent with action at the glycine recognition site (Monaghan et al> 
1988). This observation suggests that glycine site agonists have opposite effects on 
the agonist or antagonist preferring states of the glutamate recognition site. More 
recent ligand binding studies propose a more complex interaction (Grimwood et al,
1993). Glycine, D-serine and D-cycloserine partially inhibited binding of the "C-5"
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glutamate antagonist [3H]CGS 19755 (cfy-4-phosphonomethyl-2-[3H]piperidine 
carboxylate) and had little effect on [3H] glutamate or the "C-7" glutamate antagonist 
[3H]CPP. These effects can be explained by the proposal that glutamate, CPP and 
CGS 19755 bind to overlapping but nonidentical sites, and that glycine site ligands 
induce a conformational change that differentially affects the binding of these ligands. 
In the same study, in contrast to a lack of effect on [3H] glycine binding, "C-7" 
antagonists partially inhibited binding of the glycine site antagonist [3H]L-689,560 
((±)-4-rra^-2-carboxy-5,7-dichloro-4-[3H]phenylaminocarbonylamino-1,2,3,4 tetra- 
hydroquinoline). These inter-actions cannot be explained by an allosteric interaction 
and it has been suggested that a steric inhibition where glutamate site antagonists 
physically prevent access of [3H]L-689,560 to its binding site may be responsible. 
Thus two mechanisms may operate in these interactions, depending on the size of the 
ligands involved, a true allosteric change of affinity and a steric inhibition.
Voltage-dependent Mg2* block
A unique feature of the NMDA receptor is that it exhibits a voltage-dependent Mg2+ 
block (Nowak et al, 1984, Mayer et al, 1984). In the presence of Mg2+, single 
channel currents measured at resting potential are chopped into bursts and the opening 
potential of the channel is reduced (Nowak et al, 1984). The channel current induced 
by a given amount of glutamate (or NMDA) is increased when the cell is depolarised 
and NMDA responses are also greatly potentiated by reducing the extracellular Mg2+ 
concentration below physiological levels (~lmM). In addition to this site -0.65 
through the electric field of the ion channel (Johnson and Ascher, 1990) a superficial, 
high affinity divalent cation binding site - 0 .2  through the electric field has also been 
identified (Premkumar and Auerbach, 1996). This external binding site is an 
important feature of the Ca2+ permeability of the NMDA receptor since it determines 
the fraction of NMDA receptor current carried by Ca2+
Recent studies by Wang and MacDonald (1995) have shown that, at positive 
potentials, Mg2+ can enhance NMDA responses in the presence of low glycine
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concentrations. This potentiation was associated with a increase in the affinity of the 
NMDA receptor for glycine (Wang and MacDonald, 1995, Paoletti et al, 1995). It 
was suggested that Mg2+ may be acting as an agonist at the spermine site to produce 
these effects (Paoletti et al, 1995) since Mg2+, like spermine relieved the inhibitory 
effect of protons on NMDA receptor responses (Traynelis et al, 1995).
Ion channel blockade
NMDA receptors are selectively blocked by a variety of dissociative anaesthetics such 
as ketamine, phencyclidine (PCP) and MK801 (Kemp et al, 1986). It is well 
established that this type of blockade is both voltage-dependent and dependent on the 
presence of agonist (use-dependent) (Javitt and Zukin, 1989, Rogawski, 1993). 
Therefore the state of the NMDA receptor determines the degree of antagonism in that 
binding is almost completely dependent on the activation of the receptor (Foster and 
Wong, 1987).
In the absence of channel blocking agent, the channel exists in one of two states, open
(O) or closed (C). Presence of the channel blocker induces additional states, open- 
blocked (OB) and closed-blocked (CB). It is suggested that the blocking agent can 
only dissociate from the open form of the channel as detailed in the kinetic scheme 
below (MacDonald et al, 1991).
(fast)
c  -------- ►  o
1
b
T
CB  ►OB
(fast)
kD  (slow)
where k is the forward rate constant of blockade, D is the concentration of blocker 
and b is the reverse rate constant of blockade.
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While a variety of binding studies have confirmed that dissociative anaesthetics 
interact most readily with the agonist-associated (open) state of the NMDA receptor 
(Huettner and Bean, 1988, MacDonald and Nowak, 1990), it has been proposed that 
PCP-like agents may gain access to their binding site when the channel is closed. 
Drugs that interact exclusively with open channels should display single exponential 
association and dissociation kinetics. Javitt and Zukin (1989) reported that in the 
presence of L-glutamate (10pM), the kinetics of [3H]MK801 association were fit 
better by 2 exponentials. Under control conditions (absence of glutamate or glycine) 
or in the presence of AP5 99% of [3H]MK801 association could be accounted for by 
a single exponential thus, a degree of slow association of [3H]MK801 occurs under 
conditions when few NMDA receptors would be expected to be open. These results 
suggest that PCP-like agents can gain access to their binding site when the NMDA 
receptor channels is closed as well as via open channels. Bioexponential kinetics can 
be explained by agents gaining access to their recognition site by two pathways, each 
corresponding to one of the observed kinetic components. Channel blocking agents 
with pKa values close to physiological pH associate via a fast hydrophilic path 
representing access via open channels and a slow hydrophobic path representing 
binding via a path associated with closed channels. Closed channel access 
presumably requires transfer across lipid bilayer, or diffusion through hydrophobic 
domains (Javitt and Zukin, 1989, Chen et al, 1992).
Ketamine, PCP and MK801 display high affinity for the NMDA receptor channel and 
block 90-99% of agonist evoked NMDA currents at low concentrations (Foster and 
Wong, 1987). High affinity coupled with use-dependent blockade allows only 
minimal basal levels of glutamatergic activity within the brain. These agents display 
high neurobehavioural toxicity such as cognitive and sensory impairments (for review 
see McCulloch, 1992). Dissociative anaesthetics also produce transient and 
reversible histopathological changes in the cingulate cortex (McCulloch and Iversen,
1991).
More recently certain phenylcyclohexylamines (PCA's, primary amine analogues of
1 2
PCP), an analogue of MK801, ADCI and the anti-Parkinsonian, anti-viral agent 
memantine (1 -amino-3,5-dimethyladamantane hydrochloride) were found to display 
affinity for the NMDA receptor channel in the low micromolar range and to 
demonstrate more advantageous behavioural effects than PCP or MK801. These low 
affinity blockers display rapid rates of block and unblock, memantine reaches steady- 
state within 1 second of application (Chen et al, 1992). The proportion of current 
blocked increases with agonist concentration while a basal level of agonist evoked 
responses remains. The relatively rapid kinetics of these low affinity compounds may 
underlie this favourable profile (Rogawski, 1993, Chen et al, 1992).
A novel high affinity channel blocking agent WIN 63480 ((±)-12,12-diethoxy-13,13- 
dimethyl-6 ,ll-ethano-6 ,ll-dihydrobenzo[b]-quinolizinium chloride) has recently 
been reported to lack observable behavioural effects at high concentrations. While 
WIN 63480 was an effective NMDA receptor channel blocker, it is strongly 
hydrophilic (logD = -4.1) and was shown to have much less access to closed 
channels than MK801 (logD = +1.8), Ault et al, 1995). Access to closed channels 
results in a non-competitive profile of antagonism for MK801 and PCP, compared to 
a more uncompetitive profile for WIN 63480.
Consequently WIN 63480 may produce less inhibition of physiological NMDA- 
mediated processes.
The polyamine modulatory site
The highly regulated nature of polyamine biosynthesis, retroconversion and biosynthesis 
verify the critical role of these ubiquitous aliphatic polycations in cell growth and 
differentiation (Scott et al, 1993). It is now established that these low molecular weight 
nitrogenous bases do not perform a single function and the known roles of polyamines can 
be divided in to those dependent on their chemical or biological properties. Spermine and 
spermidine interact with negatively charged molecules such as nucleic acids or 
phospholipids, stabilising these highly charged structures (Wallace et al, 1987). 
Polyamines also have effects on voltage-gated cation currents, spermine and spermidine
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allosterically inhibit the binding of calcium channel ligands, and can modulate voltage- 
activated K+ current (for review see Scott et al, 1993, Johnson, 1996). Multiple 
recognition sites for polyamines have been reported to account for the complex actions 
ranging from antagonism to enhancement of glutamate responses mediated NMDA 
receptors (Johnson, 1996). Polyamines appear to exert dual effects with low 
concentrations enhancing and high concentrations inhibiting responses (Scott et al, 1993). 
The potentiating effects of polyamines (Munir et al, 1993, Fahey et al, 1993) can be 
subdivided into ’glycine-independent' stimulation where spermine increases NMDA 
currents in the presence of saturating glycine, and 'glycine -dependent' stimulation which 
increases the affinity of the receptor for glycine (Johnson, 1996). The inhibitory effect can 
also be further divided into voltage-dependent inhibition and a decreased affinity for 
glutamate (Figure 3). Ransom and Stec (1988) identified another polyamine binding site 
allosterically linked to the MK801 binding site, where low spermine concentrations 
enhance MK801 binding. In addition to endogenous polyamines, these compounds are 
also major constituents of venoms produced by a number of vertebrates.
The receptor-specific toxin sensitivity can be correlated with individual receptor 
subtype (see subunit-specific blockade).
Proton block
The strict regulation of pH within the brain is well established. It is of interest 
therefore that despite the wealth of homeostatic mechanism, neuronal activity gives 
rise to changes in intracellular and extracellular pH (Chesler and Kaila, 1992). These 
shifts occur rapidly in either the acid or alkaline direction. Alkaline and acid shifts 
typically lead to a respective increase or decrease in neuronal excitability and are of a 
large enough magnitude to influence the function of receptors.
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FIGURE 3 : The modulatory actions of polyamines on the NMDA receptor
(1) Glycine-independent stimulation : occurs at saturating glycine concentrations and 
involves an allosteric effect on the conformation of the channel protein to increase the 
frequency of channel opening. (2) Glycine-dependent stimulation : occurs at subsaturating 
glycine concentrations and increased NMDA receptor affinity for glycine. (3) Voltage- 
dependent inhibition : decreases channel conductance as a result of charge screening at the 
mouth of the channel, fast-open channel block at a site within the channel, possibly 
involving Mg2+. (4) Decreases affinity for agonist: occurs at sub-saturating concentrations 
of NMDA or glutamate
NMDA receptor responses were selectively inhibited by protons (H+) in cerebellar 
neurons. 50% inhibition of responses occurred at pH 7.3 implying that NMDA 
receptors are not fully activated under normal conditions (Traynelis and Cull-Candy,
1990). Non-competitive interactions at the agonist binding site, glycine site and 
Mg2+ site suggested that protons act at a specific site on or near the face of the NMDA 
receptor channel to decrease the frequency of channel opening. Strikingly similar 
results were obtained in cultured hippocampal neurons (Tang et al, 1990).
More recently , supporting evidence for the negative modulation by protons of 
NMDA receptors was provided by ligand binding studies. Increasing extracellular 
pH from 6.5-8.0 increased the association and dissociation rate of [3H]MK801 
binding (Rajdev and Reynolds, 1993). Yoneda and colleagues (1994) also showed 
that glutamate-dependent [3H]MK801 binding to synaptic membranes increased with 
decreasing proton concentration over the pH range 6.0-9.0. These observations 
suggest that [3H]MK801 binding is controlled by the level of NMDA receptor 
activation.
Mild acidosis (pH 6.8-7.4) has been shown to inhibit the rise in intracellular Ca2+ 
(Takadera et al, 1992, Ebine et al, 1994) and to delay spreading depression and 
improve neuronal recovery following hypoxia in hippocampal slices (Tombaugh,
1994). This beneficial effect may be dependent on the severity of the acidosis since 
Ca2+ influx in hippocampal slices at pH 6.2 was twice that measured at pH 7.3 
(O'Donnell and Bidder, 1994).
Acidosis has also been shown to be neuroprotective in ischaemia. Simon et al (1993) 
reported that mild acidosis (pH 6 .8) induced by increasing the CO2 tension in inspired 
air, attenuates ischaemic injury in the rat. However, this reduction in infarct volume 
was biphasic and the beneficial effect of acidosis was lost at pH 6.5. This is in  
agreement with the observation that a more severe acidosis (pH 6.3) induced by 
hypercapnia, exaggerated ischaemic damage in the rat (Katsura et al, 1994). It is 
suggested that inhibition of glial glutamate uptake is likely a major factor in 
attenuating the neuroprotective effect of acidosis. A toxic effect of acidosis on glia
15
was described by Giffard et al (1990), with a 9 hour exposure at pH 6.4 resulting in 
death of a third of the glial population.
It is noted that induction of hypercapnia has wider reaching effects within the central 
nervous system beyond those on NMDA receptors. An increase in cerebral blood 
flow occurs in all brain region following induction of hypercapnia (Simon et al, 1993) 
however, this vasoreactivity is lost in ischaemic areas (Dettmers et al, 1993).
In summary, modulation of the divalent ion-carrying NMDA current by protons may 
serve as a negative feedback mechanism controlling neuronal excitability under 
normal conditions and, as an intrinsic protective mechanism by which Ca2+ entry into 
neurons is regulated in pathological conditions. In situations where acidosis worsens 
the overall outcome of ischaemic damage, it may decrease the specific component of 
neuronal injury mediated by NMDA receptors.
The redox modulatory site
NMDA-evoked currents have been shown to be enhanced by disulphide-reducing 
agents (DTT, dithiothreitol) and inhibited (but not completely) by thiol-oxidising 
agents (DTNB, 5,5'-dithiobis-2-nitrobenzoic acid). Both reducing and oxidising 
agents modifiy the native receptor implying that the NMDA receptors are in 
equilibrium between a fully oxidised (disulphide) and fully oxidised (thiol) form (for 
review see Gozlan and Ben-Ari, 1995). DTT reacts at sites on the extracellular 
domain of the receptor to increase the frequency of single channel openings, the 
potentiation of NMDA-evoked currents correlates with an influx of Ca2+ through the 
NMDA channel (Aizenman and Harnett, 1992).
The variation in reports of the existence and variation in proportion of the 2 redox 
states in different preparations suggests the presence of endogenous compounds 
which interact at these sites. Potential candidates are thiol reagents such as cysteine, 
homocysteine which are released during depolarisation (Zangerle et al> 1992), and 
dihydrolipoic acid which increase NMDA responses. Disulphide reagents like lipoic 
acid and methoxalin react with free sulphydryl (SH) groups to inhibit responses. The
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endogenous reducing agent ascorbic acid has also been shown to inhibit NMDA- 
induced currents. Free radicals are also known to interact with thiol groups. Free 
radicals generated by xanthine oxidase inhibit NMDA responses. Particular attention 
has focused on nitric oxide which displays a direct action on SF1 groups of the redox 
site (Lei et al, 1992). Dynorphin, an endogenous opioid reduces NMDA-activated 
currents without involving opioid receptors. Dynorphin interacts with a site 
conformationally liked with the redox site(s) on the NMDA receptor altering the gating 
properties of the channel (Chen et al, 1995).
Fully oxidised receptors are functional, indicating redox modulation is not a switch 
turning NMDA receptors on or off, but is rather a buffer of NMDA receptor 
overactivity (Gozlan and Ben-Ari, 1995). This redox system can buffer small 
changes in redox potential that occur in relation to electrical activity thus maintaining 
activity within a controlled range. However, the buffering capacity probably plays a 
limited role in pathological conditions since it cannot overcome large changes in redox 
potential.
Modulation by zinc
The presence in high concentrations of zinc in the synaptic vesicles of mossy fibres 
within the hippocampus and it's release in to the extracellular space during neuronal 
excitation lead to the proposal that zinc could modulate neuronal excitability (Assaf et 
al, 1984). The demonstration of preferential uptake and Ca2+-dependent release of 
zinc within hippocampal slices added weight to the hypothesis that zinc was involved 
in synaptic transmission (Howell et al, 1984). Studies by Westbrook and Mayer 
(1987) in hippocampal neurons confirmed that zinc (50|iM) produced an almost 
complete inhibition of NMDA activated current via a direct effect on the receptor 
channel complex an in a voltage-insensitive manner. At this concentration zinc was 
found to potentiate kainate and quisqualate mediated currents. More recently zinc has 
also been shown to modulate the binding of antagonists at the NMDA receptor (Terse 
and Komiskey, 1997). Zinc (12.5|i.M) significantly inhibited [3H]CGP 39653
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binding to rat brain homogenate by increasing the Kj of this compound. It was 
suggested from these results that the zinc concentration of the brain may influence the 
therapeutic effects of competitive NMDA receptor antagonists.
fi opioid interactions
|i opioid receptor activation had been reported to increase NMDA receptor currents 
postsynaptically (Martin et al, 1997). The mechanism of potentiation is unclear 
however, the effects of |x opioid receptor agonists on NMDA responses have been 
proposed to be linked to this voltage-dependent Mg2+ blockade (Cheng and Huang, 
1992). p. opioid agonists cause sustained increases in NMDA-induced currents by 
activating protein kinase C (PKC). In this study PKC was found to potentiate 
NMDA receptor responses by increasing the open probability of the channel by 
reducing the voltage-dependent Mg2+ block.
Modulation by phosphorylation
Phosphorylation of glutamate receptors has been postulated as an important 
mechanism for modulating excitatory transmission (Ben-Ari et al, 1992), however the 
precise phosphatases involved were unknown. More recently Wang et al (1994) 
demonstrated that NMDA receptors were regulated by endogenous serine/threonine 
protein phosphatases in cultured hippocampal neurons. Protein phosphatases 1 and 
2A decreased the open probability of the NMDA receptor and phosphatase inhibitors 
were shown to enhance NMDA-induced currents. These observations were supported 
by the demonstration that activation of calcineurin (Ca2+/calmodulin-dependent 
phosphatase) by calcium entry through NMDA receptor channels shortens the duration 
of channel opening in rat dentate gyrus granule cells (Lieberman and Mody, 1994). It 
is apparent therefore that a negative feedback mechanism exists in vitro where 
phosphorylation of the NMDA receptor channel modulates neuronal excitability.
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Molecular biology
Two families of NMDA receptor subunits have been cloned and sequenced in the rat, 
consisting of 5 receptor subunits NMDAR1 (NR1) and 4 NMDAR2 subunits (NR2A- 
D, Nakanishi, 1992, for review see Sucher et al, 1996). An NMDA receptor-like 
subunit has also been cloned (NRL) which is closely related to NMDAR1 (Sucher et 
al, 1996). Isolated cDNA encoding a full length NMDA receptor subunit from human 
brain (nNRl) shares high sequence homology (99%) with rat brain NR1 and murine 
£1 (Nakanishi, 1992), suggesting that the cDNA clone of hNRl which codes for a 
human brain NMDA receptor subunit is descendent from rodent and murine brain 
NR1 subunits (Planells-Cases et al, 1993). Alternative splicing of the single gene can 
generate at least 8 NR1 isoforms with distinct functional properties. One of these 
splice variants coded by exon 5, exists in 2 different forms with the presence (NRlb) 
or absence (NRla) of a 21 amino acid N-terminal insert sequence, which is predicted 
to form a loop on the extracellular surface of the NR1 protein (Traynelis et al, 1995, 
Johnson, 1996). The human NR1 subunit, NMDAR1 or the murine homolog form 
homo-oligomers and exhibit electrophysiological and pharmacological properties 
characteristic of NMDA receptors when expressed in Xenopus oocytes (Seeburg, 
1993, Planells-Cases et al, 1993) but not in mammalian cells (Sucher et al, 1996). It 
is suggested that the in vivo biological activity of the NMDA receptor is dependent on 
this essential subunit, since mice carrying a disrupted allele of NMDAR1 (Grin 1) 
possessed no NMDA responses and die when neonates (Forrest, 1994). NR1 
subunits require co-assembly with NR2 subunits to yield currents of the magnitude 
found in neurons (for review see Seeburg, 1993, Sucher, 1996).
NR2 subunits therefore appear to have a modulatory role, with each recombinantly 
expressed, heteromeric NR1-NR2 receptor combination possessing distinct 
biophysical and pharmacological signatures. Subunit dependent properties include the 
strength of the Mg2+ block (Kuner and Schoeper, 1996), sensitivity to modulation by 
glycine (Monaghan et al, 1988), and affinities for agonists and antagonists (Marti et 
al, 1993, Lynch et al, 1995). Heterogeneity within the NR2 subunit family results
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from expression of 4 closely related genes, NR2 subunits share 15% homology with 
NR1 subunits (Figure 4).
Natively expressed receptors are thought to comprise NR1 and at least one other 
member of the NR2 class but the exact stoichiometry remains unknown. It has been 
suggested that NMDA receptors may form pentamers like nicotinic acetylcholine 
receptors or follow the tetrameric structure of ion channels with pore loops. It has 
been reported that NR2A and NR2B can be immunoprecipitated with NR1 
suggesting a portion of NMDA receptors form heterooligomers with at least 3 
subunits (Sheng et al 1994) however it remains unknown if these subunits represent 
functional receptors.
Previously, ideas on the transmembrane topology of ligand-gated ion channels was 
based on data from nicotinic acetylcholine receptors and the majority of glutamate 
receptor sequences were interpreted on this framework. The NR1 primary amino 
acid sequence was originally interpreted to indicate 4 transmembrane domains (TMI- 
TMTV). A long N terminal extracellular segment before TMI has been postulated to 
contain the agonist binding site. Site directed mutagenesis had highlighted three 
charged residues within this region which are critical for glutamate binding 
(Planells-Cases et al, 1993). The putative TMII was designated the channel forming 
region, with highly conserved asparagine residue in the N position (also found in 
NMDAR2 subunits) mediating Ca2+ permeability and the voltage sensitivity of the 
Mg2+ block (Seeburg, 1993, Kuner and Schoepfer, 1996). The extensive C terminal 
sequence is currently modelled to be intracellular. An interaction has recently been 
reported between the C terminus of NR2A and NR2B subunits and the domains of 
PSD-95/SAP90, an abundant synaptic protein associated with the cytoskeleton 
(Niethammer et al, 1996).
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FIGURE 4 : Phylogenic tree of ionotropic glutamate receptor subunits in the rat
NR1 and NR2A-D are NMDA receptor subunits. GluRA-GluRD are AMPA subunits. 
KA1, KA2 and GluR5-GluR7 are subunits of kainate receptors. The d subunits have yet to 
be assigned. The line length separating any pair of subunits represents the distance 
between their sequences.
It is proposed that the PSD-95 family of guanylate kinases may anchor NMDA 
receptor subunits to the cytoskeleton and assist in the assembly of receptor complexes. 
Recently several groups have put forward indirect evidence, inferred from the 
structure of the non-NMDA receptor subunit GluRl that the NR1 subunit has 3 
transmembrane domains with TMII forming a loop in the membrane to participate in 
the formation of a channel pore (Sucher et al, 1996).
Subunit specific block
Radioligand binding and electrophysiology studies have described 4 distinct 
populations of native NMDA receptors. Discrete populations are found within the 
cerebellum (Perkins and Stone, 1983, Widdowson et al, 1995) and the midline 
thalamic nuclei, while the remaining 2  differ in their affinities for agonists and 
antagonists (Monaghan et al, 1988). The anatomical distribution of each of the 
subtypes show striking parallels to the distribution of individual NR2 subunit mRNA. 
NR2A mRNA is localised in the cortex and hippocampus and distribution was similar 
to that of 'antagonist preferring' NMDA receptors, as defined by [3H]CPP binding 
(correlation coefficient 0.88). 'Agonist preferring' NMDA receptors were localised to 
forebrain regions expressing NR2B and NR1 mRNA. NR2C mRNA is almost 
exclusively localised within the cerebellum and NR2D to midline thalamic nuclei. The 
marked anatomical correspondence between distribution of mRNA and expression of 
NMDA receptors with different pharmacological profiles implies that a molecular basis 
underlies the heterogeneity in NMDA receptor properties and that the distinct 
properties of these subtypes are determined by NR2 subunits (Buller et al, 1994). 
Kutsuwada and colleagues (1992) demonstrated that different subunits are distinct 
with respect to affinities for agonists and competitive antagonists and this was 
confirmed by autoradiographic studies (Yoneda and Ogita, 1991, Bresink et al, 1995). 
[3H]MK801 binds with lower affinity in the cerebellum compared to the cortex.
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This observation was explained by preferential binding to distinct NMDA receptor 
subunits, [3H]MK801 may have a decreased affinity for NMDA receptors containing 
NR2C or NR2D subunits which are abundant within the cerebellum (Nakanishi,
1992).
It has also been suggested that the observation that low affinity NMDA channel 
blockers like amantadine and memantine bind with similar affinity to cortical and 
cerebellar binding sites may also be attributable to preferential binding to certain 
receptor subtypes (Porter and Greenamyre, 1995).
In addition to their uneven distribution throughout the brain, distinct NMDA receptor 
subtypes may be differentially involved in neurological disorders. Proton inhibition 
of NMDA receptors is determined by the presence or absence of exon 5 in the NR1 
subunit (Traynelis et al, 1995). Brain regions that express exon 5 (brainstem, 
thalamus, cerebellum, hippocampus) may be uniquely vulnerable to glutamate induced 
neuronal damage inasmuch as the attenuation of proton inhibition by NR1 exon 5 
enhances neuronal excitability and reduces the negative feedback of extracellular 
acidification occurring after excessive NMDA receptor activation (Traynelis et al,
1995). The development of subtype-specific antagonists has thus gained considerable 
interest.
A number of compounds have been identified that appear to discriminate between 
NMDA receptors composed of different subunit combinations, the best characterised 
is ifenprodil. Ifenprodil is an atypical, non-competitive NMDA antagonist which 
displays 400-fold higher affinity for NR1-NR2B than NR1-NR2A receptors 
(Williams, 1993). This agent was originally proposed to act at the polyamine site 
however, the interaction between ifenprodil and polyamines is non-competitive. 
Ifenprodil, in the presence of saturating concentrations of glycine, can potentiate the 
effect of NMDA receptor activation by low concentrations of agonist Little effect on 
NMDA responses is detected at intermediate agonist concentrations, and profound 
block is observed at high agonist concentrations (Kew et al, 1996).
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Ifenprodil inhibition of recombinant NR1-NR2B receptors in Xenopus oocytes was 
found to be pH sensitive, with less inhibition occurring at alkaline pH. The pH 
sensitivity of ifenprodil block occurs at NRlb-NR2B as well as NRla-NR2B 
receptors suggesting that it is not influenced by the presence or absence of exon 5.
The attractive pharmacological profile of ifenprodil which lacks the side effects 
exhibited by other NMDA antagonists is attributable in part to both subunit 
selectivity and, the ability of this compound to block channels during periods of high 
activity while leaving resting channels relatively unaffected. Investigation of the 
mechanisms of action of such subunit specific compounds not only provides 
attractive therapeutic strategies with minimal side effects, but helps to refine our 
understanding of the complex interactions between various modulators of the 
NMDA receptor.
1.3.2 The AMPA receptor
AMPA receptors are found in the majority of excitatory synapses, with a similar 
distribution to NMDA receptors however AMPA receptors predominate in the 
molecular layer of the cerebellum whereas NMDA receptors are localised within the 
granule cell layer (for review see Farooqui and Horrocks, 1991). Investigation of 
AMPA binding kinetics revealed the presence of a high affinity and a low affinity 
binding site. The AMPA antagonist [3H]CNQX labels both sites with the same 
affinity. Due to the low calcium permeability of these receptors they do not carry 
sufficient ions to initiate biochemical and biological processes triggered by an 
increase in calcium levels. These receptors mediate fast excitatory transmission and 
are voltage-independent. Treatment of rat brain membranes with phospholipase A2
has been shown to cause a significant increase in the affinity of the receptor for 
AMPA, without changing the number of binding sites (Farooqui and Horrocks,
1991).
23
Three selective AMPA antagonists exist DNQX (6,7-dinitroquinoxaline-2,3-dione), 
CNQX (6-cyano-7-nitroquinoxaline-2,3-dione) and the most selective NBQX (6- 
nitro-7-sulphamoylbenzo[f]quinoxaline-2,3-dione). The large body of neuroprotective 
data from studies using NBQX shows that AMPA receptors play an important role in 
the neuropathological effects of glutamate in cerebral ischaemia (Nellgard and 
Wieloch, 1992). More recently a selective AMPA antagonist LY 215490 
(decahydroisoquinoline) has also been shown to be neuroprotective (Gill and Lodge,
1994)
Molecular biology
AMPA receptors can be reconstituted in vivo by expressing 1 or coexpressing 2 of 4 
subunits, GluRl-GluR4 (Nakanishi, 1992). AMPA receptors are proposed to consist 
of pentameric assemblies. The GluR subunits are widely but differentially distributed 
throughout the CNS. The type of subunits expressed determines both the biophysical 
and pharmacological properties of the receptors. There is considerable sequence 
conservation across the 4 TM regions and subunits differ mainly in extracellular 
regions (Sheardown, 1993). All AMPA receptors are permeable to Na+ and K+ 
however only those receptors lacking a GluR2 subunit are permeable to Ca2+ (Danysz 
et al, 1995). The Ca2+ permeability can be linked to a single amino acid residue in 
the putative channel forming subunit TMII (McEntee and Crook, 1993). In GluR2 
subunits the glutamine residue is replaced by arginine (Seeburg, 1993)
GluR subunits are 900 amino acids in length and can occur in two forms with respect 
to an alternatively spliced exonic sequence of 38 residues, 'flip' and 'flop' (for review 
see Seeburg, 1993). The prenatal brain expresses mostly 'flip' and this expression 
persists throughout life. 'Flop' forms appears from postnatal stages onwards and are 
coexpressed with 'flip' forms in many cells. These developmental changes are 
proposed to have functional significance. Adults receptors display currents with a 
fast desensitising component and a steady-state component. Receptors with a 'flip' 
module display slower desensitising kinetics than adult receptors (Seeburg, 1993).
1.3.3 The Kainate receptor
The distribution of kainate receptors is complementary to that of NMDA and AMPA 
receptors with a high density of kainate sites present in the stratum lucidum of the 
hippocampus (mossy fibre system), striatum, thalamus and the inner and outer layers 
of the cortex (Farooqui and Horrocks, 1991).
Despite the presence of functional kainate receptors in neuronal cultures, synaptic 
responses were completely blocked by the 2,3-benzodiazepine GYKI 1536559, a 
selective AMPA antagonist. This evidence and the observation that kainate-elicited 
responses undergo rapid and total desensitisation (Seeburg, 1993) suggests that 
kainate receptors do not participate in conventional synaptic transmission in cultured 
cells, or in adult neuronal populations (Lerma et al, 1997). Thus, the significance for 
the CNS of receptors exhibiting high affinity kainate sites is unclear. Studies by 
Chittajallu et al (1996) showed that kainate elicits a dose-dependent decrease in L- 
glutamate release from hippocampal synaptosome and also depressed glutamatergic 
synaptic transmission.
Molecular biology
Kainate receptors can be generated in vitro from GluR5,6 ,7  and KA1 or 2 subunits 
(Seeburg, 1993). The 5 subunits form a complex mosaic of expression in rat brain 
and the combined pattern of distribution approximates the pattern of high affinity 
[3H]kainate binding sites. KA1 or 2 expression alone does not generate functional 
channels. Combined with GluR5/6, receptor properties are different from homomeric 
channels, GluR5-KA2 channels show rapid desensitisation and display a different 
current/voltage relationship compared to GluR5 channels.
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1.3.4 The AP4 receptor
AP4 receptors are characterised by the antagonistic action of AP4 on certain 
glutamate-using synapses. It has been suggested that AP4 may act at both pre- and 
post synaptic sites. Very little is known about the molecular biology of the of the 
AP4 receptor.
1.3.5 The Metabotropic receptor
Metabotropic glutamate receptors (mGluRs) are a novel family of recently cloned G 
protein-coupled receptors. These receptors are coupled to multiple second messenger 
systems including phosphoinositide hydrolysis and changes in cAMP formation (for 
review see Schoepp and Conn, 1993, Pin and Duvoisin, 1995). mGluRs can be 
classified into three groups (see molecular biology) which display different 
pharmacology. The rank order of agonist potency for group I receptors is 
quisqualate > glutamate > ibotenate > ACPD (l-amino-cyclopentane-1,3- 
dicarboxylate). The relative order of potency of group II receptors is reversed 
compared to group I. Group II receptors are distinctive in their sensitivity to L-AP4 
and their insensitivity to ACPD. mGluRs have recently been considered as a putative 
target for neuroprotective strategies because their activation affects multiple 
intracellular events contributing to both the induction and progression of neuronal 
damage. Activation of group II and group III mGluRs protects neurons against 
excitotoxic damage (Bruno et al, 1995). This effect is partly ascribed to neuronal 
mGluR2 receptors which are located presynaptically and inhibit glutamate release (Pin 
and Duvoisin, 1995). It appears that new protein synthesis and neuronal-glial 
signalling are also required for this neuroprotective activity (Bruno et al, 1997)
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Molecular biology
At least 6 subtypes of mGluRs exist termed, mGluRl-mGluR6 . These receptors are 
larger than any other G protein-coupled receptors and possess a common structural 
architecture. mGluRs possess a large extracellular NH2 terminal domain and seven 
putative transmembrane spanning domains. A number of cysteine residues are highly 
conserved in the NH2 terminal and may play a structural role (Nakanishi, 1992). 
Despite interactions being mediated through the same G protein molecules, mGluR's 
show no sequence homology with any other G protein linked receptors. mGluRs can 
be classified into three groups according to sequence similarities (Nakanishi, 1992, 
Figure 5). This classification is supported by the respective transduction mechanisms 
(Schoepp and Conn, 1993). Group I (mGluRl, MGluR5) stimulate phospholipase C 
resulting in increased IP3 formation and mobilisation of Ca2+ from intracellular 
stores. These responses are only partly sensitive to pertussis toxin (PTX) implying 
the Gi-G0 family of G proteins is involved. Group II (mGluR2, mGluR3) and 
Group III (mGluR4, mGluR6 , mGluR7, mGluR8) are coupled to the inhibition of 
adenylate cyclase. Group II receptors show a strong inhibition of forskolin stimulated 
cAMP production however, group II receptors show less than 50% inhibition, 
implying inappropriate coupling to the G protein. mGluRs of the same group show 
70% sequence identity whereas identity between groups is around 45% (Pin and 
Duvoisin, 1995).
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FIGURE 5 : Phylogenic tree of Metabotropic glutamate receptor subunits
The division of the metabotropic subunits into three groups is underpinned by 
structural homology and transduction mechanism. The sequence homology of 
subunits within and between groups is shown by the scale bar at the top of the 
diagram (%).
It is suggested that mGluRs perform regulatory functions throughout the brain 
(Nakanishi, 1992). Quisqualate stimulation of Group I mGluRs has been shown to 
inhibit voltage sensitive Ca2+ channels in cultured neurons while ACPD inhibits 
GABAa receptor mediated currents and potentiates AMPA and NMDA curents (Pin 
and Duvoisin, 1995). It is therefore proposed that mGluRs have two opposing 
effects on excitotoxic cell death. A potentiating effect arises due to neuronal excitation 
and potentiation of NMDA receptor responses and a protective effect exists due to 
presynaptic inhibition of glutamate release (Pin and Duvoisin, 1995).
28
1.4 Excitotoxicity
1.4.1 NMDA-mediated neurotoxicity
Central nervous system neurons degenerate when exposed to abnormally high 
concentrations of excitatory amino acids such as L-glutamate and L-aspartete (Olney et al, 
1971). This effect appears not to be direct, and depends on excitation of glutamate- 
releasing neurons (Medrum and Garthwaite, 1990). Excitatory amino acid induced 
lesions have a characteristic cytopathology where postsynaptic structures are destroyed 
and axons and presynaptic terminals are spared (Foster et al, 1988, Meldrum and 
Garthwaite, 1990). Structure-activity studies revealed a strong correlation between the 
excitatory potency and toxic actions of these excitatory amino acids (Olney et al, 1971) 
suggesting that 'excitotoxicity ' is a consequence of excessive activation of excitatory 
amino acid receptors (for review see Choi, 1987 and Meldrum and Garthwaite, 1990). 
The intrinsic potency of glutamate (at NMDA receptors) is high, however the effective 
potency in vivo is reduced by the presence of uptake mechanisms (Torp et al, 1994). 
Impairment of this uptake by energy depletion is probably a major cause of the increase in 
glutamate found in ischaemia. It is well documented that different neuronal populations 
display marked variations in vulnerability to glutamate (Swan et al, 1988, Swan and 
Meldrum, 1990). Different excitatory amino acid receptor agonists also selectively kill 
different populations of neurons. It appears that this variability reflects the differences in 
glutamate receptor expression throughout the brain, rat cerebellar Purkinje cells in vivo 
and in vitro are resistant to NMDA toxicity and express few NMDA receptors, however 
kainate preferentially destroys hippocampal CA3 neurons which are rich in high affinity 
kainate binding sites (Meldrum and Garthwaite, 1990). The effect of different toxins on 
the same neuronal type can also be distinguished histopathologically. NMDA induces a 
rapid progression into typical necrotic profile, with swelling and vacuolisation. AMPA 
and quisqualate produce a more gradual 'dark-cell degeneration’. Both types of 
histopathology are observed in acute degeneration in vivo , status epilepticus and cerebral 
ischaemia (for review see Meldrum and Garthwaite, 1990).
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Two processes are thought to be involved in excitotoxic cell death, however the final 
common pathway underlying these processes is likely to be excessive Ca2+ influx. 
NMDA toxicity towards all vulnerable neurons in cerebellar and hippocampal slices was 
abolished in Ca2+-free medium, or when Ca2+ buffering is increased. Ca2 + 
accumulation in neurons also parallels the cytopathalogical changes in both time course 
and the sites involved, from swelling of the Golgi apparatus, chromatin clumping within 
the nucleus, mitochondrial swelling and changes in the cytoplasm. The main piece of 
evidence for the role of Ca2+ in excitotoxicity is that NMDA antagonists like MK801 
provide dramatic protection against damage (Foster et al, 1988).
The initial phase of glutamate neurotoxicity is dependent on both Na+ and Cl". 
Continuous exposure of neurons to toxic concentrations of glutamate opens membrane 
cation channels to an ecessive influx of Na+ and a secondary passive influx of Cl- and 
water, resulting in acute neuronal swelling (Rothman, 1985). Acute neuronal swelling 
was absent in cultures when Na+ was removed from the medium (Choi, 1987, Goldberg 
and Choi, 1993).
The second phase of neurotoxicity is not dependent on the continued presence of the 
NMDA agonist and this delayed toxicity is markedly reduced in the absence of Ca2+ 
(Garthwaite and Garthwaite, 1986, Murphy et al, 1988). Delayed neurotoxicity is 
triggered primarily by the entry of Ca2+ through NMDA receptors. The activation of 
glutamate receptors is associated with the initiation of a number of secondary processes 
facilitated by the physical colocalisation of NMDA receptors with Ca2+ dependent rate- 
limiting substrates and enzymes (Tymianski et al, 1993). The secondary rise which 
precedes cell death is due to the loss of Ca2+ homeostasis. These secondary processes 
include the formation of free radicals and the activation of lipases and proteases. The 
activation of lipolytic enzymes such as phospholipase A leads to formation of arachidonic 
acid from neuronal membrane phospholipids which can be metabolised to form free 
radicals and lipid hydroperoxides (Farooqui and Horrocks, 1991).
The activation of proteases may lead to cellular damage. Intense stimulation of NMDA 
receptors has been shown to activate Ca2+-activated neural proteases (calpains) in
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hippocampal cultures (del Cerro et al, 1994). The two isoforms, calpain I and II are 
activated by micromolar and millimolar Ca2+ respectively (for review see Saido et al, 
1994, Bartus et al, 1995). Calpains degrade spectrin, microtubules, and neurofilaments 
and may be involved in breakdown of the cytoskeleton (Saatman et al, 1996). Calpains 
also convert xanthine dehydrogenase to xanthine oxidase generating free radicals (Wems 
and Lucchesi, 1990). Other targets of Ca2+-induced injury may be Ca2+-calmodulin- 
dependent protein kinases and protein kinase which cause enhanced glutamate release 
and prolonged Ca2+ influx respectively (Nichols et al, 1990). Nitric oxide synthesis can 
also lead to free radical formation. Reactions with superoxide ions produces highly toxic 
hydroxyl radicals which cause lipid peroxidation of plasma membranes (Pellegrini- 
Giampietro et al, 1990). Ca2+ also activate endonucleases which cause fragmentation of 
DNA and may have a role in programmed cell death (Onenius et al, 1989).
1.4.2 Non-NMDA mediated excitotoxicity
Two types of AMPA excitotoxicity are proposed to exist, a direct effect resulting from 
long exposures at low concentrations and, a delayed effect resulting from short exposures 
(Meldrum and Garthwaite, 1990). Application of the antagonist CNQX (6-cyano-7- 
dinitroquinoxaline-2,3-dione) during exposure to AMPA in cerebellar slices had no effect 
on neurodegeneration. However, after a 90 minute recovery period, CNQX was highly 
effective in preventing AMPA induced neuronal degeneration (Garthwaite and 
Garthwaite, 1991). It is suggested that receptor desensitisation prevents an immediate 
toxic effect AMPA induced degeneration can be inhibited by nifedipine, implying that 
Ca2+ entry through voltage operated Ca2+ channels may be involved (Weiss et al, 1990). 
Kainate-induced excitotoxicity is similar to NMDA toxicity in that it is Ca2+ dependent 
and Cl" independent In contrast to AMPA-induced degeneration, CNQX inhibits kainate 
induced toxicity during the exposure period (Garthwaite and Garthwaite, 1990).
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1.4.3 The ischaemic penumbra
Occlusion of a major intracerebral artery causes a decrease in cerebral blood flow, the 
density of which is dependent on collateral circulation and local perfusion pressure. 
Complete arrest of the cerebral circulation leads to cessation of neuronal activity and 
subsequently to deterioration of ion homeostasis. If this situation persists for more than 
5-10 minutes, irreversible cell damage is likely. The classical concept of ischaemic 
thresholds states that cell death occurs when the cerebral blood flow is less than 15-20% 
of control values (Astrup et al, 1977). That is, a threshold flow rate is required to supply 
the minimum amount of oxygen and substrates to prevent complete cell membrane 
depolarisation. The concept of the ‘ischaemic penumbra’ was introduced to define brain 
tissue perfused at a level of blood flow below that needed to sustain electrical activity but 
above that required to maintain ionic gradients. A more recent concept defines 
‘penumbra’ as viable tissue with an undetermined fate which may lead to necrosis , but 
has the capacity to recover if perfusion is improved (Heiss and Graf, 1994). The 
progression from penumbra to infarction is a function of the intensity and the duration of 
ischaemia (Jones et al, 1981). Simultaneous measurement of cerebral blood flow, 
protein synthesis and ATP concentrations following MCA occlusion showed that the 
limiting factor for cell survival within the ischaemic penumbra is the presistence of 
supressed protein synthesis (Mies et al, 1991). A number of biochemical alterations 
contribute to ischaemic cell damage and several of these features are characteristic of the 
ischaemic penumbra (for review see Obrenovitch, 1995). PET studies in both humans 
and animals have shown that increased oxygen extraction is a reliable feature for the early 
identification of viable tissue surrounding the ischaemic core. Tissue acidosis is also a 
well established feature of ischaemic tissue. In the ischaemic core, tissue depolarises 
permanently within a few minutes while spreading depression-like waves of transient 
neuronal depression are consistently observed in peri-infarct areas. Speading depression 
has been shown to contribute to ischaemic damage (Gill et al, 1992). High extracellular 
K+ is the driving force for SD propagation and Ca2+ entry through NMDA channels is 
also required for propagation (Obrenovitch, 1995).
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1.5 Therapeutic intervention in cerebral ischaemia
The adult central nervous system has minimal capacity for regeneration following 
damage. Cells at risk do not die immediately and damage can take hours or days to 
occur. Tissue damage progresses from regions most metabolically compromised to 
regions less compromised. The concept of the ischaemic penumbra therefore offers a 
window for therapeutic intervention.
1.5.1 Strategies for improving perfusion
The target of therapeutic strategies in acute CNS damage is to prevent irreversible 
damage or at least to limit its extent by therapeutic intervention. Stroke therapy can be 
directed at a wide range of pathophysiological mechanisms and there has been a great 
deal of interest in strategies improving blood flow to the ischaemic tissue. Drugs which 
improve blood flow e.g. nimodipine, are of benefit to subarachnoid haemorrhage patients 
at risk of delayed ischaemia due to vasospasm. The Intravenous Nimodipine West 
European Stroke Trial (INWEST) was abandoned due to hypotension associated 
worsening of the outcome in the nimodipine treated group (Muir and Lees, 1995). A 
second general approach applies to a subset of stroke patients.Where cerebral blood 
vessels are blocked by blood clots, it is possible to restore blood supply to ischaemic 
tissue using thrombolytic enzymes. Success has been reported following treatment with 
recombinant human tissue plasminogen activator (rt-PA). Restricting patients to those 
which could be treated within three hours from the onset of the stroke was probably an 
important determinant in the positive outcome of this trial. Other trials administering 
thrombolytic agents later than three hours (urokinase, streptokinase, rt-PA) failed to 
show any beneficial effect (Muir and Lees, 1995, McBumey, 1997). It has now been 
deemed unethical to withhold this treatment from suitable patients and all other clinical 
trials of neuroprotectivre agents in the United States must be carried out in tandem with 
rt-PA.
Tirilizad mesylate (U74006F), a lipid peroxidation inhibitor has been shown to reduce 
cortical infarct size intransient ischaemia. This effect is related to an improvement in
33
regional blood flow. This agent has been suggested as a useful adjunct to thrombolysis 
in the treatment of acute stroke patients (Xue et al, 1992).
1.5.2 NMDA antagonists
A third approach , not dependent on an improvement of blood flow (McCulloch et al, 
1992) is to limit Ca2+ overload by shutting down the main pathways through which it 
enters the cell. The predominant pathway is through NMDA receptors. From the mid to 
late 80's a large number of drug candidates which demonstrated the ability to limit the 
extent of brain damage in animal models of stroke became available. The common 
feature of these agents was blockade of the NMDA receptor (for review see McCulloch, 
1992, 1994a, 1994b). Neuroprotective effects have been demonstrated in all species 
studied (mouse, rat, cat, baboon) and the magnitude of reduction in infarct is similar 
regardless of the site targeted (approximately 50%).
Competitive antagonists
Conceptually, the simplest site to block is the neurotransmitter recognition site. Pre­
treatment with competitive antagonists such as DCPP-ene have shown anti-ischaemic 
efficacy in models of intracranial haemorrhage (Chen et al, 1991) and are 
neuroprotective against ischaemic brain damage and swelling following focal ischaemia 
in the rat (Park et al, 1994). NCP 17747 (2R,4R,5S-2-amino-4,5-(l,2-cyclohexyl)-7- 
phosphonoheptanoic acid) also afforded protection when administered before transient 
focal ischaemia and during reperfusion in the cat (Nishikawa et al, 1994).
Non-competitive antagonists
Non-competitive antagonists acting at the NMDA channel have also been widely 
investigated. A number of studies have reported that pre and post treatment with 
MK801 is protective against ischaemic damage in focal ischaemia (Park et al, 1988, 
Gill et al, 1991). Some controversy existed regarding the effects of non-competitive 
antagonists in global ischaemia. MK801 pretreatment prevented hippocampal
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neurodegeneration following unilateral carotid occlusion in the hands of Gill et al, 
(1987), but no protection was observed by Buchan and colleagues against CA1 damage 
following transient forebrain ischaemia (1991). More recently Yao et al (1994) 
demonstrated that the volume of infarction was decreased in MK801 treated groups 
following incomplete but not complete ischaemia. It appears therefore that the efficacy of 
these agents is not due to the focality, but the severity of the insult. This suggests a 
minimum level of blood flow is required for anti-ischaemic efficacy and supports the 
ability to salvage tissue in regions of moderately severe ischaemia (penumbra) and, the 
lack of efficacy in densely ischaemic core regions (McCulloch et al, 1994).
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1 . 6 NMDA antagonists as clinically useful drugs
1.6.1 Safety and tolerability
Anti-ischaemic efficacy is only one element in the selection of drugs for clinical 
evaluation. Safety and adverse effects are also of paramount importance. While NMDA 
antagonists are the furthest advanced agents in clinical development for stroke treatment, 
the number of compounds advancing towards definitive proof of efficacy in the clinic has 
decreased. Clinical development of MK801, the agent with highest affinity for NMDA 
ion channels and the first consistently shown to be neuroprotective in vivo, was 
abandoned after safety concerns over changes in brain histology in the rat (Muir and 
Lees, 1995, see below).
1.6.2 Animal studies
Administration of NMDA antagonists produces a number of effects on physiological 
parameters (for review see McCulloch et al, 1992). Competitive and non-competitive 
NMDA antagonists decrease respiration and induce hypercapnia (Kurumaji et al, 1989). 
Non-competitive antagonists produce disparate effects on blood pressure, MK801 
administration increases blood pressure in conscious animals and decreases blood 
pressure in halothane anaesthetised animals. At high doses, competitive antagonists 
induce hypotension. Administration of NMDA antagonists also produces profound 
behavioural effects. Non-competitive antagonists produce disruption of learning and 
memory, ataxia, sedation and ultimately anaesthesia (Kurumaji et al, 1991). These 
effects are apparent at concentrations required for anti-ischaemic effects. Competitive 
antagonists produce similar behavioural effects but at concentrations 3-10 times greater 
than neuroprotective doses (Kurumaji et al, 1989).
Autoradiographic studies mapping changes in local cerebral glucose utilisation following 
administration of NMDA antagonists describe markedly dissimilar alterations in function- 
related glucose use for non-competitive and competitive agents (Kurumaji et al, 1989, 
1991). Non-competitive agents like MK801 produce dose-related increases in glucose
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utilisation throughout the limbic system and widespread decreases in the neocortex. 
Competitive antagonists (like DCPPene) induce small and anatomically circumscribed 
alterations in glucose utilisation in areas such as the hippocampus, olfactory areas, 
cerebellar nucleus and superior olives. These functional changes are thought to be 
predictive of morphological alterations, since the occurrence of transient neuronal 
vacuolation coincides with areas showing hypermetabolism. This dose-dependent, 
reversible swelling and vacuolisation in medium and large sized neurones within the 
cingulate and retrosplenial cortex following administration of non-competitive NMDA 
antagonists was first described by Olney and colleagues (1989). Similar effects were 
observed with competitive antagonists (CGS 19755) but at a much higher dose relative to 
the neuroprotective dose, compared to MK801 (Hargreaves et al, 1994).
1.6.3 Human studies
All competitive and non-competitive agents cause similar symptoms and signs in humans 
regardless of the pharmacology of action, if used in large enough doses. Selfotel (CGS 
19755) has been extensively investigated in normal subjects and patients with stroke 
(Grotta et al, 1995). While a single intravenous dose was well tolerated, higher doses 
produced agitation, hallucinations, confusion and paranoia. Low doses of non­
competitive antagonist cause altered sensory perception, dysphoria, hypertension, 
nystagmus and disorientation leading to agitation, paranoia, hallucinations, severe motor 
retardation and catatonia at higher doses (Muir and Lees, 1995).
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1.7 Development of a novel NMDA antagonist
1.7.1 Basic concepts
Molecules which are cation channel blockers generally possess 2 chemical characteristics, 
a cationic region, centered on a protonatable nitrogen and a hydrophobic region. Such 
agents need to possess a high enough affinity to be selective for the ion channel, but not 
so high that its effects cannot be reversed. A relatively short half life combined with good 
blood brain barrier permeability are also desirable (McBumey, 1997).
An extensive cross-reactivity exists between a  receptor ligands and ligands acting at the 
NMDA receptor ion channel and vice-versa. It was reasoned that chemical alterations to 
the chemical structure of N,N'-di-otolylguanidine (DTG), a potent a  site ligand, might 
generate compounds that were selective for the NMDA receptor ion channel over the a  
site (Reddy et al, 1994). More than 50 diarylguanidines were synthesised in an effort to 
find high affinity ligands for the NMDA ion channel. It was found that tri-and 
tetrasubstituted versions of N,N-dinaphthyl- and N-naphthyl-N'-(3-substitutedphenyl)- 
guanidines exhibited remarkably high affinity and selectivity for the NMDA receptor ion 
channel site. One of these compounds N-l-naphthyl-N'(3-ethylphenyl)-N’N- 
methylguanidine (aptiganel hydro-chloride, CNS 1102, Ceres tat®) was selected as a 
candidate for development as a treatment to limit ischaemic brain damage (Figure 6).
1.7.2 Preclinical studies
The efficacy of aptiganel has been demonstrated in vitro and in vivo. Aptiganel protects 
cultured neurons against exposure to glutamate (ED50 = 0.38|iM) at a concentration 
consistent with its affinity (Kj = 28nm) for the NMDA receptor. Aptiganel is also 
effective in reducing the volume of ischaemic damage (by 40-70%) produced by 
permanent MCA occlusion (Minematsu et al, 1993a, Cohen et al, 1994)) and reduces 
early postischaemic injury and improves perfusion in reversible ischaemia (Minematsu et 
al, 1993b).
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FIGURE 6  : Chemical structures of NMDA and a  site ligands
(a) MK801 (dizocilpine) : (+)-5-methyl-10,ll-dihydro-5i/-dibenzo[a,<f|cyclohepten 
5,10-imine and (c) CNS 1102 (Aptiganel, CERESTAT®): N-(l-naphthyl)-N’-(3 
ethylphenyl)methyl guanidine are ligands at the NMDA receptor ion channel.
(b) DTG : N,N'-di-cKolylguanidine is a a  site ligand
The pharmacokinetics of Aptiganel have been examined in a number of species 
(McBumey, 1997). Aptiganel distributes rapidly into a large volume of distribution. The 
plasma has life of aptiganel is approximately 60 minutes in rat and 90 minutes in non­
human primates. Six minutes after administration of [14C] Aptiganel hydrochloride, the 
level of radioactivity within the brain was approximately 12-fold higher than in plasma. 
All the radioactivity within the brain could be attributed to the parent compound.
1.7.3 Clinical studies
The safety and tolerability of Aptiganel in normal volunteers has been examined 
clinically. The most common side effects reported were dizziness, numbness and 
increased heart rate and blood pressure at higher doses. All effects subsided without 
medical intervention (Muir et al> 1994).
It appeared from these results that Aptiganel was well positioned to advance to a 
definitive test of the hypothesis that NMDA antagonists can limit the extent of brain 
damage. A statistically significant beneficial effect on the outcome of drug-treated 
patients would provide support for the concept of neuroprotection.
The international stroke trial was initiated in July 1996 and was designed to examine 
efficacy. However, the acquisition of new patients into this Phase HI trial was stopped in 
June 1997, when concerns were raised during an interim analysis of data over the benefit 
to risk ratio of the drug treatment (Reuters, June 1997). In September, 1997, Cambridge 
Neuroscience Inc. announced the discontinuation of their 500 patient Phase m  traumatic 
brain injury clinical trial. While interim analysis of the data showed the drug was safe 
and well tolerated on a number of safety parameters, there was insufficient evidence if its 
clinical efficacy. Despite the forward looking statements included in the press release 
such as the continuation of data analysis for possible future clinical development and to 
"explore the viability of other clinical applications" the effect of these announcements on 
the value of the company stock was undeniable (Reuters, PR Newswire, September 
1997).
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The NASDAQ forecast from recent months (Figure 7) shows a marked drop in share 
prices and a consequent increase in the volume of shares available on the market 
corresponding to the stroke trial press release at the end of June and the discontinuation 
of the TBI trial in Sepember, culminating in an overall 6 -fold decrease in share prices. 
The impact of the failure of Aptiganel highlights both the profound financial interest in 
the development of an effective neuroprotective therapy and, the clinical requirement for 
such an agent.
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Share Price ($ )
- 1 5 . 0 0
- 1 4 . 0 0
- 1 3 . 0 0
- 1 2 . 0 0
- 1  1 . 0 0
- 1 0 . 0 0
- 8 . 0 0 0
- 7 . 0 0 0
- 6 . 0 0 0
4 . 0 0 0
— 3 . 0 0 0
FIGURE 7 : Cambridge NeuroScience Inc share prices from Oct ‘96 to Sept ‘97
The solid line shows the change in Cambridge NeuroScience Inc. share prices ($) in 
relation to the average stock price on the NASDAQ market index (broken line). Marked 
decreases in value were observed in July 1997 and in September 1997, which 
correspond to announcements of the termination of the traumatic brain injury and stroke 
clinical trials of Cerestat (CNS 1102)
1.8 Receptor imaging in the central nervous system
No other factor has influenced the study of receptors more than the development of 
tritiated and radioiodinated ligands with high affinity and specific activity for target sites. 
This ability to localise radioactivity labelled compounds in thin sections of tissue by 
autoradiography offers the opportunity to study drug receptors with good spatial 
resolution. Localising neurotransmitter receptors by autoradiograpic techniques has 
several important applications. It allows a unique view of the biochemical organisation of 
the brain and it provides an adjunct to histochemical methods for the study of 
neurotransmitters per se. Autoradiography can also be used as a neuropathological tool, 
since receptors are primarily localised to neurons and receptor changes may reflect 
underlying pathological processes (Kuhar, 1986).
1.8.1 Autoradiography
The NMDA receptor subtype of glutamate receptors has been subject to intense 
investigation due to its key role in a variety of physiological and pathophysiological 
processes. Radioligand binding studies have contributed to the understanding of ligand 
interactions at a number of ligand binding sites on the NMDA receptor complex. The 
most potent and selective ligands for NMDA receptors are those which bind non- 
competitively to a site within the associated ion channel e.g. [3H ] l - [ l- (2 -  
thienyl)cyclohexyl]piperidine (pH]TCP) and [3H]MK801. The utility of these ligands is 
partly dependent on their use-dependency and sensitivity to the state of activation of the 
receptor (Hosford et al, 1990* MacDonald and Nowak, 1990).
Quantitative localisation of [3H]TCP binding to rat brain sections (Sircar and Zukin,
1985) showed a distribution pattern of binding sites that was similar to that observed with 
[3H]phencyclidine (PCP), but more sharply defined. Highest levels were observed 
within the hipocampus and intermediate levels in the frontal cortex, striatum, amygdala 
and cerebellum. No specific binding was observed within the corpus callosum.
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The application of autoradiography to map the distribution of drug receptors in target 
tissues depends on the ability to demonstrate specific receptor binding. Further studies 
confirmed a striking similarity between the relative density of [3H]TCP and NMDA 
receptor binding sites labelled with L-[3H] glutamate (r = 0.95, p < 0.001, Maragos et al,
1986), while Jarvis and colleagues (1987) showed a significant relationship existed 
between binding sites labelled by the competitive NMDA antagonist [3H]CPP and 
[3H]TCP (r = 0.88, p < 0.01).
The underlying aim of these studies was to develop a radioligand which could ultimately 
be used to investigate the role of NMDA receptors in a number of neurological diseases in 
man and, the majority of attention focused on MK801, the most potent compound at the 
channel binding site. Early studies with [3H]MK801 in rat brain sections confirmed that 
this ligand produced a map of binding sites which corresponded to the map of NMDA- 
type glutamate receptors obtained with L-[3H]glutamate (Bowery et al, 1988). Specific 
[3H]MK801 binding was prevented by PCP and ketamine. The distribution of 
[3H]MK801 binding sites was similar to that previously described for [3H]TCP, with 
highest levels in the hippocampal formation, cerebral cortex, olfactory bulb and thalamus 
and low levels in the cerebellum and hypothalamus. This data was supported by the 
uneven distribution of [3H]MK801 binding sites observed in rat brain membranes (Wong 
et al, 1988). A decrease in the density of [3H]MK801 binding sites within CA1 region of 
the hippocampus after unilateral carotid artery occlusion indicated that their presence was 
vulnerable to ischaemia (Bowery et al, 1988). More recently, [3H]dextrorphan 
recognition sites have been characterised in rat brain. [3H]dextrorphan binding is 
localised to the same site as MK801 and TCP and is both glutamate and glycine 
dependent (Franklin and Murray, 1992). The distribution of [3H]dextrorphan binding 
sites is similar to that reported for [3H]MK801, with the greatest levels of binding within 
the hippocampus and intermediate levels within the cortex, thalamus and striatum (Roth 
etal, 1996).
The criteria for receptor binding in in vivo imaging studies is similar to those for in vitro 
homogenate binding studies. The receptor site should be saturable by the radioligand of
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interest and, increasing doses of unlabelled ligand should reduce the binding of the 
radiolabelled ligand in a dose-dependent fashion. Appropriate competition by various 
receptor ligands known to bind to the receptor of interest should be demonstrated. The 
regional distribution of the radioligand should be consistent with the known pattern of 
receptors.
Wallace et al (1992) used quantitative autoradiography to assess the in vivo uptake of 
pH]MK801 and to compare it with in vitro pH]MK801 binding after focal ischaemia. 
These investigations showed that in vitro binding does not determine the in vivo uptake 
of [3H]MK801. Fifteen minutes post-ischaemia, in vivo uptake of [3H]MK801 was 
similar to cerebral blood flow autoradiograms obtained with [14C]iodoantipyrene, with 
uptake in regions of middle cerebral artery territory approximately 75% lower than 
contralateral regions. At 60 minutes, [3H]MK801 uptake was 60% greater in middle 
cerebral artery territory than in contralateral region. The increased levels of [3H]MK801 
in ischaemic areas is consistent with the effect of glutamate on [3H]MK801 binding to the 
NMDA receptor complex in synaptosomes (Foster and Wong, 1987). Uptake was 
therefore determined by both the regional density of receptors (little uptake was observed 
within white matter) and, local extracellular glutamate concentrations. pH]MK801 
uptake in areas outwith the middle cerebral artery territory was different from in vitro 
autoradiograms, no laminar heterogeneity in pH]MK801 uptake was observed within 
the contralateral cortex.
In vitro, the concentrations of glutamate and glycine are relatively constant, therefore 
autoradiograms reflect the regional heterogeneity of NMDA receptors. These 
observations suggest that in vivo, at constant glutamate levels, factors other than the 
number of.receptors (lipophilicity) influence local radioisotope levels and uptake reflects 
receptor activation. An increase in extracellular pH has been shown to increase the rate of 
association and dissociation of pH]MK801. This supports the hypothesis that the rates 
of pH]MK801 binding are controlled by the level of activation of the NMDA receptor 
(Rajdev and Reynolds, 1993)
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A number of problems have been described using tritiated ligands in autoradiography. 
Significant tissue quenching or absorbtion occurs due to the low energy of the (3 
emissions produced by tritium. The amount of energy reaching the film emulsion is 
dependent on the density of material from which the (3 particle is emitted. White matter 
has a higher density than grey and therefore produces more quenching (Kuhar and 
Unnerstall, 1985). A long exposure time (4-8 weeks) is also required due to the low 
energy (3 emissions. In addition to these problems, [3H]MK801 binding has been 
reported to be differentially modulated by the presence of divalent cations, implying this 
ligand is unsuitable for the study of NMDA receptors in intact cellular systems (Enomoto 
et aly 1992). Iodinated analogues of MK801 have preferential properties over 
[3H]MK801. The higher energy of some emissions from 125I overcome the problems of 
quenching and, the extremely high specific activity of iodinated ligand allows 
visualisation of autoradiograms with high anatomical resolution following 24-48 hours of 
exposure (Jacobson and Cottrell, 1993). Iodo-MK801 is also relatively insensitive to the 
inhibitory actions of divalent cations (Rajdev and Reynolds, 1992).
The use of (+)-3-[125I]iodo-MK801 ([125I]MK801) to study in vivo labelling of the 
NMDA receptor complex in the normal rat brain was described by Gibson et al (1992). 
At 15 minutes, the pattern of [125I]MK801 uptake was essentially the same as that 
obtained using a blood flow tracer. Blockade of [125I]MK801 uptake by unlableeled 
MK801 was demonstrable, when examined 4 hours post-injection. No blockade was 
observed at times before 4 hours. While in vitro autoradiography was consistent with 
previous reports on NMDA receptor distribution this study provided no systematic 
validation of the [125I]MK801 binding site as a true receptor. Jacobson and Cottrell 
(1993) showed that [125I]MK801 binding to thin sections could be displaced by 
(+)MK801 but not by (-)MK801. Binding was also displaced by PCP but not by 
naloxone, GABA or kainic acid. [125I]MK801 binding was completely eliminated by 
heat treatment, providing further evidence of binding to a traditional receptor.
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The utility of [125I]MK801 in pathological situations was examined by McCulloch et al 
(1992). In the presence of increased glutamate concentrations [125I]MK801 binding to 
normal and ischaemic tissue is increased. Following MCA occlusion, the initial uptake of 
[125I]MK801 reflects cerebral blood flow. At later time points the retention of the tracer 
is increased within the MCA territory, reflecting the elevated concentrations of glutamate 
in ischaemia and the glutamate dependence of MK801 binding (McCulloch et al, 1992). 
Coadministration of MK801 significantly reduced [125I]MK801 in ischaemic areas and 
only slightly in non-ischaemic areas. It was concluded from these results that highly 
lipophilic agents such as MK801 are not suitable in vivo ligands in the normal brain, due 
to high non-specific binding and a failure to reliably demonstrate displacement. The 
enhanced uptake in ischaemic areas appears to map the extent of NMDA receptor 
activation (increased uptake in areas of increased extracellular glutamate) implying 
[125i]MK801 autoradiography can be used to map dynamic processes, providing a 
strategy for defining the localisation of areas of NMDA receptor activation.
1.8.2 SPECT and PET
Postmortem autoradiographic studies of human brain receptors are flawed by 
methodological limitations such as small population samples, conditions of death, 
premortem effects of drugs, and postmorten or age-related non-specific receptor changes. 
In vivo characterisation of receptor density and functional state would preclude most of 
these limitations.
Two main categories of functional imaging exist PET (Positron Emission Tomography) 
and SPECT (Single Photon Emission Computed Tomography), based on the properties of 
the radionuclides used. Positron emitting radionuclides decay releasing a positively 
charged particle (P+). This positron interacts rapidly with a neighbouring electron and 
emits two 51 IKeV photons 180_ apart. A single photon is a y radiation usually emitted 
in random directions. The imaging devices, positron scanners and single photon cameras, 
measure the location and density of different y rays emitted by PET and SPECT ligands 
respectively. While PET imaging has higher sensitivity and a better quantification
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capacity, SPECT imaging is more readily available and does not require a local cyclotron 
to manufacture radioligands.
The majority of routine imaging procedures are performed using single photon 
radionuclides in conjunction with gamma cameras or single photon emission computed 
tomography (SPECT). Technetium (99mTc) is the most widely used, in over 85% of 
imaging procedures (for review see Kung, 1993, Masdeu et al, 1994), however Iodine-123 
with a half life of 13 hours and 159KeV y rays is also well suited for SPECT imaging. 
The most widely used radiopharmaceuticals targeted to the brain generally measure 
perfusion and are detailed below (Gibson et al, 1993). A less common application of 
[123I]iodoamphetamine has been to image patients with systemic lupus erythematosus. 
Scans from patients with psychiatric manifestations of the disease showed areas of 
hypoperfusion (Kodama et al, 1995)
Target Radiopharmaceutical Parameter measured
Brain [99mTc]HMPAO relative cerebral blood flow
[ " mTc]ECD relative cerebral blood flow
[123I]iodoamphetamine relative cerebral blood flow
["mXcjDTPA lesions (stroke, tumours)
In addition to their use in determining perfusion, the non-invasive imaging techniques of 
nuclear medicine provide a powerful tool to map biochemical interactions in man with 
high sensitivity and can be used in the discovery and development of new drugs. An 
important application of these imaging techniques is to monitor the occupancy of 
receptors by therapeutic drugs and to relate the findings to clinical status, providing a 
better adjustment of drug dosage and an indication of therapeutic efficacy. So far the 
measurement of receptor occupancy has been most extensively applied to the study of 
anti-psychotic drug binding (Farde, 1996).
Baron et al (1985) were among the first to demonstrate the feasibility of studying specific 
receptors in the human brain with PET, using [* iCJpimozide to label dopamine receptors. 
More recently, clinical studies have been carried out using iodinated benzamide
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derivatives to image D2 dopamine receptors, especially [123I]iodobenzamide (IBZM,
Kung et al, 1990). [123I]IBZM SPECT images have been useful in relating antipsychotic 
drug D2 receptor occupancy with the administered dose in schizophrenic patients,
showing qualitatively diminished activity in the basal ganglia following haloperidol 
treatment (Vallabhajosula et al, 1997).
The number of radioligands for imaging neuroreceptors systems is increasing and it is 
now possible to image GABAa receptors using [123I]Iomazenil (Busatto et al, 1994) and
muscarinic cholinergic receptors, among others. [123I]quinuclidinylbenzilate (QNB) has 
been employed to image muscarinic receptors. Kinetic modelling indicated that this 
ligand take a long time (approximately 18 hours) to reach optimal specific to non-specific 
binding ratios. Clinical studies in Alzheimer patients have shown that deficit regions 
could be visualised by RS-QNB. Much effort has been applied to the development of 
other stereoisomers of QNB with lower affinity for the receptor which may produce 
imaging agents which are more readily displaced by endogenous transmitter. More 
recently [123I]Iododexetamine has been reported as a potential SPECT ligand to image 
muscarinic receptors (Boundy et al, 1995)
Much interest has been devoted to the development of radiotracers with the ability to trace 
NMDA receptor activation and ongoing neurodegenerative processes. The whole 
understanding of excitotoxicity in man is largely based on extrapolation from rodent data, 
so clarification of the mechanisms involved in man would help assess neuroprotective 
agents in clinical trials.
The first PET studies, TCP and a number of analogues were fluorinated to provide 
potential in vivo radioligands for the NMDA receptor. l-(l-[5-(2'-[18F]fluoroethyl)-2- 
thienyl]-cyclohexyl)piperidine ([18F]FE-TCP) showed heterogeneous distribution in the 
brain following intravenous administration in the rat which was similar to the know 
distribution of PCP-labelled sites (Blin et al, 1989). Brain regions were normalised to the 
cerebellum and ratios for CA1, striatum and cortex were 2.08, 1.7 and 1.5 respectively 15 
minutes after administration. This localised regional cerebral distribution was blocked by 
coinjection of unlabelled FE-TCP with largest reductions observed within the 
hippocampus followed by the striatum and cortex. It was suggested that the
low affinity for the NMDA receptor and the high non-specific binding (due to 
lipophilicity) may make this an unsuitable radioigand for PET investigations of the 
NMDA receptor complex. Fluorinated analogues of TCP such as l-[l-2-thienyl)-4- 
([l8F]fluoro)-cyclohexyl]-l, 2, 5, 6 , tetrahydropyridine showed good uptake into rat brain 
following intravenous injection (Ouyang et al, 1996). However specific uptake improved 
only marginally with time compared to the cerebellum. Preliminary PET studies in the 
Rhesus monkey showed good uptake but little retention in receptor rich areas. (1S*,2R*)-
2-(hydroxymethyl)- and (IS*,2R*)-2-(methoxymethoxymethy 1)-1 -(N-piperidy 1) -l-[2-(2'- 
[18F]fluoroethyl)thiophenyl]cyclohexane also showed no selective accumulation of 
radioactivity (Shibayama et al, 1996).
Other studies investigated analogues of MK801 to image the NMDA receptor complex, 
Orita etal (1993) used 5b-fluoroethyl-MK801 ([18F]FE-MK801), labelled with 18F. The 
in vitro affinity of this ligand was similar to that of MK801, IC50 for displacing [3H]TCP
binding to homogenates was 20nM. Fifteen minutes after intravenous injection uptake 
ratios (relative to the cerebellum) for cortex and striatum were 1.1 and 1 .6  respectively. 
The uptake of [18F]FE-MK801 was also examined in non-basal conditions. Pretreatment 
with PCP did not measurably decrease specific binding. Transient arterial hypoxia was 
used to induce acute glutamate release in an attemp to increase specific binding to open 
receptors, however no clear cut increase in specific binding was observed.
The synthesis of (+)-3-[123I]MK801 with high purity and good yield provided the potential 
to imaging of NMDA receptor activation in man by SPECT (Owens et al, 1997). Clinical 
assessment of [123I]MK801 was carried out in 5 patients, 4 with subarachnoid 
haemorrhage and 1 with intracranial haemorrhage. All patients had clinical indications of 
ischaemia and images were taken at post-ictus times between 1 and 5 days. Initial uptake 
of [123I]MK801 into the ipsilateral hemisphere was decreased which was consistent with 
reduced blood flow. In 2 patients increased retention of [123I]MK801 was observed at 
later time points in cortical areas adjacent to the site of the haematoma, consistent with 
receptor activation. The remaining three patients displayed no evidence of increased
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retention. These results propose that it may be possible to image excessive NMDA 
receptor activation following an ischaemic episode. The utility of this tracer is limited by 
the high lipophilicity and reported non-specific accumulation in white matter areas. 
[123i]MK801 is therefore not a suitable agent for imaging in the normal brain, or to 
image moderate alterations in NMDA receptor activation. An agent with lower 
lipophilicity is therefore necessary to pursue further investigation of glutamate NMDA 
receptor mediated processes in the human brain
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1.9  Synthesis of A -(l-N ap thyI)-A '-(3 -[125I]iodophenyl)-/V , - 
methylguanidine ([125I]CNS 1261)
Development of a suitable radioiodinated agents for use as NMDA radiotracers in SPECT 
would provide a valuable tool to investigate mechanisms of excitotoxicity in man and to 
evaluate neuroprotective therapies. To this end, an analogue of N-(l-napthyl)-N'-(3- 
ethylphenyl)-A'-methylguanidine (Cerestat, CNS 1102), N-(l-napthyl)-Af'-(3- 
[125I]iodophenyl)-N'-methylguanidine ([125I]CNS 1261), was synthesised by J. Owens 
and A.Tebbutt at the West of Scotland Radioisotope Dispensary, Glasgow, Scotland, as 
a potential radioligand to image NMDA receptor activation in vivo. Radioiodination of 
the iodine moiety on the phenyl ring of CNS 1261 produced a radioligand with high 
specific activity which is suitable for in vivo autoradiography.
Precursor synthesis
The synthetic route to //-(l-naphthyl)-//’-(3-tributylstannylphenyl)-N’-methyl- 
guanidine (3) is summarised in Figure 8, scheme 1.
3-Iodo-N-methylaniline (1) was prepared in a 79% overall yield by protection with 
formic acid followed by a borane reduction. N  -methyl-3-tributylstannylaniline (2) 
was synthesised in 71% yield using a palladium catalysed substitution with 
hexabutylditin. It was found necessary to use the free base of N-methyl-3-Iodo-aniline 
(1) to ensure reasonable yields (> 70 %), if the hydrochoride salt was used the product 
yield decreased substantially. Synthesis of N - ( l - n a p h t h y l ) - N ’- (3 -  
tributylstannylphenyl)-//'-methyl guanidine (3) was achieved by the acid catalysed 
addition of N-methyl-3-tributylstannylaniline (2) to 1-naphthylcyanamide (5). A low 
yield (20 %) was recorded due to competing protodestannylation.
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Chemistry
Scheme 1
NH2
(X
(a) i. formic acid, toluenne ii. BH3.THF
(b) Pd(PPh3)4, (SnBu3)2
(c) H+, 1-naphthylcyanimide
Radiochem istry
Scheme 2
NHChL NHCH,
A" „ A . 'SV?-.IX ~iX    hnt nw
SnBu3 NH
(1) (2) (3)
FIGURE 8 : Synthesis of [l25l]CNS 1261
Radiochemistry
Electrophilic iododestannylation and iododesilylation provide an effective method for the 
introduction of iodine into complex organic molecules with high specific activities. 
Various oxidants have been used including Chloramine-T, N-chlorosuccinimide, 
iodogen, and peracetic acid.
Radioiodinated [125I]CNS 1261 (4) was prepared by iododestannylation of N-(l- 
naphthyl)-N’-(3-tributylstannylphenyl)-N’-methylguanidine (3). Peracetic acid as the 
oxidant consistently gave the best results, with a 59 % isolated radiochemical yield and > 
99 % radiochemical purity after semi-preparative HPLC purification, with a synthesis 
time of 1 h (Figure 8, scheme 2). Aliquots of the [125I]CNS 1261 were dried under a 
stream of nitrogen and reconstituted in physiological buffer as required.
CHAPTER n  
METHODS
2.1 Affinity and selectivity of CNS 1261
2.1.1 Whole crude synaptosomal membrane (WCSM) preparation
Frozen whole rat brains were thawed on ice, cerebella and brain stems were removed and 
the forebrains placed in ice cold 0.32M sucrose and weighed. 2-3 forebrains were 
transferred to 40ml fresh 0.32M sucrose then homogenised with a teflon-glass 
homogeniser (Thomas C) for 8 strokes on setting 3.
The homogenate was centrifuged in a J6-B Beckmann centrifuge at 1,000 x g for 10 
minutes at 4°C. The supernatant was decanted and centrifuged in the J2-21M Beckmann 
centrifuge at 20,000 x g for 20 minutes at 4°C.
The pellet was pooled and resuspended in 40ml ice-cold Milli-Q purified H20 and 
homogenised (Brinkmanm polytron) for 30s. The homogenate was then centrifuged at
8.000 x g for 20 minutes at 4°C. The upper third layer of supernatant and the upper 
buffy coat (upper tannish layer of pellet) were pooled and homogenised for 30s, then 
decanted into 40ml tubes for centrifugation at 48,000 x g for 10 minutes at 4°C.
The pellet was resuspended in 20ml of ice-cold 50mm Tris acetate, pH 7.4 and 
homogenised for 10s. Another 20ml of Tris acetate was added to the homogente, mixed, 
then centrifuged at 48,000 x g for 10 minutes at 4°C. The pellet was resuspended in 
20ml 50mm Tris acetate, homogenised for 10s and diluted 1:10 with artificial 
cerebrospinal fluid (ACSF) assay buffer (final composition: 147mm NaCl, 2.5mm KC1, 
2.5mM CaC12, 1.3mm MgC12, and 10mm HEPES, brought to pH, 6.4, 7.4 or 8.4 at 
room temperature with NaOH). 1% Triton X-100 was added to a final concentration of 
0.01% and the tubes were vortexed then incubated at 37°C for 15 minutes.
An additional 20ml of ACSF assay buffer was added and the homogentate allowed to 
cool on ice for 10-15 minutes before it was centrifuged at 48,000 x g for 10 minutes at 
4°C. The resulting pellet was resuspended in 20ml ACSF assay buffer, homogenised for 
5s, then a further 20ml ACSF assay buffer added. The homogenate was centrifuged at
48.000 x g for 10 minutes at 4°C. The protein content of the pellet was determined after 
a further two further cycles of washing.
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2.1.2 Assay procedure
The binding assay was performed in triplicate in a total volume of 500pl Glutamate and 
glycine were added at a concentration of l|im each in 5mM Tris acetate and at IOjiM 
each in ACSF assay buffer to maximally stimulate [3H]MK801 binding. [3H]MK801 
was added at a final concentration InM in Tris acetate buffer and at 12nM in ACSF buffer 
in the presence or absence of various concentrations of CNS 1261. The binding reaction 
was initiated by adding lOOjig of WCSM preparation to each tube, vortexing the tubes 
and incubating for 4 hours at room temperature.
The incubation was terminated by rapid filtration under vacuum through glass fibre filters 
(presoaked in 0.05% PEI for 45 minutes), followed by three 4ml washes, using a 
Brandel 48-well cell harvester. Filters were transferred to vials and 5ml of Cytoscint ES 
scintillation cocktail added. Vials were shaken for 15 minutes prior to counting. 
Non-specific binding was defined as binding measured in the presence of glutamate, 
glycine and IOjiM PCP. This value was subtracted from all other conditions to yield 
specific binding.
IC50 values and Hill coefficients were calculated in RS-1 (BBN Software products) by 
fitting displacement curves using non-linear least squares regression analysis. The 
association affinity constant (KO was calculated using the Cheng-Prusoff equation:
Ki = IC50 / 1 + ([[3H]MK801] / Kd)
where the [3H]MK801 concentration = InM in Tris acetate, 12nm in ACSF assay buffer.
2 .1 .3  Commercial screening of CNS 1261
The effect of CNS 1261 on the binding of ligands to the NMDA receptor, and to other 
neurotransmitter receptors was further investigated by submitting the compound for 
commercial screening (NovaScreen, Maryland, USA). The effect of two doses of CNS 
1261 (lOnM and ljiM) were examined in a total of 42 radioligand binding assays.
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The individual protocols for each of the 42 binding assay are not detailed here, however a 
brief outline of the basic assay procedure is detailed below.
Binding assays were performed in duplicate under conditions known to maximally 
stimulate binding of the radioligand of interest. Radioligands were added in a final 
concentration of 0.5-20nM in the appropriate buffer in the presence or absence of various 
concentrations of CNS 1261. In the absence of CNS 1261 all radioligands displayed 
between 60 and 90% specific binding. The binding reaction was initiated by adding an 
aliquot of receptor preparation (generally rat forebrain membranes) to the assay mix. 
Reactions were terminated by rapid filtration onto glass fibre filters. Radioactivity 
trapped onto the filters was determined and compared to control values in order to 
assertain any interactions of CNS 1261 with the binding site in question. ‘Activity* was 
defined as > 50% inhibition of radioligand binding. Assays in which activity was 
detected were repeated twice to confirm findings.
2 .2  Effect of CNS 1261 on local cerebral glucose utilisation
2 .2 .1  Surgical preparation of animals
Rats were initially anaesthetised with 5% halothane in a nitrous oxide and oxygen gas 
mixture (70%:30%). Anaesthesia was subsequently maintained by administration of 0.5- 
1% halothane via a face mask. The femoral vessels were exposed bilaterally by blunt 
dissection. Polyethylene cannulae (Portex, external diameter 0.96mm, internal 0.58mm, 
15cm long) were inserted approximately 2cm into the femoral arteries and veins and 
secured by silk threads. Incision sites were infiltrated with local anaesthetic gel 
(Xylocaine, 2%), sutured and covered with gauze pads. Animals were covered using a 
surgical stocking and a plaster of Paris bandage (Gypsona, Smith and Nephew Medical 
Ltd.) applied to the pelvis and lower abdomen to immobilise the animal. Care was taken 
to avoid restriction of thoracic movements. The plaster was taped to a lead brick for 
support At this point the halothane was discontinued and the animals allowed to recover 
for at least 2 hours before any further manipulations were performed. A pressure 
transducer was connected to one femoral artery in order to measure arterial blood
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pressure. Animals were maintained normothermic by means of a rectal thermometer and 
an external heating lamp.
2 .2 .2  The [14C]2-deoxygIucose technique
Local rates of cerebral glucose use were measured in conscious rats using the method 
developed by Sokoloff (1977). The procedure was initiated by an intravenous injection 
of [14C]2-deoxy glucose (specific activity 55mCi/mmol, 50p.Ci in 0.7ml) at a constant 
rate over 30 seconds. Fourteen timed arterial blood samples (100|il) were taken over the 
subsequent 45 minutes and immediately centrifuged. Plasma aliquots were assayed to 
determine 14C and glucose concentrations by means of scintillation analysis and semi­
automated glucose oxidase enzyme assay (Beckman, Glucose Analyzer 2) respectively. 
Further arterial blood samples were taken at predetermined intervals before and after 
tracer administration for analysis of pCC>2, pC>2 and pH using a blood gas analyser (Ciba 
Coming, Blood gas system 288). Forty-five minutes post-tracer administration, animals 
were killed by decapitation. Brains were removed, frozen in isopentane at -42°C and 
processed for quantitative autoradiography.
2 .2 .3  Preparation of autoradiograms
At the end of the 45 minute experimental period, rats were decapitated and the brains 
removed. Brains were frozen in isopentane chilled to -42°C for ten minutes. Frozen 
brains were mounted onto microtome chucks using embedding matrix (Gurr) and covered 
in cryoprotectant (Lipshaw). The entire procedure was performed within 5 minutes of 
decapitation. Brains were stored at -20°C (for no longer than 3 days) prior to being cut 
into 20|im coronal cryostat sections. Triplicate sections were collected at 200|im 
intervals throughout the brain. Sections were thaw-mounted onto heated glass cover 
slips and dried rapidly on a hot plate at 60°C. The coverslips were then glued onto card. 
Autoradiograms were generated by exposing the sections together with precalibrated 
epoxy resin 14C standards (11 standards with concentration range 44-1886nCi/g tissue 
equivalents) to Biomax film (Kodak) in light tight cassettes for 7-14 days. At the end of
55
the exposure time film were developed manually in LX-24 X-ray developer (Kodak) for 
5 minutes. Development was stopped by a 30 second rinse in Indicator stop-bath (85% 
acetic acid, Kodak). After fixing for 10 minutes (FX-40 fixative, HX-40 hardener, 
Kodak), films were washed for 30 minutes in filtered running water. Films were briefly 
rinsed in Photo-flo glaze (Kodak) and suspended in a drying cabinet.
2.2.4 Quantification of autoradiograms
Autoradiograms were analysed using a computer based image analysis system (M4 
MCID, Imaging Research Inc.). The optical densities of images produced by 
precalibrated epoxy resin 14C standards were measured providing a calibration curve of 
optical density against isotope concentration and allowing subsequent quantification of 
tissue isotope concentration for 36 regions of interest in nCi/g. In general six bilateral 
readings were taken from sections where structures could be identified from the rat 
brain atlas of Paxinos and Watson (1986).
Sokoloff and colleagues (1977) described a theoretical model based on an operational 
equation (Figure 9) where the rate of glucose utilisation can be calculated from (1) the 
levels of glucose and [14C]2-deoxyglucose in the plasma during the experimental period 
and (2) the total concentration of 14C within a given region at the end of the experiment, 
provided the values of predetermined constants are known.
Standard values for the rate constants ki* , k2*, k3* and K are detailed below 
grey matter white matter
ki* 0.189 0.079
k2* 0.245 0.133
k3* 0.052 0.020
Lumped constant (K) 0.483
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Ci * (T) - ki * e “(k 2* + k 3 * ) T I Cp* e ' ( k 2* + k 3 * )1 dt
J 0
Ri = ----------------------------------------------------------------------------------------
K  [I  T(C p*/C p ) dt - e  - (k 2* +  k 3 * )T  ■ I T (C p * /C p )  e  “(k 2 * +  k 3 * > 1 dt]
J 0 J o
FIGURE 9 : The Operational Equation
The rate of glucose utilisation (Ri) in any region of cerebral tissue is calculated from 
Q * , the total tissue concentration of 14C in that region measured by densitometry at the 
end of the experiment (T).
Cp* and Cp , the concentrations of [14C]2-deoxyglucose and glucose in the plasma at 
given times throughout the experiment (t).
ki*, k2* and k3 *, the rate constants for deoxyglucose transport to and from the plasma 
and tissue precursor pools and for the phosphorylation of deoxyglucose by hexokinase.
K , the lumped constant (Sokoloff et al, 1977)
2 .2 .5  Experimental protocol
Prior to drug administration animals were prepared for [14C]2-deoxyglucose 
autoradiography as described in section 2.2.1. The 2-deoxyglucose procedure was 
performed according to protocol outlined in section 2.2.2 after the injection of the 
following compound. CNS 1261 (1, 3 and lOmg/kg) was administered by intravenous 
injection at a constant rate over 1 minute, 15 minutes prior to the administration of 2- 
deoxyglucose. Control animals received an intravenous injection of saline 15 minutes 
prior to tracer injection.
2 .2 .6  Data analysis
«
LCGU values measured in 36 regions of interest following intravenous injection of CNS 
1261 (1,3 and lOmg/kg) were compared with LCGU values of corresponding regions 
on control animals for multiple comparisons. One-way analysis of variance (ANOVA) 
was used initially to identify the anatomical regions in which significant alterations in 
glucose use occurred, followed by independent Student's t-tests to identify the drug 
groups producing significant changes relative to control values.
A Bonferroni correction factor was applied to probability values from the t-tests, to take 
into consideration the multiple comparisons between treated and control groups.
2 .2 .7  /  ranking
Alterations in glucose utilisation produced by CNS 1261 admimistration were compared 
to those of MK801 (from an experiment performed by Kurumaji et al, 1989) by 
examination o f"/" ranking function values generated in each region independently for 
the effects of CNS 1261 (1,3 and lOmg/kg) or MK801 (0.05.0.5 and 5mg/kg).
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"f" is an arithmetic function which provides an index of the degree of responsiveness of 
each CNS region to each of the 2 drugs, taking into consideration the entire dose- 
response data available following administration of multiple drug doses (Forder al, 1985)
/ =  I  ( xc - xTi )2
Xc is the mean of loge (glucose use) for control group members
xxi is the mean of loge (glucose use) for the ith dose of the treatment group in question
T is either CNS 1261 (1, 3and lOmg/kg) or MK801 (0.1, 1 and lOmg/kg)
2 .3  In vivo [125I]MK801 autoradiography
2 .3 .1  Surgical preparation of animals
Rats were initially anaesthetised in a perspex chamber with 5% halothane in a nitrous 
oxide and oxygen gas mixture (70%:30%). A tracheotomy was performed and animals 
were artificially ventilated. Anaesthesia was subsequently maintained by administration 
of 0.5-1% halothane. The femoral vessels were exposed bilaterally by blunt dissection. 
Polyethylene cannulae (Portex, external diameter 0.96mm, internal 0.58mm, 15cm long) 
were inserted approximately 2cm into the femoral arteries and veins and secured by silk 
threads.
2 .3 .2  The [125l]MK801 technique
The amount of radioactivity in discrete brain regions after intravenous injection of 
[l25i]MK801 was measured in halothane anaesthetised rats by a modification of the 
technique described by McCulloch (1992).
The procedure was initiated by intravenous injection of [125I]MK801, specific activity 
2200Ci/mmol, at a constant rate over 30 seconds (200pCi in 0.8ml). Fourteen timed 
arterial samples (100|il) were taken over the subsequent 120 minutes and immediately 
centrifuged. Plasma aliquots were assayed to determine 1251 and glucose concentrations 
by means of liquid scintillation analysis and semi-automated glucose oxidase enzyme
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assay (Beckman, Glucose Analyzer 2) respectively. Further arterial blood samples were 
taken at predetermined intervals before and after tracer administration for analysis of 
PC 0 2, p0 2 and pH using a blood gas analyser (Ciba Coming, Blood Gas System 288). 
Blood pressure was monitored throughout the experimental period and animals were 
maintained normothermic by means of a rectal thermometer and external heating lamp. 
Animals were killed by decapitation 120 minutes after tracer administration and the brain 
removed and processed for quantitative autoradiography as described below in section 
2.3.3.
2 .3 .3  Preparation of autoradiograms
Brains were removed and frozen in isopentane chilled to -42°C for ten minutes. Frozen 
brains were mounted onto microtome chucks using embedding matrix (Gurr) and covered 
in cryoprotectant (Lipshaw). The entire procedure was performed within 5 minutes of 
decapitation. Brains were stored at -20°C (for no longer than 3 days) prior to being cut 
into 20|im coronal cryostat sections. Triplicate serial sections were taken at 200|im 
intervals throughout the brain. Triplicate sections were thaw-mounted onto heated glass 
coverslips and dried rapidly on a hot plate at 60°C. The coverslips were then glued onto 
card. Autoradiograms were generated by exposing the sections together with 1251 
microscales (10 standards in the concentration range 660-31300nCi/g tissue equivalents) 
to SB-5 or Biomax MR film (Kodak) in light tight cassettes for 7-21 days. At the end of 
the exposure time films were developed manually in LX-24 X-ray developer (Kodak) for 
5 minutes. Development was stopped by a 30 second rinse in Indicator stop-bath (85% 
acetic acid, Kodak). After fixing for 10 minutes (FX-40 fixative, HX-40 hardener, 
Kodak), films were washed for 30 minutes in filtered running water. Films were briefly 
rinsed in Photo-flo glaze (Kodak) and suspended in a drying cabinet
2 . 3 .4  Quantification of autoradiograms
Autoradiograms were analysed using a computer based image analysis system (M4 
MCID, Imaging Research Inc.). The optical density of images produced by precalibrated
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[125I] microscales were measured providing a calibration curve of optical density against 
isotope concentration in nCi/g, allowing subsequent quantification of tissue isotope 
concentration for the regions of interest in nCi/g. Six bilateral readings were taken from 
sections where structures could be identified from the rat brain atlas of Paxinos and 
Watson (1986).
Regional 125I concentrations (nCi/g) were corrected for isotope decay (60 day half-life) 
allowing direct comparison between non-contemporaneous experiments.
2 .4  In vivo [125I]CNS 1261 autoradiography
2 .4 .1  Surgical preparation of animals
Animals were prepared for [125I]CNS 1261 autoradiography according to the method 
described in section 2.3.1.
2 . 4 . 2  The [125I]CNS 1261 technique
The amount of radioactivity in discrete brain regions after intravenous injection of 
[125I]CNS 1261 was measured in halothane anaesthetised rats according to the technique 
described in section 2.3.2. for the [125I]MK801 procedure. However in this case, the 
procedure was initiated by intravenous injection of [125I]CNS 1261 (specific activity > 
2200Ci/mmol, 200|iCi in 0.8ml) over 30s.
2 . 4 . 3  Preparation of autoradiograms
Brains were removed and frozen in isopentane chilled to -42°C for ten minutes. Frozen 
brains were mounted onto microtome chucks using embedding matrix (Gurr) and covered 
in cryoprotectant (Lipshaw). The entire procedure was performed within 5 minutes of 
decapitation. Brains were stored at -20°C (for no longer than 3 days) prior to being cut 
into 20pm coronal cryostat sections. Triplicate sections were collected at 200pm 
intervals throughout the brain. Section were thaw-mounted onto heated glass coverslips 
and dried rapidly on a hot plate at 60°C. The coverslips were then glued onto card.
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Autoradiograms were generated by exposing the sections together with 1251 microscales 
(10 standards, concentration range 660-31300nCi/g tissue equivalents) to Biomax MR 
film (Kodak) in light tight cassettes for 5-9 days. At the end of the exposure, time films 
were developed manually in LX-24 X-ray developer (Kodak) for 5 minutes. 
Development was stopped by a 30 second rinse in Indicator stop-bath (85% acetic acid, 
Kodak). After fixing for 10 minutes (FX-40 fixative, HX-40 hardener, Kodak), films 
were washed for 30 minutes in filtered running water. Films were briefly rinsed in 
Photo-flo glaze (Kodak) and suspended in a drying cabinet.
2 .4 .4  Quantification of autoradiograms
Autoradiograms were analysed using a computer based image analysis system (M4 
MCID, Imaging Research Inc.). The optical density of images produced by precalibrated 
[125I] microscales were measured providing a calibration curve of optical density against 
isotope concentration in nCi/g, allowing subsequent quantification of tissue isotope 
concentration within regions of interest Six bilateral readings were taken from sections 
where structures could be identified from the rat brain atlas of Paxinos and Watson 
(1986). Regional 125I concentraions (nci/g) were corrected for isotope decay (60 day 
half-life) allowing direct comparison between non-contemporaneous experiments.
2 .5  Uptake and retention of [l^IJCNS 1261 and [125l]MK801 in 
normal rat brain
2 .5 .1  Experimental design
Animals were surgically prepared for in vivo autoradiography as described in sections
2.3.1. and 2.4.1. [125I]CNS 1261 or [125l]MK801 (200pCi, 0.8ml) was administered at 
time 0 and autoradiographic techniques were carried out as described in sections 2.3.2. 
and 2.4.2. Animals were killed 5, 30, 60 and 120 minutes after administration of the 
tracers and the brains removed and processed as detailed in section 2.4.3.
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2 .5 .2  Data analysis
[125I]CNS 1261 uptake (strictly the amount of radioactivity following intravenous 
injection of [125I]CNS 1261, in nCi/g) was measured in 37 discrete brain regions for 
each time point and corrected for isotope decay. The correceted values were expressed as 
a ratio of [125I]CNS 1261 uptake in regions of interest relative to [125I]CNS 1261 uptake 
within the cerebellum. Region of interest/cerebellar ratios for [125I]CNS 1261 were 
compared to corresponding ratios from animals receiving [125I]MK801by Student's 
unpaired t-tesL
2 .6  Relative lipophilicity of [125I]CNS 1261 and [125I]MK801
2 .6 .1  Calculation of LogD values for [l25I]CNS 1261 and [125I]M K801
Calculation of LogD values was carried out at Cambridge NeuroScience Inc. Precise 
experimental details were unavailable.
2.6.2. Calculation of brain/aqueous partition ratios
Male Sprague-Dawley rats were killed by an overdose of halothane and the brains 
removed and frozen in isopentane at -42°C for 10 minutes. Brains were stored, mounted 
on swivel-headed chucks at -20°C until required. Serial coronal sections (20jim) were 
cut at the level of the caudate nucleus and thaw mounted onto microscope slides.
Serial sections (20pm) were cut from a block of cortex from a human control brain. 
Sections were thaw-mounted onto microscope slides. White matter was removed from 
the sections by dissecting with a scalpel blade. Both rat and human sections were stored 
at -20°C until required.
Sections from rat and human brain were washed for 1 hour in 50mm Tris HC1 buffer, 
pH7.4 at 4°C. Total binding was assayed by applying 0.5nM [125I]CNS 1261 or 
[125j]MK801 in a volume of 0.2ml to each rat brain section (0.4ml for human sections). 
Non-specific binding was determined in adjacent sections using a solution containing 
0.5nM radiolabelled ligand and 0.5|iM unlabelled MK801. Aliquots of the incubation
62
solutions were taken for liquid scintillation analysis. Triplicate sections were incubated 
with their respective solutions for 2, 5, 10, 20, 30 or 60 minutes. Excess solution was 
poured off and the sections dipped in fresh buffer at 4°C. Sections were wiped from the 
slides using glass filter disks. The filters were placed in glass scintillation vials and 
allowed to dry overnight. Scintillation fluid was added to the vials and the amount of 
radioactivity bound assayed by liquid scintillation analysis
2 .6 .3  Data analysis
The amount of non-specifically bound radioactivity on each filter was expressed as nCi/g 
of brain tissue. The average weight of a brain section was obtained from the volume of 
the section (average area of the section, measured by MCID image analysis system, 
multiplied by the thickness of the section) assuming that the specific gravity of brain is 1. 
The brain/aqueous partition ratio (g/ml) at each time point was calculated by dividing the 
radioactivity bound per g of brain tissue by the amount of radioactivity present per ml of 
incubation solution at each time point
2 .7  Metabolism of [125I]CNS 1261 and [125I]MK801 in the rat
2 .7 .1  Determination of metabolites in rat plasma
Male Sprague-Dawley rats were anaesthetised with halothane and the left femoral artery 
and vein cannulated. Blood samples (1ml) were taken 5, 15, 60, 120 minutes after 
administration of 7.4MBq (200pCi) of tracer. The volume of blood removed at each time 
point was replaced by a slow intravenous injection of saline. Samples were immediately 
centrifuged and the plasma removed and stored on ice.
A 20fil aliquot of plasma was removed from each sample for gamma counting. 300pl of 
acetonitrile was added to 300|il of plasma from each time point Acetonitrile removes 
tracer which is weakly bound to protein (’bioavailable tracer'). The mixture was 
vortexed then centrifuged at 2000 x g for lOmin and the supernatant removed. 300fil of 
the supernatant was injected on to a 250 X 4.6mm Genesis C18 column (Jones
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Chromatography). The column was eluted with the following solvent system : 0.1% 
Trifluoroacetic acid in water; 0.1% trifluoroacetic acid in acetonitrile (50 / 50); flow rate 
lml / min., UV detection at 230nm, radionuclide detection set for 125I.
2 .7 .2  Determination of metabolites in rat brain
Animals were decapitated 120 minutes post intravenous injection of radioiodinated tracer 
and the brain removed and homogenised in lml of 0.9% saline using a small hand-held 
glass homogeniser. Equal volumes of homogenate and acetonitrile were mixed and 
centrifuged at 2000 x g for 10 minutes to give a clear supernatant. The supernatant was 
injected directly onto the hplc column and processed in the same way as the plasma 
samples.
2 .7 .3  Experimental analysis
All chromatographic data was analysed using Packard FLO-ONE software. The 
background signal was subtracted from each trace and the start and end times of each 
peak assigned manually.
2 .8  Effect of pharmacological doses of MK801 on the uptake and 
retention of [125I]CNS 1261 in the normal rat brain
2 .8 .1  Experimental design
Animals were surgically prepared for [125I]CNS 1261 autoradiography as detailed in 
section 2.4.1. MK801 was administered as an intravenous bolus dose followed by an 
infusion (0.4mg/kg + 6pg/kg/min or 1.2mg/kg + 16|ig/kg/min.) at a rate of 7.9|il/min. 
[125I]CNS 1261 (200pCi) was administered 30 minutes after the start of the infusion. 
Animals were killed 120 minutes post-injection of tracer and their brains removed and 
processed as detailed in section 2.4.3.
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2 .8 .2  Data analysis
[125I]CNS 1261 uptake was measured in 37 discrete brain areas in each treatment group 
and the values compared to [125I]CNS 1261 uptake in corresponding regions of animals 
killed 120 minutes after administration of the tracer (controls). As described previously 
values were expressed as a ratio of the concentration of radioactivity (nCi/g) uptake in 
each region of interest relative to concentration of radioactivity within the cerebellar 
cortex. Ratios from treated groups were compared to control values by ANOVA 
followed by Student's unpaired t-test with a Bonferroni correction to take into account 
simultaneous multiple comparisons.
2 .9  Uptake and retention of [125I]MK801 and [125I]CNS 1261 
following changes in arterial CO2 tension
2 .9 .1  [125I]MK801 uptake following changes in arterial CO2 tension
Prior to manipulations, animals were surgically prepared as described in section 2.3.1. 
Hypercapnic acidosis or hypocapnic alkalosis was induced via adjustment of the 
respiratory status of the animals, since brain extracellular fluid is not buffered against 
changes in CO2 tension. Hypercapnic acidosis was induced by increasing the 
concentration of CO2 in the inspired air to approximately 20% (paC0 2  = 180mmHg, pH 
= 6.9). Hypocapnia was induced in a second group of animals via hyperventilation to 
give a paCC>2 of 20mmHg. Changes were induced 15 minutes prior to intravenous 
administration of [125I]MK801 (200pCi) and were maintained throughout the 
experimental period. The [125I]MK801 autoradiographic procedure was then carried out 
as described in section 2.3.3. however in these experiments, fifteen serial sections were 
collected from 3 predetermined planes, at the level of the striatum, dorsal hippocampus 
and cerebellum.
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2 .9 .2  Data analysis
[125i]MK801 uptake (strictly the amount of radioactivity following intravenous injection 
of [125I]MK801 in nCi/g)) was measured in 9 discrete brain areas in each treatment group 
and corrected for isotope decay. The corrected values were expressed as a ratio of 
[125i]MK801 uptake in regions of interest relative to uptake within the cerebellum. 
Region of interest/cerebellar ratios were compared to corresponding values from 
normocapnic animals (ANOVA and subsequent Student's unpaired t-test with Bonferroni 
correction applied for simultaneous multiple comparisons).
2 . 9 . 3  [125I]CNS 1261 uptake following changes in arterial CO2 tension
Prior to manipulations, animals were surgically prepared as described in section 2.4.1. 
Hypercapnic acidosis was induced via adjustment of the respiratory status of the animals. 
Hypercapnic acidosis was induced by increasing the concentration of CO2 in inspired air 
to approximately 20% (paCC>2 = 180mmHg, pH = 6.9). Changes were induced 15 
minutes prior to intravenous administration of [125I]CNS 1261 (200jiCi) and were 
maintained for the remainder of the experimental period. The [125I]CNS 1261 
autoradiographic technique was then carried out as detailed in section 2.4.2.
2 . 9 . 4  Data analysis
[125I]CNS 1261 uptake (strictly the amount of radioactivity following intravenous 
injection of [125I]CNS 1261 in nCi/g)) was measured in discrete brain areas in each 
treatment group and corrected for isotope decay. The corrected values were expressed as 
a ratio of [125I]CNS 1261 uptake in regions of interest relative to uptake within the 
cerebellum.
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2 .10  Uptake and retention of [125I]CNS 1261 following 
intracortical injection of NMDA
2 .10 .1  Experimental design
Animals were surgically prepared as detailed in section 2.4.1. Animals were then turned 
prone and the head fixed in a stereotaxic frame. A burr hole was drilled in the skull 4mm 
lateral to Bregma (co-ordinates taken from Paxinos and Watson, 1996). A fine needle 
was used to make a small hole in the dura without damaging any underlying vessels. A 
needle (20 gauge) attached to a Hamilton syringe was inserted into the left parietal cortex. 
Coordinates for injection (relative to Bregma) were: anterior posterior +0.0mm; lateral 
+4.0mm. The needle was lowered to a depth of 1.5mm (below the dura) over 2 minutes 
to minimise mechanical damage. NMDA (27 nmoles, volume = 3pl)) was injected at a 
constant rate over 2 minutes. Solutions for injection were made up in CSF (composition: 
NaCl 124mm; NaHC03 25.5mM; KC1 1.2.mM; KH2 PO4 1.2mM; CaCl2 2.5mM; 
MgCl2 l.OmM; 0.01% Evan's Blue dye. A second group of animals received an 
injection of CSF only. In both cases the needle was left in position for the remainder of 
the experiment Fifteen minutes after injection of NMDA (or CSF), [125I]CNS 1261 
(200pCi) was administered intravenously to initiate the [125I]CNS 1261 technique. 
Animals were killed 5, 60 or 120 minutes after injection of tracer and the brains 
processed for autoradiography as detailed in section 2.6.3.
2 .10 .2  Histological examination of lesion
Sections adjacent to those taken for autoradiography were stained with haematoxylin and 
eosin. Briefly, sections were dehydrated in alcohol, stained in haematoxylin for 5 
minutes, washed and stained in eosin for 30 seconds. Sections were examined by light 
microscopy to determine the anatomical extent of cell loss following injection of CSF or 
NMDA. The size of the lesion, identified by an area of pallor, was compared to the 
lesion size delineated by alterations in [l25I]CNS 1261 uptake.
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2 .1 0 .3  Data analysis
The lesions evident on autoradiograms were initially described by their appearance. The 
size and extent of each lesion was also measured. The area of the lesion (mm2) was 
measured in triplicate at the level of its first appearance by area analysis using an M4 
image analyser and precalibrated area standards. This was repeated at 400}im intervals 
throughout the extent of the lesion. A stereotaxic atlas was used to designate stereotaxic 
coordinates (relative to bregma) to the brain levels to produce 2-D maps which could be 
used to compare the lesions
[125I]CNS 1261 uptake was measured in 37 discrete brain areas following injection of 
NMDA or CSF. As described previously values were expressed as a ratio of the 
concentration of radioactivity (nCi/g) uptake in each region of interest relative to 
concentration of radioactivity within the cerebellar cortex.
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CHAPTER IE 
RESULTS
3.1  CNS 1261 binds to the NMDA receptor complex with high 
affinity and selectivity
3 .1 .1  Affinity of CNS 1261
CNS 1261 was found to displace [3H]MK801 binding to homogenates with 
Ki = 25nM in tris buffer and 44nm in CSF(Cambridge Neuroscience in house data).
3 .1 .2  Selectivity of CNS 1261
The effect of CNS 1261 on the binding of ligands to the NMDA receptor, and to other 
neurotransmitter receptors was more extensively investigated by submitting the 
compound for commercial screening (NovaScreen, Maryland, USA).
CNS 1261 (lOnM) inhibited [3H]MK801 binding by 26.7 ± 2.2%, which was consistent 
with the reported Ki for this compound. At this concentration, CNS 1261 did not 
produce any biologically significant effects in any of the other assays investigated.
CNS 1261 (lpM) was extremely selective and only showed activity (>50% inhibition of 
binding) in the MK801 binding site assay (Table 2). CNS 1261 (1|JM) produced a 99% 
inhibition of [3H]MK801 binding. The effect of CNS 1261 on [3H]MK801 binding was 
confirmed by repeating the assay a further 2 times. The results from these assays were 
consistent with the initial results (lOnM: 27 ± 2%, lpM: 99 ± 1%) At this concentration 
(l|iM), some 40 times in excess of its affinity for the MK801 binding site on the NMDA 
receptor, CNS 1261 displayed marginal effects (£ 20% inhibition) in three assays (Table 
2). CNS 1261 had no effect (< 20% ) on the remaining 38 radioligand binding assays 
examined (Table 3).
In an extensive commercial screen at the concentrations examined, CNS 1261 binding 
appears to be selective for the MK801 binding site on the NMDA receptor.
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TABLE 2
Inhibition of ligand binding by CNS 1261
% inhibition of binding
ASSAY RADIOLIGAND lOnM l|iM
MK801 binding site [3H]MK801 11 ± 2 99 ± 1
Na+ channel 2 [3H]batrachotoxin -1 ± 3 38 ± 1
oc-1 adrenoceptor [3H]prazosin 20 ± 1 33 ±1
GAB A uptake [3H]GABA 16 ± 8 21 ± 2
CNS 1261 (l|iM ) was extremely selective and only demonstrated activity (> 50% 
inhibition) in the MK801 binding site assay. Marginal effects (> 20% inhibition) were 
observed at three of the other 41 assays examined. Data are expressed as mean ± 
S.E.M., n = 2. Negative values indicate stimulation of binding. Data taken from 
commercial screen carried out by NovaScreen, Maryland, USA.
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TABLE 3
CNS 1261 displayed no activity in a range of radioligand binding assays
% inhibition
ASSAY RADIOLIGAND lOnM luM
AMPA [3H]AMPA -2 ± 5 3 ± 5
Adenosine (ns) pH]NECA -9 ± 3 -4 ± 4
a-2 adreneoceptor pH]RX 821002 4 ± 4 13 ± 4
p-adreneoceptor pHJDHA -2 ± 2 8 ± 2
Dopamine 1 pH]SCH 23390 7 ± 3 1 ± 4
Dopamine 2 pH] sulpiride 1 ± 0 9 ± 1
GABAa pH]GABA 0 ± 7 9 + 4
UABAb pH]GABA (+ isoguavacine) 20 ± 1 9 ± 4
Glycine (strychnine sensitive) [3H]strychnine 4 ± 3 2 ± 1
Histamine 1 [3H]pyrilamine 3 ± 0 17 ± 2
Histamine 2 [3H]tiotidine 10 ± 8 14 ± 3
Histamine 3 pHJN^methylhistamine 12 ± 4 8 ± 6
Angiotensin II [125I]Sarl, Ile8-angiotensin II -10 ±1 -11 ± 2
Noradrenaline uptake [3H]desmethylimipramine -2 ± 0 11 ± 3
Serotonin uptake [3H]citalopram 1 ± 0 6 ± 1
Choline uptake pHJcholine chloride 6 ± 6 1±1
Dopamine uptake [3H]WIN 35,428 -10 ± 5 10 ±1
Adenosine uptake [3H]nitrobenzylthioinosine 1 ± 6 -1± 1
Glutamate uptake pH] glutamate 6 ± 2 12 ± 3
Chloride channel PH]TB0B 2 ± 0 1 ± 0
Ca2+ channel (type T &L) [3H]nitrendipine 2 ± 0 2 ±  1
Ca2+ channel (type N) [125I] co-conotoxin 0 ± 2 2 ± 1
K+ (low conductance) [125I]apamin -11 ± 3 -2 ± 1
K+channel (ATP) pH] glibenclamide 7 ± 1 8 ± 2
Kainicacid pH]kainic acid -1 ± 4 5 ± 0
Muscarinic (c) pH]quinuclidinylbenzilate 1 ± 4 6 ± 2
Muscarinic (p) pH]quinuclidinylbenzilate -22 ± 1 -22 ± 12
Nicotinic (neuronal) pH]N-methylcarbamylcholine 19 ± 0 16 ± 1
NMDA PH]CGP 39653 -13 ± 0 -15 ±1
Serotonin (5-HTi) pH]hydroxyltryptamine binoxylate 9 ± 3 8 ± 0
Serotonin (5-HT2) pH]ketanserin 9 ± 3 8 ± 0
Seroronin (5 -HT3) r3H]GR65630 2 ± 1 16 ± 2
Glycine (strychnine insensitive) pH] glycine -4±  2 1 ± 2
Benzodiazepine (c) pH]flunitrazepam 9 ± 1 15 ± 3
Opiate (ns) [3H]naloxone 0 ± 2 5 ± 2
Vasopressin-1 [3H] phenylalanyl-3,4,5-vasopressin -19 ± 3 -2 ± 3
K+ channel (voltage dependent) [125I]charybdotoxin -16 ± 5 13 ±1
Na+ channel 1 pHJsaxitoxin 3 ± 1 -12±3
38 radioligand binding assays 
displayed as mean ± S.E.M., n= 
binding, ns = non-specific, c =
. 'Activity' was defined as >50% inhibition. Data are 
■2. Negative values indicate a stimulation of radio-ligand 
central and p = peripheral (NovaScreen)
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3.2. Effect of CNS 1261 on local cerebral glucose utilisation
The effect of three doses of CNS 1261 (1, 3 and lOmg/kg) on local cerebral glucose 
utilisation were examined in the conscious lightly restrained rat. The pattern of alterations 
in glucose utilisation produced by CNS 1261 were compared to those obtained in a 
previous study using MK801 carried out by Kurumaji et al (1989).
3.2.1. General observations
Administration of CNS 1261 produced changes in overt behaviour of the animals at all of 
the doses examined. A degree of sedation and a reduced response to external stimuli was 
observed in all animals however, animals remained conscious throughout the 
experimental period. These effects appeared at around 5 minutes post-injection of CNS 
1261 and lasted for the duration of the experiment The normal grooming, sniffing and 
exploratory behaviour (displayed by all control rats) was absent in animals treated with 
CNS 1261. CNS 1261-treated animals exhibited stereotypical behaviour consisting of 
neck stretching and repetitive side-to-side and cyclical head movements. The severity of 
these effects was dose related and was most pronounced in the group receiving the 
highest dose of CNS 1261.
Administration of CNS 1261 (lmg/kg) had no significant effects on any of the 
cardiovascular and respiratory variables measured (Table 4). Treatment with CNS 1261 
(lOmg/kg) induced a modest, significant increase in arterial carbon dioxide tension. CNS 
1261 administration produced an immediate, transient hypotension . However at each 
dose examined CNS 1261 ultimately effected a sustained increase in mean arterial blood 
pressure relative to control values at times beyond 10 minutes (Figure 10). Arterial 
plasma glucose concentration was unaffected by administration of CNS 1261.
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TABLE 4
Effect of CNS 1261 adminstration on physiological variables
CNS 1261
PARAMETER VEHICLE 1 mg/kg 3mg/kg lOmg/kg
paC02 (mmHg) 34 ± 1 37 ± 1 38 ±1 41 ± 1*
arterial pH 7.43 ± 0.01 7.41 ± 0.01 7.41 ± 0.01 7.3 ± 0.01
pa02 (mmHg) 94 ± 3 98 ± 2 95 + 2 88 ± 2
MABP (mmHg) 136 ± 4 142 ± 5 151 ±3* 157 ±3**
temperature (°C) 36.4 ± 0.3 36.2 ± 0.5 36.1 ±0.4 36.0 ± 0.4
glucose (mM) 9.6 ± 0.7 8.6 ± 0.7 9.9 ± 0.2 10 ± 1
weight (g) 347 ± 16 323 ±11 345 ± 12 366 ±14
n 8 6 6 6
Arterial plasma glucose concentration was measured immediately prior to administration 
of [14C]2-deoxyglucose. Other physiological variables were assessed 30 minutes after 
radioisotope administration. *p<0.05, **p<0.01 for statistical comparison between each 
drug treated group and saline-treated controls (ANOVA, Srudent's t-teist with Bonferroni 
correction). Data are derived from 26 animals and are expressed as mean ± S.E.M. (n = 
6- 8).
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3.2.2. Local cerebral glucose utilisation
Administration of CNS 1261 produced highly circumscribed changes in glucose 
utilisation. The glucose use alterations associated with systemic administration of CNS 
1261 (1 ,3  and lOmg/kg) in 36 regions of interest are presented in Tables 5-7 (see 
Figures 11-13).
Following intravenous administration of CNS 1261 (1 mg/kg) 6 of the regions examined 
displayed significant alterations in glucose use. Moderate decreases were observed in 
the auditory cortex, posterior cingulate cortex, retrosplenial cortex and inferior colliculus. 
Glucose use was elevated in entorhinal cortex (caudal) and within the fornix. 
Administration of CNS 1261 (3mg/kg) caused significant alterations in glucose use in 11 
of the 36 regions examined. Glucose use was decreased in layer IV of the auditory 
cortex and the inferior colliculus. Prominent increases in glucose use were observed in 
layer IV of the visual cortex, anteroventral thalamus, hippocampus molecular layer, 
dentate gyrus, entorhinal cortex (caudal), mamillary body, posterior cingulate cortex, 
retrosplenial cortex and fornix.
At the highest dose examined (lOmg/kg) CNS 1261 administration produced alterations 
in glucose use that could be readily visualised on autoradiograms (Figure 11). Moderate 
decreases in glucose utilisation (approximately 30%) were observed in layer IV of the 
frontal, sensory-motor and auditory cortices and in the inferior colliculus (Figure 12). 
Distinct, significant elevations in glucose use were observed in a number of structures 
within the limbic system (Figure 13), namely, the entorhinal cortex (caudal), 
hippocampus molecular layer, dentate gyrus, anteroventral thalamus, mamillary body, 
posterior cingulate cortex, retrosplenial cortex and also within the fornix. There were no 
significant alterations in glucose use in the other four regions of white matter examined. 
The magnitude of these changes was generally in the region of 80%. however, extremely 
large magnitude changes were observed within the entorhinal cortex and mamillary body, 
where glucose use was increased by 238% and 125% respectively.
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VEHICLE CNS 1261
PC C
FIGURE 11 : Changes in glucose utilisation following administration of CNS 1261
Representative [14C]2-deoxyglucose autoradiograms of coronal rat brain sections at the 
level o f the anteroventral thalamic nucleus (upper), hippocampus molecular layer (middle) 
and inferior colliculus (lower). Administration of CNS 1261 (lOmg/kg) produced marked 
increases in glucose use in a number o f regions of the limbic system, including the 
anteroventral thalamus (AV), hippocampus molecular layer (Mol), dentate gyrus (DG), 
posterior cingulate cortex (PCC) and entorhinal cortex (Ent). Profound reductions in 
glucose use were observed within the inferior colliculus
200
B
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entorhinal cortex (caudal)
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FIGURE 12 : Effect of CNS 1261 on glucose use in the entorhinal cortex and inferior 
colliculus.
Local cerebral glucose utilisation in the entorhinal cortex (caudal) and the inferior 
colliculus following intravenous administration of CNS 1261. Data are expressed as 
mean ± S.E.M (n= 6-8). Significant elevations in glucose utilisation were observed in 
the entorhinal cortex (caudal) following administration of CNS 1261. CNS 1261 
administration markedly reduced glucose utilisation in the inferior colliculus 
**p< 0.01 ANOVA followed by Student's t-test with appropriate Bonferroni correction.
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FIGURE 13: Effect of CNS 1261 on limbic structures
Glucose utilisation in selected structures within the limbic system following 
administration of CNS 1261. Data are expressed as mean ± S.E.M (n=6-8). CNS 1261 
produced dose-dependent elevations in glucose utilisation in the mamillary body, 
retrospenial cortex and hippocampus molecular layer (posterior).
Note the similarity of the effects induced by administration of CNS 1261 in these three 
regions. In each region the greatest increase in glucose utilisation compared to control 
values was observed at 3mg/kg
The degree of responsiveness of each of the 36 regions to CNS 1261 was assessed by 
application of an arithmetic function which encompasses the entire dose-response data 
available for each region. A rank ordering of these regional responses was obtained from 
the function /.
/ =  L(xc - xji)2
xc is the mean of loge (glucose use) for control group members, xji is the mean of loge 
(glucose use) for the ith dose of the treatment group in question, T either CNS 1261 (1, 
3 and lOmg/kg) or MK801 (0.05, 0.5 and 5mg/kg).
Calculated/values for regional responsiveness to CNS 1261 treatment were compared to 
corresponding values for MK801 (Kurumaji et aU 1989) and are shown in Tables 5-7.
/  values were classified into groups where regions with /  > 0.8 were described as 
"extremely sensitive’. These regions generally displayed greater than 55% reductions or 
increases in glucose use after administration of the highest dose.
Regions with 0.5 < / <  0.8 were described as "sensitive". Regions described as 
"moderately sensitive" generally displayed 30-50% increases or decreases in glucose use 
and 0.3 < / <  0.5. "Minially sensitive" regions displayed /values < 0.3, within this 
group the magnitude of change in glucose use was less than 30%.
Examination of the frequency hierarchies showed that regions which were particularly 
sensitive to CNS 1261 (Table 8) such as the entorhinal cortex (caudal), hippocampus 
molecular layer, dentate gyrus and fornix, were also in general, sensitive to MK801 
(Table 9). Those areas least affected by CNS 1261 were also least affected by MK801, 
including most cortical areas and regions of white matter.
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Examination of frequency distribution profiles o f /  values for CNS 1261 and MK801 
(Figure 14) show that both compounds were broadly similar, displaying a wide range of 
/values and a skewed distribution, with the majority of regions being minimally sensitive 
i f  < 0.3). Differences in glucose use responses to the two agents occurred in a small 
number of regions, a greater number of regions displayed extreme sensitivity (f> 0.8) to 
CNS 1261 in contrast to MK801, such as the anteroventral thalamus, mamillary body 
and the inferior colliculus.
Correlation analysis of/values (Figure 15) showed that a significant relationship exists 
between the alterations in glucose use produced by CNS 1261 administration and those 
produced by MK801 (correlation coefficient, r = 0.87). The entorhinal cortex (rostral) 
was much less sensitive to CNS 1261 than to MK801.
These results confirm that the overall pharmacological effects of CNS 1261 were 
extremely similar to the overall effects of MK801
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FIGURE 14
(a)
30 I CNS 1261
OXJ<D
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u-<O
u.<UX>a
3c
>>oG<D3cro, 1-1
0.4 0.8 1.2 1.6 3.6 
f  value
(b)
30 n
MK801
i 1--------1------- 1--------1-----
0.4 0.8 1.2 1.6 2.0
/  value
Frequency distribution profiles of f values for (a) CNS 1261 and (b) 
MK801
/function  values represent the sensitivity of individual regions to drug treatment 
following administration of CNS 1261 and MK801. /values for both compounds were 
broadly similar with a wide range of/values and a skewed distribution.
r = 0.87
p< 0.001
oo
CJ
0.0 0.5 1.0 1.5 2.0
MK801
FIGURE 15 : Correlation analysis o f/va lues for glucose use after MK801 and 
CNS 1261 treatment
Each data point represents the /value  generated from analysis of the entire dose-response 
curve of a single structure in response to MK801 and CNS 1261.
Overall correlation coefficient, r, for all regions investigated was 0.87, indicating a high 
degree of association between regional effects of MK801 and CNS 1216. The entorhinal 
cortex (caudal) was much less sensitive CNS 1261 than to MK801
3 .3  Uptake and retention of [125I]MK801 and [125I]CNS 1261 in
normal rat brain
The uptake and retention of [125I]CNS 1261 was examined under conditions of normal 
NMDA receptor activation and was compared to that of [125I]MK801 under identical 
conditions.
3 .3 .1  General observations
Physiological variables were measured prior to, and 15 after administration of 
[125ijm K801 or [125I]CNS 1261 and are presented in Table 10. Administration of 
[125I]MK801 or [125I]CNS 1261 had no effect on any of the variables examined. There 
were no significant differences in any of the parameters between the two groups at any 
time point.
3 .3 . 2  In  vivo uptake and retention of [125I]CNS 1261
The in vivo uptake and retention of [125I]CNS 1261 was examined in 36 anatomically 
discrete regions at multiple time points in halothane anaesthetised rats. [125I]CNS 1261 
was administered and the animals sacrificed 5, 30, 60 and 120 minutes thereafter. The 
uptake of each tracer in individual regions of interest was expressed as a ratio relative to 
uptake within the cerebellar hemisphere (a within animal measure of non-specific 
binding), Tables 11-13.
[125I]CNS 1261 uptake 5 minutes after intravenous injection was greatest within areas of 
high cerebral blood flow such as the anterior thalamic nucleus and the majority of cortical 
areas examined. Intermediate levels of uptake were observed within the thalamus and 
lowest levels of uptake in the hippocampus and hypothalamus. [125I]CNS 1261 uptake 
was also low in all areas of white matter examined (Figure 16, see also Figures 20-21).
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TABLE 11
Comparison of [125I]MK801 and [125I]CNS 1261 uptake
30 minutes post-administration
STRUCTURE [125I]MK801 [125I]CNS 1261
anterior cingulate cortex 1.24 ±0.15 1.90 ±0.16
genu 0.88 ± 0.02 0.73 ± 0.03
caudate nucleus 1.13 ±0.05 1.30 ±0.02
sensory-motor cortex
layers I-III 1.12 ±0.06 1.28 ±0.01
rv 1.16 ±0.06 1.30 ±0.03
V-Vl 1.18 ±0.10 1.32 ±0.04
corpus callosum 0.90 + 0.02 0.80 ± 0.02
anterior thalamus 1.29 ±0.13 1.62 ±0.12
hippocampus CA1 1.38 ±0.16 1.17 ±0.01
hippocampus CA3 1.42 ±0.11 1.19 ±0.01
lateral habenular nucleus 1.01 ± 0.07 1.18 ±0.05
mediodorsal thalamus 1.40 ± 0.22 1.55 ±0.16
ventrolateral thalamus 1.32 ± 0.09 1.30 ±0.02
internal capsule 0.91 ± 0.04 0.70 ± 0.03
parietal cortex
layers I-m 1.16 ±0.09 1.32 ±0.04
IV 1.19 ±0.10 1.35 ±0.01
V-VI 1.20 ±0.10 1.32 ± 0.05
hypothalamus 1.00 ±0.10 1.04 ±0.01
posterior cingulate cortex 1.14 ±0.16 1.53 ± 0.06
hippocampus molecular layer 1.45 ± 0.22 1.48 ± 0.07
dentate gyrus 1.39 ±0.15 1.39 ± 0.03
auditory cortex
i-m 1.20 ± 0.08 1.54 ±0.09
IV 1.21 ±0.08 1.53 ± 0.07
V-VI 1.21 ±0.14 1.48 ± 0.03
substantia nigra pars compacta 1.00 ± 0.07 1.13 ±0.10
substantia nigra pars reticulata 0.97 ± 0.05 1.11 ±0.12
medial geniculate body 1.23 ± 0.09 1.39 ± 0.08
visual cortex
layers I-m 1.27 ± 0.09 1.55 ± 0.05
IV 1.24 ± 0.06 1.49 ± 0.02
V-VI 1.23 ± 0.02 1.50 ± 0.01
entorhinal cortex 1.16 ±0.13 1.54 ±0.13
inferior colliculus 1.04 ± 0.06 1.16 ±0.04
pons 0.98 ± 0.01 1.30 ± 0.05
cerebellar hemisphere 1.00 ± 0.00 1.00 ± 0.00
cerebellar white matter 0.84 ± 0.05 0.68 ± 0.03
superior olivary nucleus 0.93 ± 0.03 1.14 ±0.05
Uptake of [125I]MK801 or [125I]CNS 1261 in individual regions of interest were 
expressed as a ratio relative to uptake within the cerebellum. Roman numerals (I-VI) 
indicate the cortical layer examined. Data are presented as mean ± S.E.M., n = 2.
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T A B L E  12
Comparison of [125I]MK801 and [125l]CNS 1261 uptake
60 minutes post-administration
STRUCTURE [125I]MK801 [125I]CNS 1261
anterior cingulate cortex 1.34 ±0.08 1.77 ±0.18
genu 1.16 ±0.03 1.00 ±0.03*
caudate nucleus 1.11 ±0.05 1.27 ±0.02*
sensory-motor cortex 
layers I-III 1.14 ±0.08 1.41 ± 0.04*
IV 1.18 ±0.07 1.59 ±0.11*
V-VI 1.20 ± 0.08 1.52 ±0.11
corpus callosum 1.23 ± 0.07 1.18 ±0.06
anterior thalamus 1.52 ± 0.09 1.62 ±0.10
hippocampus CA1 1.87 ±0.11 1.85 ±0.09
hippocampus CA3 1.91 ±0.11 1.84 ±0.11
lateral habenular nucleus 1.04 ± 0.03 1.21 ±0.03*
mediodorsal thalamus 1.51 ± 0.03 1.54 ± 0.09
ventrolateral thalamus 1.46 ± 0.04 1.48 ± 0.08
internal capsule 1.04 ± 0.04 1.01 ± 0.05
parietal cortex
layers I-m 1.21 ± 0.05 1.48 ± 0.06*
IV 1.23 ± 0.03 ' 1.54 ±0.10*
V-VI 1.30 ± 0.03 1.53 ±0.08*
hypothalamus 0.99 ± 0.01 1.09 ± 0.03*
posterior cingulate cortex 1.31 ±0.04 1.45 ±0.15
hippocampus molecular layer 2.03 ±0.15 2.09 ±0.13
dentate gyrus 1.85 ± 0.07 1.88 ±0.12
auditory cortex 
layers I-m 1.25 ± 0.05 1.60 ± 0.09*
IV 1.28 ± 0.06 1.62 ±0.12
V-VI 1.40 ± 0.05 1.62 ± 0.09
substantia nigra pars compacta 1.09 ± 0.06 1.13 ±0.07
substantia nigra pars reticulata 1.05 ± 0.05 1.05 ± 0.05
medial geniculate body 1.35 ± 0.05 1.39 ± 0.06
visual cortex 
layers I-m 1.33 ± 0.06 1.74 ±0.10*
IV 1.31 ±0.04 1.70 ±0.04*
V-VI 1.32 ± 0.07 1.75 ± 0.04*
entorhinal cortex 1.21 ±0.13 1.85 ±0.11*
inferior colliculus 1.02 ± 0.05 1.13 ±0.03
pons 1.10 ±0.03 1.22 ±0.09
cerebellar hemisphere 1.00 ± 0.00 1.00 ± 0.00
cerebellar white matter 0.96 ± 0.05 1.15 ±0.03*
superior olivary nucleus 1.03 ± 0.06 1.22 ± 0.03
Uptake of [125I]MK801 or [125I]CNS 1261 in individual regions of interest were 
expressed as a ratio relative to uptake within the cerebellum. Roman numerals (I-VI) 
indicate the cortical layer examined. Data are presented as mean ± S.E.M, n=3. 
*p<0.05, unpaired t-test.
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TABLE 13
Comparison of [125I]MK801 and [125I]CNS 1261 uptake
120 minutes post-administration
STRUCTURE [125I]MK801 [125I]CNS 1261
anterior cingulate cortex 1.32 ±0.10 1.69 ±0.10*
genu 1.01 ± 0.07 1.42 ±0.16
caudate nucleus 1.16 ±0.08 1.38 ±0.05
sensory-motor cortex
layers I-III 1.20 ±0.11 1.40 ± 0.05
IV 1.22 ±0.10 1.39 ±0.07
V-VI 1.22 ±0.10 1.51 ±0.09
corpus callosum 1.07 ± 0.07 1.47 ± 0.08*
anterior thalamus 1.35 ±0.12 1.58 ±0.04
hippocampus CA1 1.71 ±0.10 2.44 ±0.21*
hippocampus CA3 1.63 ±0.10 2.43 ±0.19*
lateral habenular nucleus 1.18+0.07 1.20 ± 0.03
mediodorsal thalamus 1.44 ± 0.09 1.61 ± 0.09
ventrolateral thalamus 1.36 ±0.12 1.56 ± 0.09
internal capsule 1.07 ± 0.07 1.11 ±0.04
parietal cortex
layers I-m 1.32 ±0.07 1.55 ± 0.08
IV 1.32 ± 0.07 1.49 ± 0.05
V-VI 1.29 ± 0.07 1.68 ±0.10*
hypothalamus 0.98 ± 0.07 1.05 ± 0.04
posterior cingulate cortex 1.25 ±0.11 1.51 ±0.06
hippocampus molecular layer 1.72 ±0.15 2.91 ± 0.22*
dentate gyrus 1.57 ± 0.12 2.50 ±0.15*
auditory cortex
layers I-III 1.31 ±0.11 1.63 ± 0.06*
rv 1.30 ±0.10 1.64 ± 0.05*
V-VI 1.36 ±0.11 1.77 ± 0.05*
substantia nigra pars compacta 1.05 ± 0.09 1.24 ± 0.04
substantia nigra pars reticulata 1.08 ± 0.07 1.17 ±0.05
medial geniculate 1.29 ± 0.07 1.49 ± 0.05
visual cortex
layers I-m 1.33 ±0.14 1.73 ± 0.09
IV 1.32 + 0.13 1.64 ±0.09
V-VI 1.31 ±0.12 1.67 ± 0.04*
entorhinal cortex 1.24 ±0.14 1.91 ±0.11*
inferior colliculus 1.13 ± 0.09 1.08 ±0.01
pons 1.08 ±0.10 1.31 ±0.06
cerebellar hemisphere 1.00 ± 0.00 1.00 ±0.00
cerebellar white matter 0.95 ± 0.03 1.25 ±0.14
superior olivary nucleus 1.04 ± 0.05 1.19 ±0.07
Uptake of [125I]MK801 or [125I]CNS 1261 in individual regions of interest were 
expressed as a ratio relative to uptake within the cerebellum. Roman numerals (I-VI) 
indicate the cortical layer examined. Data are presented as mean ± S.E.M, n=3. *p<0.05, 
unpaired t-test.
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[ 125I]MK801 [ 125I]CNS 1261
MB
FIGURE 16 : Comparison of [125I]MK801 and [I25I]CNS 1261 uptake at 5 minutes 
Representative autoradiograms illustrate [125I]MK801 (left) and [125I]CNS 1261
(right) uptake 5 minutes after administration at the level of the caudate nucleus 
(upper), dorsal hippocampus (middle) and hippocampus molecular layer (lower). For 
both tracers, uptake was greatest in areas known to have high levels o f blood flow
125such as cortical areas and within the mamillary body. Note that [ I]CNS 1261
125images possess a greater degree of clarity relative to [ I]MK801 images. (IV :
cortical layer IV, CA1 : hippocampus CA1, L : lateral habenula, MB : mamillary 
body).
Thirty minutes after administration, [125I]CNS 1261 uptake was greatest within the 
anterior cingulate cortex (90% greater than that observed within the cerebellum). High 
levies of [125I]CNS 1261 uptake were observed within the auditory and visual cortices 
where levels were approximately 50% above cerebellar values (Figure 17). Little 
variation in [125I]CNS 1261 uptake could be observed between cortical layers. Lowest 
levels of [125I]CNS 1261 uptake were observed within white matter areas. Uptake 
within genu, corpus callosum and internal capsule was generally 30% lower than that 
witihin the cerebellar hemisphere.
At times beyond 30 minutes, the highest levels of uptake of [125I]CNS 1261 were 
observed within the hippocampus (notably CA1 and the molecular layer), with 
intermediate levels in the cortex and caudate nucleus and lowest levels in the 
hypothalamus and cerebellum (reflecting the known distribution of NMDA receptors). 
60 minutes after injection [125I]CNS 1261 uptake within hippocampal areas and within 
the entorhinal cortex was 80-100% greater than that within the cerebellum. Uptake in 
cortical areas was 50-70% above cerebellar values (Figure 18).
The relative uptake of [125I]CNS 1261 within hippocampal areas continued to increase 
between 60 and 120 minutes. [125I]CNS 1261 uptake within CA1, CA3, molecular layer 
and dentate gyrus was 150-200% greater than that observed within the cerebellum, 
intermediate levels, 50-70% above that in the cerebellum were observed within anterior 
cingulate cortex, thalamus, and auditory, parietal and visual cortices. [125I]CNS 1261 
uptake was greatest within the deepest layers (V-VI) of the cortex. Lowest levels of 
uptake were present in areas of white matter, hypothalamus and pons (Figure 19).
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[ I]MK801
FIGURE 18: Comparison o f [125I]MK801 and [125I]CNS 1261 uptake at 60 
minutes
Representative autoradiograms illustrate [125I]MK801 (left) and [125I]CNS 1261 
(right) uptake 60 minutes after administration at the level of the caudate nucleus 
(upper), dorsal hippocampus (middle) and hippocampus molecular layer (lower). 
Greatest levels of uptake for both tracers were observed within cortical areas and
125 • nhippocampal structures. Note that [ I]CNS 1261 uptake is lower than that of 
[ IJMK801 in white matter areas. (CC : corpus callosum, CA1 : hippocampus 
CA1, Mol : molecular layer).
[ I25I]MK801 [ i25I]CNS 1261
FIGURE 17 : Comparison o f [l22I]MK801 and [l23I]CNS 1261 uptake at 30 minutes
Representative autoradiograms illustrate [l2:,I]MK801 (left) and [l25I]CNS 1261 
(right) uptake 30 minutes after administration at the level o f the caudate nucleus 
(upper), dorsal hippocampus (middle) and hippocampus molecular layer (lower). 
Greatest levels of uptake for both tracers were observed within cortical areas and
125 r*hippocampal structures. Note that [ I]CNS 1261 uptake is lower than that of 
['~5I]MK801 in white matter areas. (CC : corpus callosum, CA1 : hippocampus 
CA1, Mol : molecular layer).
[ i25I]MK801 [ l25l ]C N S  1261
FIGURE 19 : Comparison o f [l25I]MK801 and [ l25I]CNS 1261 uptake at 120 
minutes
Representative autoradiograms illustrate [125I]MK801 (left) and [125I]CNS 1261 
(right) uptake 120 minutes after administration at the level o f the caudate nucleus 
(upper), dorsal hippocampus (middle) and hippocampus molecular layer (lower). For 
both tracers uptake was greatest within hippocampal structures with lower levels 
observed within the hypothalamus (CA1 : hippocampus CA1, Mol, molecular layer, 
Hypo : hypothalamus).
3 .3 . 3  C om parison of [125I]CNS 1261 uptake with [125I]M K 801
[125i]MK801 uptake and retention was examined in contem poraneous experiments and 
compared to that of [125I]CNS 1261 at each time point (Figures 16-19)
Despite general similarities in the pattern of uptake of both tracers at 5 minutes, the 
appearance of the images differed markedly. The resolution of [125I]MK801 images 
was poor and the overall appearance was similar to images produced with the blood flow 
tracer " mTc-HMPAO (Gartshore, 1996). In comparison, [125I]CNS 1261 images 
possessed a greater degree of clarity with cortical layer IV clearly visible on 
autoradiograms (Figure 20) . Increased [125I]CNS 1261 uptake was observed in the 
supraoptic and paraventricular hypothalamic nuclei. These regions were not evident in 
[125i]MK801 autoradiograms at 5 minutes (Figure 21).
At 30 minutes, [125I]MK801 uptake was greatest within hippocampal structures 
(approximately 40% greater than cerebellar levels) with intermediate levels in cortical 
areas (20% above cerebellum).
The relative uptake of [125I]CNS 1261 at this time point was generally 20% higher than 
that of [125I]MK801 within the caudate nucleus and cortical areas and approximately 40% 
greater within the entorhinal cortex and the pons. Relative [125I]CNS 1261 uptake was 
not markedly different from that of [125I]MK801 in any of the other regions examined at 
this time point
Sixty minutes after administration of the tracers, the overall pattern of [125I]CNS 1261 
uptake was similar to that of [125I]MK801 however, the relative uptake of [125I]CNS 
1261 was greater than that of [125I]MK801 in 14 of the 36 regions examined. [125I]CNS 
1261 uptake was significantly greater in the caudate nucleus, sensory-motor, parietal, 
auditory, visual and entorhinal cortices compared to [125I]MK801. Within the 
hippocampus (a region with high levels of NMDA receptors) tracer uptake relative to the 
cerebellum was similar for both ligands 60 minutes after injection.
[125I]MK801
[125I]CNS 1261
FIGURE 20 : [125I]CNS 1261 uptake is increased in cortical layer IV 5 minutes 
after administration
Representative autoradiograms of [125I]MK801 (upper) and [125I]CNS 1261 (lower) 
uptake in the sensory-motor cortex 5 minutes after intravenous administration. 
[125I]CNS 1261 uptake was increased within cortical layer IV, while [125I]MK801 
uptake was homogeneous throughout the cortex.
GP
FIGURE 21 : [125I]CNS 1261 uptake is increased within the paraventricular 
hypothalamic nucleus
Representative autoradiograms from the level of the globus pallidus comparing 
[125I]MK801 (upper) and [123I]CNS 1261 (lower) uptake in the normal brain 5 
minutes after administration. High levels o f both tracers are observed within the
125cerebral cortex and anteroventral thalamus. Only [ I]CNS 1261 uptake is increased 
within the paraventricular hypothalamic nucleus. Note the greater degree of clarity
125within the [ I]CNS 1261 autoradiogram. (AV : anteroventral thalamus, GP : 
globus pallidus, PVN : paraventricular hypothalamic nucleus).
A V
PVN
120 minutes after intravenous injection uptake of [ 12^I]CNS 1261 was significantly 
greater than that of [125I]MK801 in 12 of the 36 regions examined (anterior cingulate 
cortex, corpus callosum, hippocampus CA1 and CA3, superior layers of the parietal 
cortex, hippocampus molecular layer, dentate gyrus, auditory cortex, deep layers of the 
visual cortex and entorhinal cortex). The relative levels of [ 125I]CNS 1261 were 40-70% 
greater than that of [125I]MK801 in the majority of cortical areas examined (parietal, 
auditory, visual and entorhinal) and 40% greater than that of [125I]MK801 in most white 
matter areas (Figure 22). A degree of laminar heterogeneity in the radioisotope 
concentrations in the cerebral cortex was observed with [125I]CNS 1261, deep layers had 
higher isotope levels that superficial layers. Isotope levels were homogeneous within the 
cerebral cortex of [125I]MK801 autoradiograms. The most striking observation was that 
the relative uptake of [125I]CNS 1261 in hippocampal structures was approximately twice 
that of [125I]MK801, (140% and 70% greater than cerebellar binding respectively) 
(Figure 23).
Under conditions of normal activation at the premium time point established for imaging 
[125i]MK801 uptake (120 minutes), the relative uptake of [125I]CNS 1261 was thus 
found to be superior to that of [125I]MK801 in areas with a high density of NMD A 
recptors and hence a high level of NMD A receptor activation.
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FIGURE 22: Uptake and retention of [125I]CNS 1261 and [125I]MK801 in white matter
The uptake and retention of [125I]CNS 1261 and [125I]MK801(relative to the cerebellum) 
was examined at different time points in normal brain. Uptake over the first 60 min. was 
similar for both ligands. At 120 min. relative levels of [125I]CNS 1261 were 
approximately 40% above that of [125I]MK801. Data are mean ± S.E.M. (n = 2-4). 
*p<0.05, significantly different from [125I]MK801 (unpaired t-test).
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FIGURE 23 : Uptake and retention of [125I]CNS 1261 and [125I]MK801 in 
hippocampus
The uptake and retention of [125I]CNS 1261 and [125I]MK801 (relative to the cerebellum) 
was examined at different time points in normal brain. Uptake over the first 60 min. was 
similar for both ligands. At 120 min. relative levels of [125I]CNS 1261 were 
approximately twice that of [125I]MK801. Data are mean ± S.E.M. (n = 2-4). *p<0.05, 
significantly different from [125I]MK801 (unpaired t-test).
3 .4  Relative lipophilicity of [125I]CNS 1261 and [125I]MK801
3 .4 .1  Lipophilicity of CNS 1261
The calculated LogD value for CNS 1261 at physiological pH is shown in Table 14. The 
logD values for structurally related (CNS 1102) and unrelated (MK801 and iodo- 
MK801) non-competitive NMD A receptor antagonists are shown for comparison. CNS 
1261 has a higher LogD value and hence is more lipophilic than CNS 1102. CNS 1261 
is more lipophilic than the structurally unrelated compound MK801, but has a lower 
LogD value and is therefore less lipophilic than iodo-MK801.
3 .4 .2  Partition coefficient of [*25I]CNS 1261 and [125I]MK801 in rat 
brain
Brain/aqueous partiton ratios were calculated for [125I]CNS 1261 and [125I]MK801 in rat 
brain and are presented in Table 15. The brain/aqueous partition ratios for [3H]MK801 
are shown for comparison.
The brain/aqueous partition ratios for [125I]CNS 1261 and [125I]MK801 show a higher 
accumulation in brain tissue relative to aqueous solution. The partition ratio for 
[3H]MK801 was markedly lower than [125I]MK801 in rat brain sections.
The brain/aqueous partition ratio for [125I]CNS 1261 in rat brain was approximately 40% 
lower than that of [125I]MK801,20.6 ± 13 g/ml compared to 35.5 ± 4.6 g/mL
3 . 4 .3  Partition coefficient of [*25I]CNS 1261 and [125I]MK801 in 
human brain
The brain/aqueous partition ratio of [125I]CNS 1261 was also 40% lower than that of 
[125I]MK801 (14.8 ± 0.8 g/ml relative to 25.5 ± 1.5 g/ml) in human grey matter 
(Table 15). The partition coefficient may be indicative of the degree of non-specific 
binding.
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TABLE 14
LogD values for CNS 1261 and other non-competitive NMDA antagonists
Compound Structure LogD 7.4
CNS 1261
CQ„.
2.19
MK801 1.80
CNS 1102 y MeHNCcr 1.72
I-MK801 c M C l ,
Me 1
3.30
LogD7 4  values, the partition coefficient between organic solvent (octanol) and aqueous 
buffer (15mM HEPES buffer / 0.135M NaCl) at physiological pH, are shown for CNS 
1261, the related compound CNS 1102, MK801 and iodo-MK801.
Note that while CNS 1261 is more lipophilic than MK801 and CNS 1102, it is less 
lipophilic than iodo-MK801. Data supplied by Cambridge NeuroScience Inc.
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TABLE 15
Brain/ aqueous partiton ratios in rat and human brain
BRAIN/AQUEOUS RATIO (g/ml)
LIGAND Rat Human (grey)
[125i]CNS 1261 20.6 ± 1.3 14.8 ± 0.8
[125I]MK801 35.5 ± 4.6 25.5 ± 1.5
pH]MK801 4.5 ± 0.3 9.7 ± 0.4
Brain/aqueous partition ratios for [125I]CNS 1261, [125I]MK8Q1 and [3HJMK801 were 
calculated from the non-specific binding component of in vitro binding experiments. 
Ratios were calculated from the amount of non-specifically bound radioligand (dpm/g) 
and the amount of free radioligand present in the solution applied to the section (dpm/ml). 
Data are presented as mean ± S.E.M., n=6.
Note that [125I]CNS 1261 has a lower brain/aqueous partition ratio than [125I[MK801 in 
both rat and human sections.
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3 .5 Metabolism of [125I]CNS 1261 in the rat
3 .5 .1  Stability of [125I]CNS 1261 in vitro
Prior to investigation of the metabolism of [125I]CNS 1261 in vivo, the stability of the 
compound under routine storage conditions was examined by determination of the amount of 
deiodination which occurred. [125I]CNS 1261 was reconstituted in a 0.7% physiological 
saline solution identical to that used for intravenous injection of the tracer in vivo. The 
reconstituted tracer solution was stored at 4°C for approximately 4 weeks. High performance 
liquid chromatography (hplc) analysis of samples from the solution showed that little de­
iodination of [125I]CNS 1261 occured under the storage conditions described moreover, no 
significant deiodination of [125I]CNS 1261 was observed following incubation of the 
aqueous solution in rat plasma at 37°C for 2 hours.
The amount of authentic tracer and degradation products present in [125I]CNS 1261 injectate 
solutions from actual in vivo experiments was also examined (Table 16) and compared to that 
from experiments using [125]MK801.
[125I]CNS 1261 injectate solutions, reconstituted up to 6 hours prior to hplc analysis (and 
stored at room temperature), were found to contain aproximately 90% authentic tracer. 
[125i]MK801 injectate solutions did not contain a significantly different amount of authentic 
material
3 . 5 .2  Metabolism of [125I]CNS 1261 in the rat
Representative hplc traces from plasma samples taken at 5,15,60 and 120 minutes following 
intravenous administration of [125I]CNS 1261 are shown in Figure 24. The traces show the 
presence of two species in the plasma samples. The first species eluted with a retention time 
of 2.9 min and corresponds to iodide, the second species had a retention time of 7.6 min and 
was identified as authentic [125I]CNS 1261.
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TABLE 16
Species present in isotope solutions 6 hours after reconstitution
SPECIES [125l]CNS 1261 [125l]MK801
authentic tracer 91.2 ± 5.9 95.7 ±2.18
iodide 8.8 ± 5.9 4.3 ±2.18
other - 2.0 ± 0.0
Data are presented as mean ± S.E.M. (n = 3). Injectate solutions were reconstituted 
approximately 6 hours prior to hplc analysis. The amount of authentic material present in the 
injectate solutions was not different for the two tracers. The identity of the third species, 
present in only one of the [125I]MK801 animals was not determined.
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FIGURE 24 : Metabolism of [125I]CNS 1261 in the rat
Representative hplc traces fromplasma samples taken at 5, 15, 60 and 120 
minutes after administration of the tracer show the presence of 2 species which 
were identified as free iodide and authentic CNS 1261. The amount of 
[125IJCNS 1261 decreased rapidly over time while the amount of free iodide 
increased.
These traces show that the amount of authentic tracer decreased and the amount of free iodide 
increased with time.
[125I]CNS 1261A was metabolised extremely rapidly, such that only 15% authentic material 
remained in the plasma at 5 minutes and no authentic [125I]CNS 1261 could be detected in 
the plasma at 60 or 120 minutes (Figure 25).
Hplc analysis of all species present within the brain homogenate at 120 minutes confirmed 
that almost all the radioactivity within the brain could be attributed to authentic [125I]CNS 
1261 (95.4 ± 2.3% ). In some instances, a small fast moving peak (4.6 ± 2.3% ) could also 
be identified in brain extracts from animals killed at 120 minutes.
3 .5 .3  Metabolism of [125I]MK801 in the rat
Plasma samples were also taken from a second group of animals at 5, 15, 60 and 120 min 
following intravenous injection of [125I]MK801. Hplc traces are shown in Figure 26. The 
majority of traces showed the presence of only two species, with retention times of 2.9 min. 
and 8.3 min. which were identified as iodide and authentic [125I]MK801 respectively. The 
amount of authentic [125I]MK801 was found to decrease and the amount of iodide to increase 
with time. In a single animal, the amount of a third (unidentified) species was also found to 
increase with time. This retention time of this species was approxiamtely 4.5 minutes. 
[125i]MK801 was metabolised slowly, with approximately 55% authentic tracer present in 
the plasma at 5 minutes and approximately 20% [125I]MK801 could be detected at 120 
minutes (Figure 27). Hplc analysis of all species present within the brain homogenate at 120 
minutes confirmed that almost all (95%) of the radioactivity within the brain could be 
attributed to authentic [125I]MK801.
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FIGURE 25 : Timecourse of [125I]CNS 1261 metabolism in rat plasma.
Data represents levels of authentic [125I]CNS 1261 and iodide detected by hplc analysis of rat 
plasma samples at different time points following intravenous injection of [125I]CNS 1261. 
Data are expressed as means ± S.E.M., n=3.
Note the rapid clearance of authentic [125I]CNS 1261 from the plasma within the first 5 
minutes after injection.
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FIGURE 26 : Metabolism of [125I]MK801 in the rat
Representative hplc traces from plasma samples taken at 5, 15, 60 and 120 
minutes after administration of the tracer show the presence o f 2 species which 
were identified as free iodide and authentic MK801. The amount of 
[125I]MK801 decreased over the experiemntal period while the amount of free 
iodide increased
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FIGURE 27 : Timecourse of [125I]MK801 metabolism in rat plasma.
Data represents levels of authentic [125I]MK801, iodide and metabolites detected by hplc 
analysis of rat plasma samples at different time points following intravenous injection of 
[125I]MK80L Data are expressed as means ± S.EM., n=3.
Too few data points were available to calculate accurate plasma half-lives of the two tracers. 
However, log transforms of the plasma clearance curves (Figure 28) show that in the first 60 
minutes after injection, both [125I]CNS 1261 and [125I]MK801 clearance can be described 
by bioexponential kinetics. Log transforms of the plasma clearance curves also show that 
[12^I]CNS 1261 is metabolised much more rapidly than [125I]MK801. The rapid 
metabolism of [125I]CNS 1261 suggests that compared to [125I]MK801, this tracer will 
reach steady-state concentrations within the brain more quickly and non-specifically bound 
ligand will be washed out down its concentration gradient at a faster rate. These properties 
may improve the quality of images and decrease imaging time. [125I]CNS 1261 is thus 
metabolised in such a way as to confer significant advantages over [125I]MK801 as an in 
vivo imaging agent.
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FIGURE 28 : Comparison of plasma clearance of [125I]CNS 1261 and [125I]MK801
Data are expressed as mean ± S.E.M. (n=2-3). Log transforms of the plasma clearance of 
[125I]CNS 1261 and [125I]MK801 show both tracers display biexponential kinetics over the 
first 60 minutes following injection.
3 .6  Effect of pharmacological doses of MK801 on the uptake and 
retention of [125I]CNS 1261 in the normal rat brain
The effect of 2 doses of cold MK801 (0.4mg/kg + 6|ig/kg/min. and 1.2mg/kg + 
16|ig/kg/min) were examined on the uptake and retention of [125I]CNS 1261 in the 
normal rat brain.
3 .6 .1  General Observations
In these investigations [125I]CNS 1261 was administered 30 minutes after initiation of 
the MK801 infusion and animals were killed 120 minutes thereafter. Physiological and 
respiratory variables were recorded prior to (t =0) and 60 minutes after the start of the 
infusion (Table 17). Administration of a bolus dose and infusion of MK801 (0.4mg/kg 
+ 6}ig/kg/min. or 1.2mg/kg + 16|ig/kg/min.) induced an immediate, transient 
hypotension. Mean arterial blood pressure remained approximately 20mmHg lower than 
pre-infusion levels for the remainder of the experiment. Administration of MK801 had 
no effect on any of the parameters examined.
3.6.2. Authenticity of MK801
The batch of MK801 used in these experiments was subjected to nuclear magnetic 
resonance spectroscopy (NMRS) to determine the authenticity of the compound. NMRS 
data obtained for the batch of MK801 used (Figure 29) was compared to NMRS data for 
MK801 within the literature and confirmed that the compound analysed had an identical 
structure to MK801.
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TABLE 17
Physiological variables before and 60 minutes after 
initiation of MK801 infusion
MK801 Infusion
Physiological Sample time 0.4mg/kg + 1.2mg/kg +
variables (min) 6}ig/kg/min. 16|ig/kg/min.
PaC02 (mmHg) 0 40.5 ± 1.2 43.5 ± 3.7
60 39.3 ±3.1 40.5 ± 1.5
Arterial pH 0 7.44 ± 0.01 7.33 ± 0.05
60 7.41 ± 0.01 7.41 ± 0.01
Pa02 (mmHg) 0 154.3 ± 26.5 188.7 ± 13.1
60 158.3 ±18.1 192.5 ± 14.4
MABP (mmHg) 0 97 ± 7 85 ±5
60 79 ± 1 70 ± 5
temperature (°C) 0 37.2 ± 0.20 37.0 ± 0.03
60 37.0 ± 0.20 36.9 ± 0.22
Samples were taken immediately prior to (t=0) injection of MK801 bolus dose and 60 
minutes after initiation of infusion (t=60). [125I]CNS 1261 was administered 30 min. 
after the start of the infusion and animals were killed 120 minutes later. Administration 
of MK801 caused a sustained decrease in MABP at both doses examined. 
Administration of MK801 did not affect any of the other parameters examined (One-way 
ANOVA). Data are presented as mean ± S.E.M (n=3-4).
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FIGURE 29 : NMRS trace from a sample of MK801 used in displacement studies
Nuclear magnetic resonance spectrosopy was used to examine the the batch of MK801 
used in displacement experiments. The trace was interpreted by A. Tebbutt and 
compared to MK80I NMRS traces from the literature. It was confirmed that the 
compound analysed was authentic MK801.
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3 .6 .3  Uptake and retention of [125I]CNS 1261
The general pattern of uptake in all autoradiograms reflected NMDA receptor distribution 
with high levels observed within hippocampal structures and low levels in the 
hypothalamus and cerebellum (Figure 30). [125I]CNS 1261 uptake in each region of 
interest was expressed relative to the amount of [125I]CNS 1261 bound within the 
cerebellum (Table 18).
In both groups of animals receiving MK801, isotope levels within hippocampal regions 
were the highest of all structures examined (approximately 150-200% above that 
observed in the cerebellum). Uptake in cortical regions and hypothalamus were 60 and 
20% greater than cerebellar levels respectively.
The region of interest/cerebellar ratios of MK801 treated animals were compared to the 
corresponding ratios from previous experiments examining [125I]CNS 1261 uptake at 
120 minutes (see section 3.3.2). There was no significant difference in total [125I]CNS 
1261 binding between the control group and both groups treated with MK801 in any of 
the regions examined (Figure 31, see also Table 18).
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FIGURE 30 : Effect of MK801 on [12^I]CNS 1261 uptake in normal rat brain
Representative autoradiograms of [125I]CNS 1261 uptake in normal rat brain at the level 
of the dorsal hippocampus and cerebellum. Administration of pharmacologically active 
doses of MK801 (0.4 ± 6|ig/ml/min. or 1.2 ± 16|ig/ml/min.) had no effect of [125I]CNS 
1261 uptake within any refgion examined. Autoradiograms were compared to images 
obtained in a previous experiment investigating [125I]CNS 1261 uptake in the normal 
brain at 120 minutes.
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TABLE 18
Effect of MK801 on [125I]CNS 1261 uptake
[125r]CNS 1261 MK 801
STRUCTURE uptake (120 min.) 0.4mg/kg + 1.2mg/kg +
6|ig/kg/min 16}ig/kg/min
anterior cingulate cortex 1.69 ±0.10 1.79 ±0.11 1.63 ±"o. 13
genu 1.42 ±0.16 1.44 ±0.06 1.44 ±0.08
caudate nucleus 1.38 ±0.05 1.30 ±0.05 1.36 ±0.04
sensory-motor cortex
layers I- II 1.40 ± 0.05 1.29 ±0.08 1.42 ± 0.07
rv 1.39 ± 0.07 1.48 ±0.09 1.52 ± 0.05
V-VI 1.51 ±0.09 1.45 ±0.07 1.54 ±0.08
corpus callosum 1.47 ± 0.08 1.43 ± 0.05 L51 ±0.08
anterior thalamus 1.58 ± 0.04 1.68 ±0.10 1.56 ± 0.06
hippocampus CA1 2.44 ±0.21 2.58 ± 0.05 2.45 ±0.14
hippocampus CA3 2.43 ±0.19 2.64 ±0.13 2.58 ±0.15
lateral habenular nucleus 1.20 ± 0.03 1.24 ± 0.02 1.26 ±0.10
mediodorsal thalamus 1.61 ± 0.09 1.64 ± 0.07 1.68 ± 0.06
ventrolateral thalamus 1.56 ± 0.09 1.44 ± 0.04 1.49 ±0.10
internal capsule 1.11 ±0.04 1.23 ± 0.02 1.28 ± 0.07
parietal Cortex
layers I-IH 1.55 ± 0.08 1.52 ± 0.04 1.48 ±0.11
rv 1.49 ± 0.05 1.60 ± 0.04 1.63 ± 0.09
V-VI 1.68 ±0.10 1.59 ± 0.04 1.66 ±0.11
hypothalamus 1.05 ± 0.04 1.22 ± 0.01 1.27 ± 0.06
posterior cingulate cortex 1.51 ±0.06 1.49 ± 0.02 1.52 ± 0.07
hippocampus molecular layer 2.91 ± 0.22 2.94 ±0.10 2.89 ± 0.90
dentate gyrus 2.50 ±0.15 2.64 ± 0.08 2.58 ±0.15
auditory cortex
layers I-IH 1.63 ± 0.06 1.60 ± 0.02 1.65 ±0.14
IV 1.64 ± 0.05 1.63 ± 0.07 1.67 ± 0.09
V-VI 1.77 ± 0.05 1.79 ±0.08 1.82 ±0.11
substantia nigra pars compacta 1.24 ± 0.04 1.24 ± 0.00 1.30 ± 0.05
substantia nigra pars reticulata 1.17 ±0.05 1.16 ±0.00 1.22 ± 0.05
medial geniculate body .1.49 ± 0.05 1.47 ± 0.05 1.54 ± 0.09
visual cortex
layers I-IH 1.73 ± 0.09 1.81 ±0.04 1.81 ±0.11
IV 1.64 ± 0.09 1.78 ± 0.07 1.70 ±0.12
V-VI 1.67 ± 0.04 1.77 ± 0.08 1.76 ±0.12
entorhinal cortex 1.91 ±0.11 1.81 ±0.06 1.81 ±0.12
inferior colliculus 1.08 ± 0.01 1.14 ±0.01 1.20 ± 0.04
pons 1.31 ±0.06 1.38 ± 0.01 1.34 ± 0.07
cerebellar hemisphere 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00
cerebellar white matter 1.25 ±0.14 1.43 ± 0.04 1.33 ± 0.08
superior olivary nucleus 1.19 ±0.07 1.24 ± 0.07 1.17 ±0.05
[125I]CNS 1261 uptake following treatment with MK801 (0.4mg/kg + 6ug/kg/min or 
1.2mg/kg + 16ftg/kg/min) were compared to [125I]CNS 1261 uptake at 120 min. in a 
previous study (see section 3.3.2) using ANOVA . No significant differences in uptake 
were observed following treatment with MK801 at any of the doses examined.
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FIGURE 31 : MK801 does not displace [125I]CNS 1261 binding in normal brain.
At the doses examined, MK801 had no effect on the level of [125I]CNS 1261 binding in 
regions with high (hippocampus), intermediate (caudate nucleus) or low (hypothalamus) 
NMD A receptor density when compared to [125I]CNS 1261 uptake at 120 minutes from 
a previous experiment (ANOVA). Data are presented as mean ± S.E.M.(n=3-4).
3 .7  [125]MK801 and [125I]CNS 1261 uptake following changes in
arterial CO2 tension
This study consists of an intial short study to investigate the effect of changing arterial 
CO2 tension (hypocapnia and hypercapnia) on [125I]MK801 uptake in the rat. This is 
followed by a more extensive investigation of the effect of hypercapnia only on 
[125I]CNS 1261 uptake in the rat brain
3.7 .1  [125I]MK801 - general observations
Physiological variables were recorded before and 15 minutes after changes in CO2 
tension and are shown in Table 19. Prior to any manipulations (t = 0), physiological 
variables were deemed to be within normal limits and there were no significant 
differences between the three experimental groups.
Manipulation of respiratory status produced distinct changes in paCC>2, and consequently 
pH within the treatment groups. Hyperventilation produced a significant decrease in 
paCC>2 to approximately 22mmHg. The arterial pH of these hypocapnic animals was 
elevated from control values (pH 7.4) to pH 7.6. Increasing the concentration of CO2 in 
inspired air to 20% increased paCC>2 to approximately 180mmHg. The arterial pH of 
these hypercapnic animals was decreased from pH 7.4 to pH 6.9. No differences were 
observed in any of the other parameters.
3 .7 .2  Analysis of [125I]MK801 autoradiograms
Before quantitative analysis, [125I]MK801 uptake in normocapnic animals was observed 
to be greatest within hippocampal structures (CA1, CA3). [125I]MK801 uptake was 
similar within the caudate nucleus, thalamus and cortical regions and no lamination could 
be detected within the cortex. Levels of [125I]MK801 uptake within the hypothalamus 
and cerebellum were decreased compared to cortical regions (Figure 32).
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TABLE 19
Physiological variables following changes in arterial CO2 tension
sample NORMOCAPNIA HYPOCAPNIA HYPERCAPNIA
time (min.) (n = 8) (n = 6) n = 4
PaCC>2 (mmHg) 0 39 ± 1 41 ± 2 38 ±1
15 43 ±1 22 ± 1 * 184 ±5  *
Arterial pH 0 7.44 ± 0.07 7.41 ± 0.01 7.44 ± 0.01
15 7.42 ± 0.01 7.61 ± 0.02 * 6.94 ±0.01 *
paC>2 (mmHg) 0 167 ±11 145 ± 9 165 ± 8
15 178 ±10 196 ± 10 182 ±10
MABP (mmHg) 0 85 ± 4 87 ± 3 90 ± 5
15 86 ± 2 83 ± 1 88 ±3
temperature (°C) 0 37.1 ±0.1 37.0 ±0.1 37.0 ± 0.3
15 37.0 ±0.1 37.1 ±0.1 36.9 ± 0.1
glucose (mM) - 10.4 ±0.6 9.9 ±0.4 9.8 ±0.3
weight (g) - 388 ±11 398 ± 15 359 ±14
n - 8 6 4
Changes in CO2 tension were induced 15 before tracer administration and maintained for 
the duration of the experiment The data represents physiological variables measured 
before manipulations in CO2 tension (t=0) and immediately prior to administration of 
[125i]MK801 (t=15). * p< 0.05 for significant difference between treated and control 
animals (ANOVA, followed by Student's t-test).
Data are presented as mean ± S.E.M.
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FIGURE 32 : Effect of hypercapnic acidosis on [125I]MK801 uptake 
Representative autoradiograms from the level of the dorsal hippocampus (upper) and
125cerebellum(lower) showing [ IJMK801 uptake in normocapnic and hypercapnic
125animals. In normocapnic (control) animals highest levels of [ I]MK801 were
observed within the dorsal hippocampus (CA1) . Hypercapnia had a tendency to 
reduce [125I]MK801 uptake within the hippocampus. (CA1 : hippocampus CA1).
The overall pattern of [125I]MK801 uptake in autoradiograms from hypocapnic animals did 
not differ markedly from those of normocapnic animals. Autoradiograms from hypercapnic 
animals had a more homogeneous appearance with [125I]MK801 uptake within the 
hippocampal formation only slightly above that within the cortex (Figure 32). Consistent 
with the other experimental groups, [125I]MK801 uptake within the hypothalamus and 
cerebellum was decreased relative to cortical regions.
The uptake of [125I]MK801 in 9 individual regions of interest was expressed as a ratio 
relative to [125I]MK801 uptake within the cerebellum. [125I]MK801 uptake ratios for 
normocapnic, hypocapnic and hypercapnic animals are shown in Table 20.
Quantitative analysis of autoradiograms from normocapnic animals confirmed that 
[125ijm K801 uptake was relatively homogeneous in the majority of regions examined, 
approximately 10-20% greater than that observed within the cerebellum. [125I]MK801 
uptake within CA1 and CA3 of the hippocampus was slightly elevated and was 
approximately 30% above that observed within the cerebellum. [125I]MK801 uptake 
within the hypothalamus was comparable to that within the cerebellum (Figure 32).
No significant differences in [125I]MK801 uptake were observed between the hypocapnic 
group and control (normocapnic) animals in any of the regions examined.
Induction of hypercapnia (paC02 = 180mmhg, pH 6.9) was also found to have no
significant effects on [125I]MK801 uptake in any of the regions examined (Figure 33). 
There was a tendency however, for hypercapnic acidosis to reduce [125I]MK801 uptake 
within the hippocampus (CA1, CA3), anterior cingulate cortex and sensory-motor cortex.
A Kolmorgorov-Smimov test (SigmaStat) performed on this data showed the values for 
[125I]MK801 uptake in CA1 were not normally distributed. Since the outlying values were 
within 2 standard deviations of the mean and could not be excluded, all data was 
reanalysed using a Kruskal-Wallis test (SigmaStat). No statistical differences existed 
between the mean values of the treatment groups in any of the structures examined. These 
results support the original statistical analysis and suggest that [125I]MK801 is an 
unsuitable agent to image potential changes in NMDA receptor activation in the normal rat 
brain.
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TABLE 20
[125i]MK801 uptake following changes in arterial CO2 uptake
STRUCTURE NORMOCAPNIA HYPOCAPNIA HYPERCAPNIA
pH 7.4 pH 7.6 pH 6.9
Anterior cingulate cortex 1.12 ±0.02 1.13 ±0.02 1.07 ± 0.01
Sensory-motor cortex 1.11 ±0.02 1.08 ± 0.02 1.03 ± 0.01
Caudate nucleus 1.08 ± 0.02 1.06 ± 0.02 1.06 ± 0.01
Hippocampus CA1 1.28 ± 0.05 1.35 ± 0.04 1.15 ±0.03
Hippocampus CA3 1.22 ± 0.04 1.28 ± 0.03 1.15 ± 0.01
Hypothalamus 1.01 ± 0.02 1.01 ± 0.02 1.00 ± 0.03
Posterior cingulate cortex 1.10 ±0.03 1.10 ±0.04 1.09 ± 0.03
Thalamus 1.13 ±0.03 1.19 ±0.04 1.12 ±0.03
Cerebellum 1 1 1
Uptake in individual regions of interest was expressed as a ratio relative to uptake within 
the cerebellar hemisphere. In all groups uptake was greatest in hippocampus CA1 and 
CA3. No significant differences in uptake were observed between hypo-or hypercapnic 
groups and control animals (ANOVA followed by Student's t-test with Bonferroni 
correction). Data are presented as mean ± SEM.
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FIGURE 33 : The effect of hypercapnic acidosis on [125I]MK801 uptake
Data is redrawn from Table 20 and represent levels of [125I]MK801 uptake in 8 regions 
of interest. Highest levels of uptake in the normocapnic group were observed within the 
hippocampus (CA1 and CA3) and lowest levels were observed within the hypothalamus. 
[125I]MK801 uptake was relatively homogeneous in the other regions examined. 
Hypercapnia had a tendency to reduce [125I]MK801 uptake within the hippocampus, 
anterior cingulate cortex and sensory-motor cortex. Data are mean ± S.E.M., n=4-8.
(CA1, CA3 =dorsal hippocampus, Th = thalamus, Acc = anterior cingulate cortex, Smc 
= sensory-motor cortex, Pcc = posterior cingulate cortex, Cn = caudate nucleus, Hyp = 
hypothalamus).
3.7.3 [125I]CNS 1261 - general observations
Physiological variables were recorded before and 15 minutes after changes in arterial CO2 
tension and are shown in Table 21. Prior to any manipulations (t = 0), physiological 
variables were deemed to be within normal limits and there were no significant 
differences between the three experimental groups.
Manipulation of respiratory status produced distinct changes in paC02, and consequently 
pH within the hypercapnic treatment group. Increasing the concentration of CO2 in 
inspired air to 20% increased paCC>2 to approximately 170mmHg. The arterial pH of 
these hypercapnic animals was decreased from pH 7.4 to pH 6.9 The mean arterial 
blood pressure of hypercapnic animals was also significantly increased compared to 
control animals.
3 . 7 .4  Analysis of [125I]CNS 1261 autoradiograms
Before quantiative analysis, the highest levels of [125I]CNS 1261 uptake were observed 
within the hippocampus (CA1, CA3, molecular layer) in all autoradiograms (Figure 34). 
The uptake of [125I]CNS 1261 in 36 individual regions of interest was expressed as a 
ratio relative to [125I]CNS 1261 uptake within the cerebellum. [125I]CNS 1261 uptake 
ratios for normocapnic and hypercapnic animals are shown in Table 22.
Quantitative analysis of autoradiograms from normocapnic animals showed that 
[125i]CNS 1261 uptake was relatively heterogeneous in the majority of regions 
examined. [125I]CNS 1261 uptake was 60-90% above cerebellar values in cortical areas 
with the highest levels of uptake within deep layers (V-VI). Highest levels of [125I]CNS 
1261 uptake were observed within hippocampal regions (CA1, CA3 and molecular layer) 
where uptake was 2-300% greater than that observed within the cerebellum. Low levels 
of uptake were observed in cerebellar white matter and superior olives where uptake was 
approximately 30% greater than that observed within the cerebellum.
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TABLE 21
Physiological variables following changes in arterial CO2 tension
sample time 
(min.)
NORMOCAPNIA HYPERCAPNIA
PaCC>2 (mmHg) 0 42 ± 3 40 ± 1
15 41 ± 2 166 ± 10**
Arterial pH 0 7.42 ± 0.01 7.44 ± 0.02
15 7.40 ± 0.01 6.93 ±0.01**
pa02 (mmHg) 0 161 ±17 198 ± 10
15 173 ±33. 208 ± 3
MABP (mmHg) 0 86 ± 3 80 ± 3
15 80 ± 2 101 ±2**
temperature (°C) 0 36.7 ± 0.32 37.1 ± 0.09
15 36.8 ± 0.57 37.2 ±0.19
weight (g) - 334 ±30 330 ±25
n - 3 3
Changes in CO2  tension were induced 15 minutes before tracer administration and 
maintained for the duration of the experiment. The data represents physiological 
variables measured before manipulations in CO2  tension (t=0) and immediately prior to 
administration of [125I]CNS 1261 (t=15). **p< 0.01 for significant difference between 
hypercapnic and normocapnic animals (Student's unpaired t-test). Data are presented as 
mean ± S.E.M.
106
TABLE 22
[125I]CNS 1261 uptake following changes in arterial CCb tension
STRUCTURE
anterior cingulate cortex 
genu
sensory motor cortex
layer I-HI
layer IV
layers V-VI
caudate nucleus
corpus callosum
anterior thalamus
hippocampus CA1
hippocampus CA3
lateral habenular nucleus
mediodorsal thalamus
ventrolateral thalamus
internal capsule
parietal cortex
layers I-EU
layer IV
layer V-VI
hypothalamus
posterior cingulate cortex
hippocampus molecular layer
dentate gyrus
auditory cortex
layers I-IH
layer IV
layer V-VI
substantia nigra pars compacta
substantia nigra pars reticulata
medial geniculate body
visual cortex
layers I-IH
layer IV
layers V-VI
entorhinal cortex
inferior colliculus
pons
cerebellar cortex 
cerebellar white matter 
superior olives
Normocapnia Hypercapnia
pH 7.4 pH 6.9
2.01 ±0.21 1.09 ±0.13*
1.75 ±0.28 1.65 ±0.15
1.64 ±0.13 1.09 ±0.07**
1.73 ±0.15 1.00 ±0.04**
1.86 ±0.18 1.16 ±0.04**
1.66 ±0.13 1.39 ±0.20
1.82 ± 0.06 1.92 ±0.31
2.03 ± 0.24 1.74 ± 0.25
3.19 ±0.19 2.22 ± 0.33
3.42 ± 0.23 2.12 ±0.26**
1.40 ± 0.05 1.51 ±0.30
1.89 ± 0.20 1.33 ±0.03*
1.51 ±0.14 1.30 ± 0.05
1.77 ± 0.30 1.45 ±0.19
1.70 ±0.14 1.09 ± 0.07**
1.66 ± 0.08 1.15 ±0.08**
1.91 ±0.19 1.40 ± 0,08
1.33 ±0.14 1.02 ± 0.05
1.52 ±0.21 1.31 ±0.16
4.13 ±0.36 2.50 ± 0.35*
3.85 ± 0.25 2.31 ±0.24*
1.84 ±0.16 1.18 ±0.04**
1.93 ±0.14 1.28 ± 0.08**
2.39 ±0.18 1.59 ± 0.20*
1.27 ± 0.25 1.30 ±0.10
1.13 ±0.25 1.32 ± 0.05
1.50 ± 0.35 1.56 ± 0.25
1.73 ± 0.20 1.30 ±0.21
1.80 ±0.12 1.42 ± 0.23
2.00 ± 0.19 1.46 ±0.19
2.31 ±0.10 1.51 ±0.28
1.00 ± 0.20 1.21 ±0.11
1.42 ± 0.29 1.44 ± 0.08
1.00 ± 0.00 1.00 ± 0.00
1.28 ± 0.26 1.25 ± 0.25
1.22 ±0.21 1.19 ±0.01
Uptake of [125I]CNS 1261 in individual regions of interest were expressed as a ratio 
relative to uptake within the cerebellum. Roman numerals (I-VI) indicate the cortical 
layer examined. [125I]CNS 1261 uptake was greatest in the hippocampus in both 
groups. Data are presented as mean ± S.E.M., n = 3. *p<0.05. **p<0.01 (Students 
unpaired t-test).
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Induction of hypercapnia had a tendency to reduce [125I]CNS 1261 uptake in all of the 
regions examined. Hypercapnia had a marked effect in 13 of the 36 regions examined, 
significantly reducing [125I]CNS 1261 uptake in anterior cingulate cortex, sensory motor 
cortex (layers 1-VI), hippocampus CA3, mediodorsal thalamus, parietal cortex (layers I- 
IV), hippocampus molecular layer, dentate gyrus and auditory cortex (layers I-VI). 
Following hypercapnia the highest levels of uptake were still observed within 
hippocampal regions, despite [125I]CNS 1261 uptake being reduced by over 100%. This
I reduction in [125I]CNS 1261 uptake within the hippocampus is clearly visible in the
I
autoradiographic images (Figure 34). Reductions in [125I]CNS 1261 uptake of 50-80%
| were observed in cortical regions. Reductions in [125I]CNS 1261 uptake in regions with
i
| a lower density of NMD A receptors were of a smaller magnitude, typically <30% and
i
! were not significant.
| Relative [125I]CNS 1261 uptake in the same 8 regions examined in section 3.7.2 were
| redrawn from Table 22 and are shown in Figure 35.
| These results suggest that [125I]CNS 1261 can image the heterogeneity in NMDA
receptor activation within the normal brain and, is a suitable agent to image reductions in!
I NMDA receptor activation induced by hypercapnic acidosis.
I
i
Ii
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FIGURE 34 : Effect of hypercapnic acidosis on [125I]CNS 1261 uptake
Autoradiograms from individual experiments of [125I]CNS 1261 uptake at the level of the 
dorsal hippocampus. [125I]CNS 1261 uptake in normocapnic animals (upper) was 
compared to that in hypercpnic animals (lower). Hypercapnic acidosis decreased the 
amount of [125I]CNS 1261 uptake within CA1 and CA3 regions of the hippocampus in 
all animals.
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FIGURE 35 : Effect of hypercapnic acidosis on [125I]CNS 1261 uptake
Data is redrawn from Table 22 and represent levels of [125I]CNS 1261 uptake in 8 
regions of interest Highest levels of uptake in the normocapnic group were observed 
within the hippocampus (CA1 and CAS) and lowest levels were observed within the 
hypothalamus. Hypercapnia significantly reduced [125I]CNS 1261 uptake within the 
hippocampus CA3, thalamus, anterior cingulate cortex and sensory-motor cortex.
** p < 0.01, * p < 0.05 (Student's unpaired t-test). Data are mean ± S.E.M., n=4-8
(CA1, CA3 =dorsal hippocampus, Th = mediodorsal thalamus, Acc = anterior cingulate 
cortex, Smc = sensory-motor cortex (IV), Pcc = posterior cingulate cortex, Cn = caudate 
nucleus, Hyp = hypothalamus).
3.8. [125I]CNS 1261 uptake following intracortical injection of NMDA 
or CSF
3.8.1. Verification of dose
Initial investigations examined the effect of injecting NMDA (9 fimoles) in a volume of 
l|il. The practical aspects of injecting such a small volume of fluid and the inability to 
locate the position of the injection site on autoradiograms prompted a change to the 
experimental protocol. The injection volume was increased to 3|il, thus increasing the 
amount of NMDA injected to 27|imoles.
The ability of this dose of NMDA to induce receptor activation was verified by [14C]2- 
deoxyglucose autoradiography. [14C]2-deoxy glucose (50p.Ci) was administered 15 
minutes after intrastriatal injection of NMDA. Brains were removed and processed for 
autoradiography 45 minutes after injection of tracer.
Following NMDA injection, increases in glucose utilisation were observed in all layers 
of the sensory motor cortex (Table 23). The general pattern of uptake at the site of 
NMDA injection showed a pale core region where glucose utilisation was reduced by 
50% relative to the corresponding area of the contralateral cortex, surrounded by a rim 
of increased glucose utilisation (Figure 36). Glucose utilisation in this rim was 
approximately 2.5 times greater than in corresponding region of the contralateral 
hemisphere.
3.8.2. General Observations
In these investigations, [125I]CNS 1261 was administered 15 minutes after intrastriatal 
injection of NMDA (or CSF) and the animals sacrificed at 5min., 60min.and 120min. 
thereafter. Physiological and respiratory variables were recorded prior to injection of 
NMDA or CSF (t=0 min.) and before intravenous administration of [125I]CNS 1261 
(t=15 min.) and are shown in Table 24.
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TABLE 23
Changes in glucose utilisation following intracortical injection of NMDA
Glucose Use (jimoles/lOOg/min.
Animal 1 Animal 2
STRUCTURE ipsi contra ipsi contra
anterior cingulate cortex 82 82 74 75
genu
sensory motor cortex
33 31 33 30
layers I-DI 113 73 69 59
layer IV 92 62 73 63
layers V-VI 43 51 127 60
caudate nucleus 86 95 83 86
corpus callosum 32 35 43 38
anterior thalamus 84 86 52 48
hippocampus CA1 41 41 34 42
hippocampus CA3 77 82 64 79
lateral habenular nucleus 82 82 83 76
mediodorsal thalamus 53 56 48 43
ventrolateral thalamus 53 61 58 50
internal capsule 
parietal cortex
23 24 20 16
layers I-HI 83 78 47 47
layer IV 63 64 44 45
layers V-VI 64 64 48 46
hypothalamus 41 42 42 47
posterior cingulate cortex 88 86 67 70
hippocampus molecular layer 45 50 55 51
dentate gyrus 
auditory cortex
97 100 95 85
layers I-IH 76 98 65 63
layer IV 80 87 52 58
layers V-VI 66 81 54 59
substantia nigra pars compacta 77 81 88 88
substantia nigra pars reticulata 72 68 46 45
medial geniculate body 
visual cortex
50 52 38 42
layers I-DI 62 73 51 56
layer IV 67 80 48 52
layers V-VI - 58 62 47 47
entorhinal cortex 58 61 51 45
inferior colliculus 62 59 56 53
pons 37 38 45 41
cerebellar hemisphere 35 38 44 36
cerebellar white matter 23 21 24 22
superior olivary nucleus 44 49 53 50
Glucose utilisation was measured by [14C]2-deoxyglucose autoradiography following 
injection of NMDA into the ipsilateral sensory-motor cortex. Data are individual 
values of glucose use within the ipsilateral and contralateral hemispheres of the 2 
experimental animals investigated. Roman numerals indicate the cortical layer 
examined.
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FIGURE 36 : Glucose use within the parietal cortex is increased following injection 
of NMDA
Representative autoraiogram illustrating glucose use afer unilateral injection of 
NMDA into the parietal cortex (left hemisphere) at the level of the injection site. 
Increased glucose use is evident in the zone of tissue bordering the injection site 
(arrowheads). Glucose use in this border zone was 250% above that in 
corresponding regions of the contralateral hemisphere.
Injection of NMDA or CSF into the sensory-motor cortex had no effect on any of the 
parameters examined. The physiological variables of animals receiving an intracortical 
injection of NMDA were not different from animals receiving an injection of vehicle at 
any of the time points examined. No differences in physiological variables were 
observed within the experimental groups.
3.8.3. Histology
Additional brain sections from these animals were stained with haematoxylin and eosin 
(H & E). While fresh frozen brain sections do not preserve cell morphology as well 
as tissue fixed with formaldehyde, these sections gave an indication of the changes 
caused by intracortical injection of NMDA and CSF and confirmed the presence of an 
injection site. In all sections, an area of pallor was evident following staining which 
corresponded in shape and size to the pale zone surrounding the injection site on 
autoradiographic films (Figures 37-39). At all time points a boundary could be 
delineated between the area of pallor and surrounding histologically normal tissue 
however this was more defined following injection of NMDA (Figure 40).
At all time points examined, the area of pallor was larger following NMDA injection. 
In addition to the loss of stain within this area, neuronal cells had a shrunken 
appearance. At later time points there was evidence of shrunken neurons outwith the 
area of pallor. In all cases cells within the contralateral hemisphere were histologically 
normal (Figures 41-43).
3.8.4. Uptake and retention of [125I]CNS 1261
The in vivo uptake and retention of [125I]CNS 1261 was examined in 38 anatomically 
discrete regions 5,60 and 120 minutes after intracortical injection of NMDA or CSF. 
[125I]CNS 1261 uptake in individual regions of interest was expressed as a ratio 
relative to uptake within the cerebellar hemisphere. Ratios of [125I]CNS 1261 uptake 
relative to cerebellar levels are shown in appendix 2.
CSF injection NM D A injection
FIGURE 37 : Effect of NMDA (or CSF) injection on [125I]CNS 1261 uptake 5 min. 
after administation
125Representative autoradiograms (upper) showing [ IJCNS 1261 uptake 5 min. after 
intracortical injection o f CSF (left) or NMDA (right). Corresponding haematoxylin 
and eosin (H&E) stained sections (lower) show that the size and shape of the area of 
pallor in these sections is similar to that observed in autoradiograms. The site of the
125injection is marked with an arrow. Note the decrease in [ IJCNS 1261 uptake within 
the insular cortex in both autoradiograms (arrowhead).
CSF injection NM DA injection
FIGURE 38 : Effect of NMDA (or CSF) injection on [12:>I]CNS 1261 uptake 60 min. 
after administation
125 nRepresentative autoradiograms (upper) showing [ IJCNS 1261 uptake 60 min. after 
intracortical injection of CSF (left) or NMDA (right). Corresponding haematoxylin 
and eosin (H&E) stained sections (lower) show that the size and shape of the area of 
pallor in these sections is similar to that observed in autoradiograms. Note the rim of 
increased [123I]CNS 1261 uptake surrounding the area of pallor in both 
autoradiograms (arrows).
CSF injection NM DA injection
FIGURE 39 : Effect ofNM DA (or CSF) injection on [123I]CNS 1261 uptake 120 min. after 
administation
125Representative autoradiograms (upper) showing [ IJCNS 1261 uptake 120 min. after 
intracortical injection of CSF (left) or NMDA (right). Corresponding haematoxylin and eosin 
(H&E) stained sections (lower) show that the size and shape of the area of pallor in these
125sections is similar to that observed in autoradiograms. Note the rim of increased [ IJCNS 
1261 uptake surrounding the area of pallor in following NMDA injection (arrows).
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FIGURE 40 : Comparison of the boundary between the area of pallor and histologically 
normal tissue at 120 minutes
High power (x 50) photomicrographs taken from the boundary zone between the area of 
pallor and histologically normal tissue 120 minutes after intracortical injection of NMDA 
(upper) or CSF (lower) into the ipsilateral cortex. Note that the boundary was more 
defined following NMDA injection.
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FIGURE 41 : High power photomicrographs from the ipsilateral and contralateral cortex 
5 minutes after injection of NMDA or CSF
High power photomocrographs (x 50) were taken from the area of pallor (ipsilateral 
cortex) and from the corresponding area of the contralateral hemisphere 5 minutes after 
intracortical injection of NMDA (upper) or CSF (lower). Note the loss of staining within 
the ipsilateral cortex (left).
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FIGURE 42 : High power photomicrographs from the ipsilateral and contralateral cortex 
60 minutes after injection of NMDA or CSF
High power photomocrographs (x 50) were taken from the area of pallor (ipsilateral 
cortex) and from the corresponding area of the contralateral hemisphere 60 minutes after 
intracortical injection of NMDA (upper) or CSF (lower). Note the loss of staining within 
the ipsilateral cortex (left).
FIGURE 43 : High power photomicrographs from the ipsilateral and contralateral cortex 
120 minutes after injection of NMDA or CSF
High power photomocrographs (x 50) were taken from the area of pallor (ipsilateral 
cortex) and from the corresponding area of the contralateral hemisphere 120 minutes after 
intracortical injection of NMDA (upper) or CSF (lower). Note the loss of staining within 
the ipsilateral cortex (left).
Five minutes after intravenous injection the distribution of [^IJC N S 1261 in the 
contralateral hemisphere was highest within areas known to have high blood flow, 
such as the anterior thalamus and cortical areas (layers V-VI > layer IV > layers I-M, 
Figure 37). High levels of uptake were also observed within the supraoptic and 
paraventricular hypothalamic nuclei and mamillary body. Intermediate levels of uptake 
were observed in thalamus and lowest levels of uptake in the hippocampus and 
hypothalamus.
Intracortical injection of NMDA or CSF produced distinct alterations in [125I]CNS 
1261 uptake within the ipsilateral hemisphere. Intracortical injection of both NMDA 
and CSF produced a general decrease in [125I]CNS 1261 uptake in the anterior 
cingulate, sensory motor, parietal, auditory, posterior cingulate, visual and entorhinal 
cortices. A reduction on [125I]CNS 1261 uptake was also observed within the insular 
cortex (Figure 37). In addition, intracortical injection of NMDA produced an intensely 
'white zone' on the autoradiograms which was localised around the injection site. 
This 'white zone' extended through all the cortical layers and for approximately 
400|im on either side of the injection site. This 'white zone' was bounded by a 
narrow margin of increased [125I]CNS 1261 uptake.
Intracortical injection of CSF produced a smaller and less intense 'white zone' at the 
injection site. A narrow boundary of increased uptake was less evident in these 
animals.
Sixty minutes after intravenous injection the highest levels of [125I]CNS 1261 uptake 
were observed within the hippocampus (80% above that within the cerebellum). 
Injection of NMDA or CSF produced alterations in [125I]CNS 1261 uptake within the 
ipsilateral cortex. NMDA injection produced a lesion with a pale core area surrounded 
by a narrow border of increased uptake, the size and extent of the lesion is detailed in 
Figure 44.
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FIGURE 44 : Size and extent of lesions 60 minutes after injection of NMDA or CSF
The size of the lesions on individual [125IJCNS 1261 autoradiograms 60 minutes after 
intracortical injection of NMDA (upper) and CSF (lower) were measured by area 
analysis and plotted against stereotaxic level. NMDA injection produced larger more 
extensive lesions than CSF injections.
At its maximum the pale core area measured between 2-6 mm2 and extended 
approximately 6mm. [125I]CNS 1261 uptake within the pale core area was 
approximately 50% lower than in the corresponding area of cortex on the contralateral 
hemisphere. [125I]CNS 1261 uptake within the border zone was 40% above that in 
the darkest area of the contralateral hemisphere.
In contrast, CSF injection produced much smaller, more localised lesions (Figure 44). 
Extremely small (<1 mm2) lesions were measured in two animals and a slightly larger 
lesion (2mm2) in the third animal investigated. A rim of increased [125I]CNS 1261 
uptake was observed around the largest lesion (20% above contralateral hemisphere), 
however this was less evident than in NMDA-induced lesions.
120 minutes after intravenous injection, [125I]CNS 1261 uptake was similar to that 
described in previous experiments at 60 minutes and reflected the classical pattern of 
NMDA receptor distribution, with highest levels within the hippocampus, intermediate 
levels in the thalamus and lowest levels within the hypothalamus and cerebellum. Both 
NMDA and CSF injection produced alterations in [l25I]CNS 1261 within the 
ipsilateral cortex. NMDA injection produced a large lesion, the size and extent of 
which is shown in Figure 45. The lesion could be characterised as an extensive area 
of pallor (40% lower than contralateral levels) extending from the cortical surface to 
immediately above the corpus callosum. At its maximum, the area of pallor measured 
between 4-8 mm2 and extended approximately 6mm from the injection site. A narrow 
margin of increased [125I]CNS 1261 uptake was observed surrounding this paler core 
area. [12^I]CNS 1261 uptake in this area was approximately 70% higher than in 
corresponding areas of the contralateral hemisphere. CSF injection produced a 
smaller, much more circumscribed lesion than NMDA injection (Figure 45). This 
lesion could still be described as an areal of pallor (< lmm2) bounded by a rim of 
increased uptake (20% above contralateral values), however this was less evident than 
in NMDA-induced lesions.
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FIGURE 45 : Size and extent of lesions 120 minutes after injection of NMDA or CSF
The size of the lesions on individual [125I]CNS 1261 autoradiograms 120 minutes 
after intracortical injection of NMDA (upper) and CSF (lower) were measured by area 
analysis and plotted against stereotaxic level. NMDA injection produced larger more 
extensive lesions than CSF injections.
In a single animal, [125I]CNS 1261 uptake at 120 minutes after intracortical injection 
of CSF did not reflect the pattern described in previous experiments with the same 
procedure (Figure 46). Notes taken during this experiment state that some damage 
was caused to pial vessels during removal of the bone. Sub cortical blood was evident 
when the brain was cut and processed for autoradiography indicating inadvertant 
rupture of a blood vessel during injection. H & E staining showed an area of pallor 
extending beyond the subcortical white matter into the caudate nucleus. Disruption of 
white matter was evident within this area (Figure 46). This animal was excluded from 
the CSF injection group due to these observations. Examination of this autoradiogram 
showed fairly homogeneous low levels of [12^ I]CNS 1261 uptake throughout the 
brain. However, areas of increased [125I]CNS 1261 uptake (approximately 3 times 
greater than in corresponding contralateral areas) exist within the ipsilateral cortex and 
within the caudate nucleus.
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FIGURE 46 : [i23I]CNS 1261 uptake is increased in areas of damage
The upper figure shows a representative autoradiogram from an experiment with 
abnormal [125I]CNS 1261 uptake following CSF injection. [12dI]CNS 1261 was 
increased at the injection site and in subcortical region within the ipsilateral 
hemisphere (arrows). High power photomicrographs (lower) show that there is 
damage within the subcortical white matter of the ipsilateral cortex (left) . 
Contralateral subcortical white matter is shown on the right for comparison.
CHAPTER IV 
DISCUSSION
4.1 CNS 1261 acts as a non-competitive NMDA receptor antagonist
Potential candidates for use as in vivo imaging agents must satisfy a number of criteria 
in vitro. Ligand binding must be pharmacologically selective, and of high affinity for 
the receptor target of interest.
Initial in vitro binding experiments showed that CNS 1261, an analogue of Cerestat 
(Aptiganel, CNS 1102) inhibited [3H]MK801 binding to rat brain membranes with Kj =
25nM in Tris buffer. Wong et al (1988) reported that MK801 displaced [3H]MK801 
binding to rat brain homogenates with Kj = 3nM, with similar results for the inhibition
of [3H]TCP binding. CNS 1261 is therefore approximately 10 times less potent than 
MK801 in inhibiting [3H]MK801 binding. The association affinity constant (Kj) of
CNS 1261 is comparable with the reported values for inhibition of [3H]MK801 binding 
by known non-competitive NMDA receptor antagonists TCP and PCP (14nM and 
42nM respectively). The dissociative anaesthetic ketamine inhibits [3H]MK801 binding 
with Kj = lpM (Wong et al, 1988).
Results of the commercial screen show that at the doses examined, CNS 1261 caused a 
99% inhibition of [3H]MK801 binding. CNS 1261 showed little affinity for other 
subtypes of glutamate receptor, inhibiting [3H]AMPA binding by only 3%. CNS 1261 
also did not display affinity at the transmitter recognition site or the glycine site of the 
NMDA receptor complex.
Non-competitive antagonists can generally be classified into groups which exhibit more 
or less selectivity between MK801 and a  opioid sites (Wong et al, 1988). Modification 
of the structure of DTG (N, N'-di-o-tolylguanidine), a known selective a  receptor ligand, 
led to the synthesis of novel diarylguanidines which exhibit high selectivity for the 
NMDA receptor ion channel site and weak or negligible for a receptors. Compounds 
having ortho or meta substituents on the phenyl rings, such as CNS 1102 (N-(l- 
naphthyl)-Af-(3-ethylphenyl)-N-methylguanidine), show greater affinity for the NMDA 
receptor ion channel site (Reddy et al, 1994). CNS 1261, a structural analogue of CNS 
1102, displays a clear selectivity for the NMDA receptor ion channel site and does not
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display activity in the opiate receptor binding assay (5% inhibition of pH]naloxone 
binding).
It was of interest that CNS 1261 was found to inhibit [3H]prazosin binding to the a l  
adrenoceptor by 33%. While 'activity' in a given assay was described as > 50% 
inhibition, this effect may be an indication of potential sympathomimetic effects of this 
compound.
Observations from in vitro binding experiments suggest that CNS 1261 displays both 
high affinity and selectivity for the MK801 binding site within the NMDA receptor 
channel.
The [14C]2-deoxyglucose autoradiographic technique allows an anatomically 
comprehensive assessment of function-related alterations in cerebral glucose use in vivo. 
The functional activity of any brain region is intrinsically linked with the energy 
consumption within that region. Local alterations in glucose use have been used to 
demonstrate the involvement of discrete brain areas during various physiological and 
pharmacological interventions. The systemic administration of NMDA channel blocking 
agents such as MK801 result in overt behavioural responses and marked alterations in 
glucose use within the central nervous system which can be distinguished from those 
produced by competitive NMDA antagonist (Kurumaji et al, 1989, Shaikey et al, 1994). 
CNS 1261 administration produced behavioural effects at all doses examined (1, 3, 
lOmg/kg) consisting of stereotypical side-to-side and cyclical head movements, sedation 
and a reduced response to external stimuli These overt behavioural changes were similar 
to those described by others following administration of MK801 (Kurumaji et al, 1989, 
McCulloch and Iversen, 1990).
Administration of CNS 1261 (3mg/kg and lOmg/kg) to conscious animals produced a 
dose-dependent moderate hypertension (e.g. 20-40 mmHg increase in mean arterial 
pressure compared to pre-injection levels). A modest increase in PaCC>2 was also 
observed following administration of CNS 1261 (lOmg/kg). Studies investigating the 
effect of MK801 on glucose use reported comparable effects on cardiovascular and
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respiratory parameters. Administration of competitive NMDA antagonists, such as CPP 
did not significantly alter arterial pressure (Kurumaji et al, 1989, Nehls et al, 1990., 
Sharkey et al, 1994). In ligand binding studies, CNS 1261 does not interact with 
dopamine, serotonin, muscarinic, GABA or benzodiazepine binding sites, however 
sympathomimetic effects are implied from its moderate activity at the a - 1 adrenoceptor. 
The increase in mean arterial pressure after administration is consistent with such an 
effect. Baroreceptor reflexes activated by a rise in arterial pressure cause a reflex 
bradycardia and inhibition of respiration which may account for the observed increase in 
CO2 tension following administration of the highest dose of CNS 1261 
CNS 1261 administration (l-10mg/kg) resulted in statistically significant increases in 
glucose use within the hippocampus molecular layer, dentate gyrus, limbic system 
(posterior cingulate cortex, caudal entorhinal cortex mamillary body, anteroventral 
thalamus), retrosplenial cortex and the myelinated fiber tracts of the fornix. Glucose use 
within the neocortex and inferior colliculus was particularly sensitive to CNS 1261 
administration. The overall pattern of alterations in glucose use produced by 
administration of CNS 1261 was extremely similar to that described for MK801 
(Kurumaji et al, 1989, Nehls et al, 1990, for review see McCulloch and Iversen, 1991, 
Kurumaji et al, 1993). The regional changes in glucose utilisation following 
administration of CNS 1261 do not correlate simply with the NMDA receptor density 
(Jarvis et al, 1987, Wong et al, 1988). While glucose use was increased in areas such as 
the hippocampal molecular layer which possesses a high number of NMDA receptors, no 
changes in glucose use were observed within the CA1 region of the hippocampus which 
has one of the highest densities of NMDA receptors in the central nervous system 
The magnitude of elevations in glucose use within limbic structures was generally in the 
region of 80%, however exceptionally large increases in glucose use (100-200%) were 
observed within entorhinal cortex (caudal) and within the mamillary body.
The dentate gyrus and hippocampus receive a major glutamatergic innervation from the 
entorhinal cortex via the perforant pathway (White et al, 1977). The activation and 
hypermetabolism observed in some limbic structures following administration of CNS
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1261 is consistent with an increased firing in the perforant pathway in response to 
receptor blockade within the hippocampal formation. Agents producing a use-dependent, 
non-competitive blockade of the NMDA receptor increase firing in the perforant pathway, 
leading to a progressive intensification of the blockade and corresponding increase in 
glucose use not only within the hippocampus and entorhinal cortex, but throughout the 
entire Papez circuit (entorhinal cortex -> hippocampus -> mamillary body -> anterior 
thalamus -> cingulate cortex -> entorhinal cortex). Lesions of the entorhinal complex 
remove the ability of MK801 to increase glucose use in the hippocampus molecular layer 
and dentate gyrus (Kurumaji and McCulloch, 1990)
The use of the/ranking function provides a means of incorporating all the information 
available from the dose-response relationships for each agent in each of the 36 regions 
investigated and provides a valuable approach for comparing and contrasting the 
anatomical patterns of glucose use alterations evoked by CNS 1261 and MK801 
treatment The utility of the/ranking function has previously been illustrated by its 
ability to separate the functional effects of the benzodiazepine diazepam, from those of the 
GABA agonists muscimol and THDP (Kelly et al, 1986). Despite the broad similarities in 
regional responsiveness to CNS 1261 and MK801, differences in/values were observed 
in a small number of regions indicating subtle differences in sensitivity in the effects of 
the two agents on glucose use in certain central nervous system regions. In the present 
study glucose use in the majority of regions examined was generally equipotent The 
entorhinal cortex (caudal) was the most responsive region to both agents, how ever/ 
values for CNS 1261 and MK801 were 3.45 and 1.85 respectively. In the same way, 
glucose use in the anteroventral thalamus, mamillary body, inferior colliculus and fornix 
was more sensitive to CNS 1261 than MK801. In contrast, the entorhinal cortex (rostral) 
was much less sensitive to CNS 1261 than to MK801 i f - 0.024 and 0.79 respectively). 
The clustering of /  function data for both agents into a well accepted functional system 
suggests that the similarity of effects of the 2 agents are not random numerical artefacts. 
The precise mechanism underlying the subtle functional heterogeneity of the 2 agents is 
unknown. It is suggested that this does not reflect an action on other receptor
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populations since both agents display high affinity and specificity for the NMDA channel 
binding site. The heterogeneity may imply preferential actions of the compounds on 
different subtypes of NMDA receptor in certain brain regions (Nakanishi, 1992).
The overall pharmacological effects of CNS 1261 on radioligand binding in vitro and on 
glucose use in vivo are consistent with the action of a non-competitive NMDA receptor 
antagonist. This is further confirmed by the action of CNS 1261 on electrically-induced 
cortical spreading depression (CSD) in vivo.
CSD is a transient suppression of electrical activity with associated membrane 
depolarisation which propagates across the cortex at a rate of 2-5mm/min. This 
phenomenon has been associated with the pathology of a number of neurological 
conditions, including stroke, epilepsy, and migraine with aura (McLachlan and Girvan, 
1994). While the driving force for CSD propagation is high extracellular K+ (>10- 
12nM), a transient, localised release of glutamate and Ca2+ influx through the NMDA 
receptor are also essential (Nellgard and Wieloch, 1992, Obrenovitch, 1995). CSD is 
consistently observed in regions adjacent to the ischaemic core produced by middle 
cerebral artery occlusion, and has been implicated as a factor which ultimately determines 
infarct size (Nedergaard and Hansen, 1995). This short study was carried out at Pfizer 
Central Research, Sandwich. While this study was not central to ligand development, it 
provided a further insight into CNS 1261 pharmacology in vivo (protocol detailed in 
Appendix 1). CNS 1261 (lmg/kg) completely abolished initiation and propagation of 
CSD in all animals studies. Inhibition of responses occurred 14 ± 1 (n = 4) min. post­
injection. Blockade of responses remained evident 90 minutes post-administration.
4 .2  [125I]CNS 1261 uptake in the normal ra t brain
[125i]MK801 has been employed to map the distribution of activated NMDA receptor 
complexes throughout the central nervous system (McCulloch et al, 1992, Wallace et al, 
1992). The principle underlying this technique is that ligands acting at the NMDA 
receptor ion channel bind in a use-dependent manner, i.e. MK801 (and Iodo-MK801)
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preferentially gain access to the binding site within the channel when the receptor has 
been activated (Huettner and Bean, 1988, MacDonald and Nowak, 1990). MK801 and 
Iodo-MK801 are highly lipophilic molecules and readily cross the blood-brain barrier. 
Therefore, following intravenous injection of tracer levels of [125I]MK801, the 
subsequent autoradiographic detection and measurement of [125I] in discrete brain 
regions allows quantitative mapping of [125I]MK801 binding. Within the normal brain, it 
is suggested that the level of NMDA receptor activation reflects the distribution of 
receptors such that uptake of radiolabelled tracers directed towards the NMDA ion- 
channel binding site is greatest in areas with a large population of receptors 
(hippocampus), lower in areas of intermediate density (cortex and thalamus) and least in 
areas with a paucity of receptors (hypothalamus and cerebellum, Monaghan and Cotman 
1985).
In the present thesis a modification of the [125I]MK801 in vivo binding technique 
described by McCulloch et al (1992) was used to investigate the in vivo uptake and 
retention of [125I]CNS 1261, to elucidate whether this novel tracer can be used to map 
the distribution and hence the activation of the NMDA receptor-channel complex in the 
normal brain.
In order to take into account the degree of non-specific binding of tracers within the 
brain, densitometric measures of isotope levels in forebrain structures were compared 
with cerebellar isotope levels. It was suggested that tracer uptake within the cerebellum 
serves as a measure of non-specific binding due to the paucity of NMDA receptors in this 
region (McCulloch et al, 1992).
Quantitative autoradiographic studies using [3H]MK801 describe a 5 fold greater receptor 
density within the CA1 region of the hippocampus than in the cerebellum (150 fmol/mg 
compared to 30 fmol/mg respectively, Bowery et alt 1988). This is supported by 
observations from studies using [3H]TCP where receptor densities were 2-6 fold greater 
in CA1 than in the cerebellum (Sircar and Zukin, 1985, Hosford et aU 1990). In addition 
to these findings radioligand binding studies have demonstrated differences in the affinity
121
of ligands for NMDA receptors throughout the rat brain. The affinity of [3H]TCP was 
10 times higher for NMDA receptors within the cortex and hippocampus compared to the 
medulla oblongata and cerebellum, implying non-competitive NMDA receptor antagonists 
bind preferentially to sites within the forebrain (Vignon et al, 1986). Studies by Sakurai 
(1991) confirmed these observations however the differences in affinity were of a small 
magnitude (< 1 log unit). Other radioligand binding studies showed that cerebellar 
receptors were not labelled by low concentrations of [3H]MK801 (Bowery et al, 1988). 
Studies by Nakanishi (1992) showed that the heterogeneity can be attributed to 
differential expression of subunits, the cerebellum expresses NR2C subunits which have 
been shown to possess a lower affinity for antagonists. Therefore, due to both the lower 
density of NMDA receptors and the observed lower affinity of non-competitive 
antagonists in this region, the cerebellum appears to be an appropriate measure of non­
specific binding.
The initial uptake of lipophilic molecules that enter the central nervous system with no 
diffusion restriction should be dominated by their rate of delivery to the tissue (Rapoport 
et aU 1976). Five minutes after administration, both [125I]CNS 1261 and [125I]MK801 
uptake was observed to be highest in areas known to have high blood flow, such as the 
anterior cingulate cortex and lateral habenulae (Table 25). Low levels of tracer were 
observed in areas with low blood flow. Despite similarities in the overall pattern of 
distribution of the two tracers, the appearance of the autoradiograms were markedly 
different
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TABLE 25
Tracer uptake appears to reflect cerebral blood flow (CBF) 5 minutes after administration
STRUCTURE CBF
(ml/lOOg/min.)
[l25l]MK801
OiCi/g)
[125I]CNS 1261 
(|xCi/g)
Lateral habenular nucleus 146 152 62
Anterior cingulate cortex 119 120 61
Hippocampus 109 76 33
Corpus callosum 36 52 22
The absolute amount of [125I]MK801 or [125I]CNS 1261 uptake (|iCi/g) within selected 
structures 5 minutes after administration was compared to cerebral blood flow values for 
these regions. Cerebral blood flow values (ml/lOOg/min.) were taken from a previous 
study carried out by Gotoh et al, 1990. It can be seen that the highest levels of tracer 
were observed within areas with high CBF values. Low levels of tracer were observed 
within white matter areas such as the corpus callosum which has correspondingly lower 
CBF values.
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[125i]MK801 uptake was diffuse and was reminiscent of autoradiograms produced by 
the blood flow tracer [99mTc]HMPAO (Gartshore, 1996).
In contrast a greater degree of resolution was observed in [125I]CNS 1261 
autoradiograms and increased uptake was observed in layer IV of the cerebral cortex 
and within the supraoptic and paraventricular hypothalamic nuclei. The increased 
uptake within these regions may be attributed to the high capillary density of these 
regions. The distribution of capillaries within the brain is heterogeneous (Zeman and 
Innes, 1963). The heterogeneity is structurally organised and correlates with the number 
of synapses within the region, the total length of the vessels in a unit volume of tissue is 
much greater in grey matter than in white matter. Capillary density also differs greatly 
within grey matter regions, with sensory and correlation centres more richly vascular 
than motor regions. Brain areas that possess a high density of capillaries also have high 
basal levels of glucose use and blood flow (Edvinsson et al, 1993). The paraventricular 
and supraoptic hypothalamic nuclei are the most richly vascular grey areas observed in 
the whole brain with approximately 2000mm of capillaries in 1mm3 of tissue. Within 
the cerebral cortex different laminae also differ in their vascularity, parietal cortex layer 
I possesses approximately 900mm of capillaries in 1mm3 of tissue while layer IV has 
1300mm.
It appears therefore that the high levels of [125I]CNS 1261 uptake within layer IV and 
within the hypothalamic nuclei can be accounted for by the large capillary surface area 
and hence the high cerebral blood flow of these regions. This relationship appears to 
extend to other brain areas with lower blood flow. Lower levels of [125I]CNS 1261 
uptake were observed within the cerebellum (800mm) and the ventromedial 
hypothalamus (500mm).
The precise reason underlying the observation that [125I]MK801 uptake is not increased 
within layer IV of the cerebral cortex or the hypothalamic nuclei at early time points is 
unknown. However, it is suggested that even at very early time points the high 
lipophilicity of [125I]MK801 causes this tracer to be distributed in a manner not solely 
dependent on blood flow.
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At times beyond 30 minutes, the overall pattern of uptake of both [125I]CNS 1261 and 
[125f]MK801 appeared to reflected the known distribution of NMDA receptors (Bowery 
et al, 1988) with highest levels within the hippocampus and low levels in the 
hypothalamus and cerebellum. Closer inspection of the autoradiograms showed that 
NMDA receptor density did not determine tracer uptake in all regions examined. Isotope 
concentrations within the cerebral cortex 120 minutes after [125I]MK801 administration 
were homogeneous, and did not reflect NMDA receptor density. In contrast 120 minutes 
after [125I]CNS 1261 administration isotope levels did show some heterogeneity but this 
also did not reflect NMDA receptor density. [125I]CNS 1261 uptake was increased 
within the deep layers of the cortex relative to the superficial layers and, it is well 
established that the greatest concentration of NMDA receptors is within the outer layers of 
the neocortex (Bowery et al, 1988, Maragos et al, 1988). Wallace et al (1992) also 
showed that the density of NMDA receptors in vitro did not determine the uptake of 
[3H]MK801 in vivo . These observations suggest that factors other than receptor density 
(lipophilicity) determine local isotope uptake under conditions of basal NMDA receptor 
activation.
At 120 minutes the relative uptake of [125I]CNS 1261 within hippocampal regions (CA1, 
CA3, molecular layer) was approximately twice as great as that of [125I]MK801. It was 
proposed that a greater relative uptake of [125I]CNS 1261 within the hippocampus 
(hippocampus/cerebellar ratio) could result from a faster washout of [125I]CNS 1261 
from the cerebellum compared to [12^ I]MK801 rather than an increased uptake in the 
hippocampus. Therefore, the normalisation procedure was examined to determine if the 
increase in relative uptake could be attributed to differences in the rate of washout of the 
tracers from the cerebellum. The absolute amount of radioactivity (fiCi/g) within a region 
of high, intermediate and low NMDA receptor density (hippocampus CA1, mediodorsal 
thalamus and hypothalamus respectively) was plotted against time over the last 60 
minutes of the experiment for both [125I]MK801 and [125I]CNS 1261 along with the 
cerebellum (Figure 47).
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FIGURE 47 : Washout rates of [125I]MK801 and [125I]CNS 1261 from regions of 
interest
Over the final 60 minutes of the experimental period, [125I]MK801 washed out of 
regions with high, intermediate and low NMDA receptor densities at the same rate. In 
contrast there was some degree of retention of [125I]CNS 1261 within the hippocampus 
CA1. Data are mean ± S.E.M.
For [125I]MK801 the washout slope was the same for all regions examined. The 
washout rate was not affected by the NMDA receptor density. [125I]MK801 was shown 
to wash out of the hippocampus at the same rate as from the cerebellum, therefore the 
relative uptake of [125I]MK801 within the CA1 region changed little over the terminal 60 
minutes of the experiment. This graph also shows that normalisation to the 
hypothalamus, another region with a paucity of NMDA receptor, would have given the 
same relative uptake values
Figure 47 shows that there is virtually no washout of [12^ I]CNS 1261 from CA1 region 
over this time therefore the ratio of uptake in the CA1 region relative to the cerebellum 
increased over the same time period. In contrast, the rate of [125I]CNS 1261 washout 
from other regions was approximately the same as that from the cerebellum. In this case, 
normalisation to the hypothalamus would also have given the same relative values of 
tracer uptake. Comparison of the tracer washout rates from the cerebellum over the 
remaining 60 minutes of the experimental period indicates that [125I]MK801 washes out 
at a similar rate than [125I]CNS 1261. It can be concluded therefore that the increased 
relative uptake of [l^JCNS 1261 within the hippocampus 120 min after administration is 
not due to a faster washout of this tracer from the cerebellum compared to [125I]MK801, 
but to retention of the tracer in regions with a high density of NMDA receptors.
4.3 [125I]CNS 1261 produces superior images to [125I]MK801 in the
normal brain
Comparison of the uptake of [125I]MK801 and [125I]CNS 1261 in the normal brain at 
120 minutes, showed that under identical experimental conditions the relative uptake of 
[125I]CNS 1261 within hippocampal regions was greater than that of [125I]MK801. A 
number of factors contribute to the amount of tracer within a brain region at a give time 
including cerebral blood flow, the concentration of tracer within the plasma and the 
lipophilicity of the tracer. It has been suggested that the most critical physical property 
for a high affinity radiotracer is lipophilicity (Audus et al, 1992) since hydrophilic ligands
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do not cross the blood-brain-barrier and very lipophilic compounds display excessive 
non-receptor binding.
The blood-brain-barrier consists of a phospholipid bilayer which confers selective 
permeability to nonionised species. The solubility of unionised species can be measured 
conveniently as the octanol/water partition coefficient. LogD7.4 (octanol/buffer) values 
for CNS 1261 and IodoMK801 were 2.19 and 3.30 respectively, showing that while 
both compounds are extremely lipophilic, CNS 1261 is substantially less so than 
MK801. The presence and position of an iodine moiety in these structures appears to 
underlie this lipophilicity since the LogD values of the 'precursor' compounds, CNS 
1102 and MK801, are similar (1.72 and 1.8 respectively).
The membrane permeability of a compound is also proportional to a partition parameter 
which represents the ability of the compound to partition between a lipid phase and 
aqueous solution (von Geldern et al, 1996). The 'brain/aqueous partition ratio* is 
generally considered to be a measure of lipophilicity (Rapoport, 1976) and represents the 
tendency of a compound to distribute into the brain (lipid) rather than the aqueous phase 
(plasma) and may be calculated from the non-specific binding of radioiodinated ligands to 
rat and human brain sections in vitro. The brain/aqueous partition ratios for both 
[125I]CNS 1261 and [125I]MK801 were high (15-35g/ml) confirming that these tracers 
are extremely lipophilic. In both rat and human brain sections, the brain/aqueous 
partition ratios for [12^I]CNS 1261 were 40% lower than those obtained for 
[125I]MK801, implying [125I]CNS 1261 may display a lower non-specific binding 
component in vivo.
Highly lipophilic compounds can bind tightly to serum proteins such that the free fraction 
of compound available to cross the blood-brain-barrier is reduced. It was of interest 
therefore to determine the extent of [125I]MK801 and [125I]CNS 1261 binding to protein 
in rat and human plasma. Results showed that both tracers were approximately 95% 
protein bound.
An essential property for a candidate SPECT ligand is that metabolism produces no 
lipophilic breakdown products. The low levels of activity found in rat plasma samples
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after administration of a radiolabelled tracer were detected using an hplc flow monitor 
which markedly increase radio hplc detection sensitivity. Several methods of plasma 
sample preparation were investigated for use in this system. The preferred method was 
the precipitation of plasma proteins with an aqueous miscible organic solvent followed by 
centrifugation to leave a clear supernatant. The supernatant was then directly applied to 
the hplc column. This method has the advantage of allowing the direct measurement of 
both aqueous and organic soluble radiolabelled species in the sample. Using this method 
a measurement of the authenticity of the tracer within the brain at a given time point was 
also obtained. This method has been previously applied to small groups of rats to study 
[125I]QNB, and to study [123I]BZM metabolism in plasma in man. Hplc analysis of 
plasma samples was carried out by J. Owens at The West of Scotland Radionuclide 
Dispensary.
From the results of the hplc plasma analysis it appears that both tracers undergo 
deiodination on first pass metabolism. Two species were identified within the plasma of 
rats receiving [125I]CNS 1251, authentic CNS 1261 and free iodine. A small amount of 
a third species, along with authentic MK801 and free iodide, was identified within the 
plasma of animals receiving [125I]MK801. The identity of this species is unknown, but 
it may be a non-lipophilic metabolite of [125I]MK801 since this species was not present 
within the brain. [125I]CNS 1261 is metabolised much more rapidly than [125I]MK801 
and it is suggested that this rapid metabolism following administration of a bolus dose 
may confer advantages over a tracer with a slower metabolism.
4 .3 .1  Kinetic modelling
A 3 compartment model (Figure 48) was used to examine the hypothetical brain 
concentrations arising from tracers with an input function like .that of [125I]CNS 1261 
where the tracer is rapidly cleared from the plasma (Figure 25). This was compared to 
hypothetical brain concentrations obtained following administration of a tracer with a 
slower input function like [125I]MK801 (Figure 27).
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A number of the specifications of this model require discussion. The model is set up to 
reflect the situation where a tracer compound moves from the plasma into a second 
compartment within the brain which describes free and non-specifically bound tracer.
K1 on
K2
Free and NS 
(brain)Plasma
Specific
(brain)
A third compartment describes tracer bound specifically to receptors within the brain. The 
factors influencing the movement of tracer between these three compartments are 
described below.
1. The amount of tracer delivered to the brain is described by an input constant K1 which 
is determined by the plasma concentration of tracer, the free fraction within the plasma, 
cerebral blood flow, and the extraction fraction.
• Plasma concentration is described by a graph of percentage of authentic tracer within 
the plasma against time (see Figures 25 and 27).
• The free fraction was set at 0.03, a value obtained from the literature for iomazenil.
• Cerebral blood flow (ml/g/min.) was variable and values of 0.2, 0.4 and 
0.8ml/g/min. were used to represent tracer uptake into white matter and grey matter 
with low and high flow respectively.
• The extraction fraction is dependent on the capillary surface area S, the capillary 
permeability P and perfusion (flow) F. The dependence on blood flow reflects the 
fact that at higher flows, the tracer spends less time within the capillary. The 
extraction fraction itself may vary as blood vessels dilate and constrict
2. The elimination rate constant K2 describes the amount of tracer flowing out of the 
brain into the plasma. K2 can be expressed as Kl/(V2*fl) where K1 is the association 
rate constant, V2 is the volume of distribution of the free and non-specifically bound
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compartment and f 1 is the free fraction of tracer within the blood. K2 is dependent on the 
concentration of tracer within the brain, the partition coefficient of the tracer, the 
extraction fraction and cerebral blood flow.
The partition parameter or X represents the lipophilicity of the tracer and was set at 20 for 
[125I]CNS 1261 and 35 for [125I]MK801 (see Table 15), this also represents the volume 
of distribution of the tracer.
3. Unbound ligand reversibly binds to receptors at a rate dependent on the concentration 
of the 2 reactants. The rate constant for this reaction is known as the association constant 
kon- kon was set at a value of 0.07. Bmax equals the concentration of receptors available 
for binding. For tracer doses this is equal to the receptor density (unless investigating 
receptor blockade by an administered drug). Bmax was set at 10 to represent an area with 
a high number of receptors.
4. The rate of dissociation of the tracer from the receptor is determined by the 
dissociation rate constant koff and the concentration of tracer within the specifically bound 
compartment, koff was set at 0.1.
Hypothetical brain concentrations arising from the two types of input function are shown 
in figure 49. The total brain concentrations of tracers with a rapid plasma clearance like 
[125I]CNS 1261 reach steady-state more rapidly than tracers which are metabolised more 
slowly like [125I]MK801. Non-specifically bound tracer is also observed to wash out 
down its concentration gradient at a faster rate.
Comparison of the actual washout rates of total [125I]MK801 and [125I]CNS 1261 
uptake from the cerebellum, an area which represents non-specific binding, confirms the 
latter observation (Figure 50). It is proposed that the lower lipophilicity and rapid 
metabolism, leading to faster washout of non-specifically bound tracer may underlie the 
ability of [125I]CNS 1261 to produce superior images to [125I]MK801.
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FIGURE 49 : Hypothetical brain uptake following administration of a tracer with 
rapid or slow plasma clearance
A three compartment model was used to model the hypothetical uptake and retention of 
a tracer with a rapid plasma clearance (like [125I]CNS 1261) and one with a slow 
plasma clearance (like [125I]MK801). Total brain uptake is shown in the upper 
figures and non-specific uptake in the lower figures. Hypothetical brain uptake and 
retention for the tracer with rapid clearance was modelled using the plasma input curve 
of [125I]CNS 1261 and a lambda value of 20. Slow clearance was modelled using 
the [125I]MK801 plasma input curve and a lambda value of 35. Numbered lines 1,2 
and 3 represent uptake and retention at cerebral blood flow values of 20, 40 and 
80ml/100g/min respectively. All other factors influencing uptake and retention of 
tracers were the same for both tracers.
According to this model, tracers with rapid plasma metabolism reach steady state 
concentrations within the brain more rapidly and, non-specifically bound tracer 
washes out down its concentration gradient faster that tracers with slower metabolism.
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FIGURE 50 : Actual rates of tracer washout from the cerebellum
The actual rate of [125I]MK801 washout from the rat cerebellum was compared to that of 
[125I]CNS 1261. The less lipophilic tracer [125I]CNS 1261 was shown to wash out of 
the cerebellum at a faster rate than [125I]MK801. The cerebellum has a low density of 
NMDA receptors and serves as a within animal measure of non-specific binding.
4 .4  Displacement of [125I]CNS 1261 from normal rat brain
It has been established that 120 minutes post administration, [125I]CNS 1261 uptake 
generally reflects the classical pattern of NMDA receptor distribution. It was postulated 
that a reduction in [125I]CNS 1261 uptake by administration of unlabelled MK801 would 
confirm that enhanced uptake in areas of high receptor density such as the hippocampus, 
represents increased binding of this tracer to the NMDA receptor ion channel.
A preliminary experiment was performed to examine the effect of coinjection of MK801 
(0.5mg/kg) and [125I]CNS 1261 (200|iCi). It was apparent from the partition coefficients 
of the two compounds that [125I]CNS 1261 would gain access to the brain more rapidly 
than cold MK801 (partition coefficients 25 and 4 respectively), however it was proposed 
that since the dose of MK801 administered was some 5000 times in excess of the tracer 
dose and the affinity for the NMDA receptor was approximately 12 times greater than that 
of [125I]CNS 1261 that some displacement would occur.
[125I]CNS 1261 uptake following coinjection of MK801 was comparable to the images 
obtained 120 minutes post-administration of [125I]CNS 1261. Concomitant 
administration of cold MK801 did not cause displacement of [125I]CNS 1261, indeed 
[125I]CNS 1261 binding was greater in 34 of the 37 regions examined in the MK801 
treated film. In hippocampus CA1, CA3 and molecular layer, [125I]CNS 1261 binding 
was approximately 20% greater in MK801 treated animals, however further experiments 
were not carried out to substantiate this data. It is suggested that [125I]CNS 1261 binding 
could be increased due to masking of a non-specific binding site by MK801, thus 
increasing the amount of tracer available for specific binding, but it is most likely due to 
the effect of MK801 on cerebral blood flow. Gibson et al (1992) reported that 
coinjection of unlabelled MK801 (4mg/kg) produced an increase in [125I]MK801 uptake. 
MK801 has been shown to increase cerebral blood flow by as much as 2-fold (Nehls et 
al, 1990).
The receptor binding kinetics of [125I]CNS 1261 may have an impact on the ease with 
which it can be displaced by MK801. It has been reported that lower affinity NMDA
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antagonists such as memantine exhibit faster rates of block and unblock than compounds 
such as MK801 (Rogawski, 1993) and hence reach steady state more rapidly. While 
CNS 1261 displays nanomolar affinity for the NMDA receptor channel, it has a 10 fold 
lower affmity than MK801 and it is possible that as a result, the on/off rate at the receptor 
may be faster for CNS 1261. It was postulated that blockade of [125I]CNS 1261 binding 
may therefore be easier to demonstrate than displacement
Modification of the initial protocol resulted in the administration of MK801 as a bolus 
dose followed by an infusion (0.4 + 6|ig/ml/min or 1.2 + 16|ig/mL/min). 
Administration of MK801 produced an immediate hypotension (20mmHg decrease 
relative to preinjection values) that persisted throughout the experimental period. This 
was consistent with the observations of Kurumaji and McCulloch (1989) that 
administration of MK801 to halo thane anaesthetised rats effected a decrease in mean 
arterial blood pressure.
The doses of MK801 were chosen to produce steady state plasma and brain 
concentrations of MK801 prior to administration of [125I]CNS 1261 (30 min. after 
initiation of the infusion) and throughout the experimental period. A study by Willis et al 
(1991) using the same dosing regimen showed that initial peak levels of MK801 (in 
plasma and CSF) following the bolus dose reached equilibrium within 10 minutes. The 
lowest dose chosen gives a mean plasma concentration of 113.2ng/ml which has been 
shown to produce a significant reduction in the volume of ischaemic brain damage (Gill et 
aU 1991).
There was no significant difference in the levels of [125I]CNS 1261 uptake between the 
control group and both groups treated with MK801 in any of the region examined.
The results presented above show that we have been unable to demonstrate displacement 
or blockade of [125I]CNS 1261 binding in normal non-pathologic tissue by 
pharmacologically active doses of MK801. Since the batch of MK801 used in these 
studies was subjected to nuclear magnetic resonance spectroscopy and confirmed to be 
authentic, this lack of blockade may be due in part to differences in lipophilicity and/or 
kinetics of the two compounds. A second proposal is that under conditions where the
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basal level of NMDA receptor activation is low, [^IJC N S 1261 may not a sensitive 
enough tracer to image the putative changes in NMDA receptor activation caused by 
MK801. This suggestion is supported by the observation that a reduction in 
[125i]MK801 uptake in normal brain was not observed 1 hour after coadministration of 
MK801. However, a 40% blockade of [125I]MK801 uptake in was observed 4 hours 
after coinjection, a sufficient time to permit washout of non-specifically bound ligand 
(Gibson et al, 1992).
4 .5  Application of [125I]CNS 1261
The consensus view is that highly lipophilic agents like MK801 are unsuitable in vivo 
ligands in the normal central nervous system. Non-specific binding is high and 
displacement has not been reliably demonstrated. In the present thesis the data obtained 
in normal non-pathological tissue confirms this view. Despite the inability to demonstrate 
displacement of [125I]CNS 1261 from the normal brain, the lower lipophilicity, rapid 
plasma clearance and hence lower non-specific binding of this novel tracer confer 
significant advantages over [l25I[MK801, producing superior images under identical 
experimental conditions. [125I]CNS 1261 is therefore a more suitable candidate for in 
vivo imaging within the normal central nervous system.
The ability to image changes in NMDA receptor activation in vivo must be demonstrated 
for a tracer to be of any value in man. McCulloch demonstrated a marked elevation in 
levels of [125I]MK801 uptake in ischaemic areas (neocortex and striatum) following 
middle cerebral artery occlusion. These areas are generally accepted to be areas of 
excessive NMDA receptor activation.
There is accumulating evidence that external proton concentration is an important 
determinant of neuronal responses mediated by NMDA receptors. Acidosis is effective in 
reducing inward currents induced by NMDA in cultured neurons (Traynelis and Cull- 
Candy, 1990, Tang et al, 1990) and is protective against neuronal injury induced by
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glutamate. Yoneda et al (1994) demonstrated a negative modulation by protons of 
[3H]MK801 binding to the NMDA receptor channel in rat brain synaptic membranes. 
This observation was supported by the observation that decreasing the pH of the 
environment of cultured forebrain neurons slowed the association and dissociation rates 
of [125I]MK801, by decreasing the amount of time that the channel spends in the open 
state (Rajdev and Reynolds, 1993). Varying the pH of the extracellular fluid therefore 
provides a mechanism of controlling the level of NMDA receptor activation without 
affecting agonist concentrations.
The brain extracellular fluid is not buffered against changes in arterial CO2 tension, 
therefore increasing the percentage of CO2 in inspired air was a convenient mechanism of 
producing hypercapnic acidosis in experimental animals. Changes in CO2 tension induce 
a decrease in arterial pH and a parallel decrease in extracellular fluid pH (Figure 51). 
Arterial pH therefore gives a reasonable indication of the pH of the extracellular fluid and 
intracerebral electrodes were not implemented in these investigations.
NMDA-induced currents were reduced by approximately 70% in cerebellar neurones 
when the bath pH was reduced to 6.8 (Traynelis and Cull-Candy. 1990). Increasing the 
CO2 in inspired air to 20% increased arterial pCC>2 to 180mmHg and decreased pH to 
6.9. It was proposed that this change in pH would be sufficient to decrease the acrivation 
of NMDA reeptors within the brain. In the same way, NMDA receptors are not fully 
activated at physiological pH therefore increasing the arterial pH to 7.6 should relieve the 
proton blockade and increase NMDA receptor activation.
In addition to the reported changes in arterial pC02 and pH, induction of hypercapnia 
caused an immediate transient hypotension followed by a recovery to levels slightly 
above pre-induction values.
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FIGURE 51 : Relationship between pCC>2 and pH in plasma and brain
Data redrawn from Siesjo (1972). Increasing CO2 tension through hypercapnic ventilation
induces a decrease in arterial pH and in the pH of the extracellular fluid (ECF) of the brain. 
For a given pCC>2 the pH within the ecf was slightly lower that that within the plasma
Cerebral blood flow has been shown to respond considerably to alterations in CO2 
tension, with an average increase of 4.9ml/100g/min. for every mmHg change in arterial 
pC02 (Hernandez et al, 1978).
[125I]MK801 uptake in hypercapnic animals was not different from that in normocapnic 
animals and it is thought that the increase in pH from 7.4 to 7.6 was not a strong enough 
stimulus to increase NMDA receptor activation. This is supported by the pH dependence 
of the NMDA current measured in hippocampal neuron following application of NMDA 
(Tang et al, 1990). The data was fitted to a sigmoidal curve with a pKa of 6.9. pH 7.4 
was near the upper plateau of the curve therefore, a change of 0.2 pH units produced little 
increase in NMDA activated current and hence NMDA receptor activation. There was 
no significant difference in the relative levels of [125I]MK801 within the dorsal 
hippocampus of normocapnic and hypercapnic animals despite the observed decrease in 
total [125I]MK801 uptake within this region on the autoradiograms of hypercapnic 
animals. The failure to obtain a significant decrease in [125I]MK801 uptake following 
hypercapnia may be attributed to the poor signal to noise ratio of this tracer due to high 
levels of non-specific binding in the cerebellum, [125I]MK801 uptake in the hippocampus 
was 30% above that in the cerebellum and 20% greater than cerebellar levels in other 
regions.
In contrast to the results obtained with [125I]MK801, an identical level of acidosis 
produced a sigificant decrease in the relative uptake of [125I]CNS 1261 in vivo compared 
to normocapnic values. Hypercapnic acidosis (pH 6.9) also reduced [125I]CNS 1261 
uptake in other areas with a fairly high density of NMDA receptors. [125I]CNS 1261 
uptake within the hippocampus was 2-300% above that observed within the cerebellum 
and 60-90% above cerebellar levels in the majority of other regions examined. It 
appears from these results that [125I]CNS 1261 is a better tracer to image the putative 
decrease in NMDA receptor activation induced by hypercapnic acidosis due to the higher 
relative uptake of this tracer in normocapnic animals.
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The utility of [125I]CNS 1261 in measuring changes in NMDA receptor activation was 
further examined by measuring [125I]CNS 1261 uptake at different time points after 
intracortical injection of NMDA. Injection of 0.009M NMDA into the nucleus basalis 
magnocellularis (NBM) produced significant alterations in glucose use in cortical regions 
innervated by the NBM efferents (Browne, 1993) and is therefore sufficient to cause 
increased neuronal activity. Injection of 0.009M NMDA into the parietal cortex produced 
a lesion with a core area of decreased glucose use surrounded by a zone of increased 
glucose utilisation. The increase in glucose use appears to map the diffusion front of the 
injection and it is suggested that the pale area within the boundary represents an area 
where receptors have recieved a lethal dose of NMDA and are no longer functional.
It has been described previously that the initial uptake of [125I]CNS 1261 reflects cerebral 
blood flow. Five minutes after injection of NMDA or CSF tracer uptake was decreased 
within the ipsilateral hemisphere, particularly in the insular cortex. Although the total 
volume injected was extremely small, it was injected into a medium with no capacity for 
expansion. It is possible that the increase pressure arising from the increase in volume 
partially occludes blood vessels thus hindering the delivery of tracer to the ipsilateral 
hemisphere. The decreased tracer uptake within the insular cortex is similar to that 
obtained in [14C]iodoantipyrine autoradiograms from models of subdural haematoma 
(Miller et al, 1990). The additional volume added within the rigid confines of the skull 
causes compression of the base of the ventral surface of the brain restricting tracer uptake. 
Injection of NMDA produces localised increases in cerebral blood flow which are 
reflected in the markedly increased uptake of [125]CNS 1261 surrounding the injection 
site.
At times beyond 5 minutes, NMDA injection results in a sizeable lesion which extends in 
anterior and posterior directions and is characterised by an area of pallor as shown by 
H&E. The histopathological features of the lesion included loss of staining and shrinkage 
of neurons. The lesion was similar to that described following glutamate perfusion 
(Fujisawa et al, 1993), in that a sharp boundary between the lesion and histologically 
normal tissue could be readily detected, however there was no evidence of triangulated
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neurons. In comparison, injection of CSF produced a much smaller, less well defined 
lesion.
120 minutes after injection of NMDA autoradiograms showed an area of decreased 
[125I]CNS 1261 uptake immediately adjacent to the injection site surrounded by a rim 
of increased uptake. [125I]CNS 1261 uptake in the contralateral hemisphere was similar 
to that observed in the normal brain at 120 minutes. CSF injections produced a smaller 
area of pallor on autoradiograms and the rim of increased [125I]CNS 1261 uptake was 
less evident. The pattern of tracer uptake is consistent with the hypothesis that 
receptors within the core area are no longer functional due to excitotoxic damage and, 
receptors within the boundary of the lesion are being activated by NMDA. It has been 
established that the association rate of ligand binding to the NMDA receptor is 
dependent on the activation state of the receptor (Rajdev and Reynolds, 1993). Kinetic 
modelling (see Figure 48) was used to investigate the impact of changes in association 
rate and hence in receptor activation on tracer uptake. The rate of association of 
[125I]CNS 1261 under conditions of normal receptor activation was set at 0.07, a value 
of 0.01 was used to represent the association rate within the core region where receptors 
were proposed to be relatively non-functional and, a value of 1 was used to represent the 
association rate within the boundary region where receptors are putatively abnormally 
activated. The hypothetical brain uptake obtained using the 3 compartment model 
confirms that very little washout of tracer occurs from 'activated' receptors over the 
course of the experimental period and at 120 min. tracer uptake in this area 
(representing the rim) is increased compared to areas of normal activation (Figure 52). 
In contrast, tracer uptake washes out of the 'core' area where receptors are closed much 
faster and low levels of uptake are present at the end of the experiment. The decreased 
binding of [125I]CNS 1261 within areas representing the core in this model indirectly 
demonstrates displacement of the tracer.
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FIGURE 52 : Effect of varying association rate on the hypothetical uptake and 
retention of a tracer with rapid plasma clearance
Kinetic modelling (see Figure 48) was used to investigate the impact of changes in 
association rate (kon) and hence receptor activation on tracer uptake. In this model the 
rate of association of a tracer ([125I]CNS 1261) under conditions of normal receptor 
activation, was set at an arbitrary value of 0.07. Therefore, a value of 0.01 was used 
to represent the association rate within a region where receptors were relatively non­
functional ('blocked') and, a value of 1 was used to represent the association rate to 
activated receptors. The hypothetical brain uptake obtained using the 3 compartment 
model confirms that very little washout of tracer occurs from 'activated' receptors at 
the end of the experimental period (120 min.) and tracer uptake in this area is 
increased compared to areas of normal activation. In contrast, tracer uptake washes 
out of areas where receptors are closed much more quickly.
normal
'blocked'
[l25I]CNS 1261 uptake 60 minutes after injection of NMDA also showed an area of 
decreased tracer at the site of injection surrounded by an area of increased uptake. 
Imaging at an earlier time point did not demonstrate a larger area of elevated [125I]CNS 
1216 uptake within the rim on the autoradiograms. Post-mortem washing of sections 
from control experiments showed that [125I]CNS 1261 binding within the hipocampus 
was reduced by 50% at around 30 minutes therefore, 60 minutes appears to be too late a 
time point to capture any increase in binding that may have been present. Sixty minutes 
after injection of CSF, small lesions (1mm2) were observed in 2 animals while the third 
animal possessed a much larger lesion (2mm2). The mechanism underlying the 
development of this larger lesion is unknown since there was no evidence of blood in or 
around the injection site.
These results suggest that the increased [125I]CNS 1261 uptake within the boundary zone 
of the lesion reflects increased binding to NMDA receptors. This is supported by the 
difficulty in defining a zone of increased [125I]CNS 1261 uptake following CSF 
injection. The observation that areas of increased [125I]CNS 1261 uptake in subcortical 
areas corresponds to areas of damage in histological sections adds further weight to this 
hypothesis. Tissue damage causes glutamate release and subsequent NMDA receptor 
activation. [125I]CNS 1261 was also able to map the evolution of the lesion as the pale 
core region of decreased uptake increased in size between 60 and 120 minutes. This 
implies that areas of increased uptake within the boundary zone at 60 minutes eventually 
become incorporated into the core area observed at 120 min. as the NMDA diffuses away 
from the injection site over time. These observations reinforce the view that [125I]CNS 
1261 is mapping a dynamic process.
The use of [125I]CNS 1261 in man with SPECT imaging therefore provides a potential 
strategy for defining areas of NMDA receptor activation.
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4 .6  SPECT imaging in man with [123I]CNS 1261
The initial clinical assessment of [123I]CNS 1261 and its potential to provide SPECT 
images in vivo of NMDA receptor activation during cerebral ischaemia has been 
investigated. The study was approved by the Local Research Ethics Committee of the 
Institute of Neurological Sciences and by the Administration of Radioactive Substances 
Advisory Committee. Three patients were studied with clinical indications of possible 
ischaemia. Patient A presented with a large right frontal infarct and SPECT was carried 
out 24 hours after onset Patient B presented with a left middle cerebral artery infarct and 
SPECT was performed 6 hours after stroke onset. Patient C had evidence of multiple 
small infarcts and SPECT was carried out 18 hours after onset. Three normal 
volunteers (2 males and 1 female, 58-88 years) were recruited as control subjects. 
SPECT imaging was carried out on a Strichman SME 810 dedicated neuro-scanner. 
[123I]CNS 1261 (80-180MBq) was administered intravenously and images of the brain 
captured at regular time points post-injection. The patients lay unrestrained, except for a 
cushioned head support, during scanning. Multiple timed samples of venous blood were 
taken and the presence of authentic CNS 1261 and any metabolites determined by hplc. 
The objective of the imaging experiments was to investigate the kinetics of [123I]CNS 
1261 and not the regional distribution therefore, the scanning protocol involved 
acquisition of images from a single slice at the level of the occipital cortex at 25 
timepoints over 90 minutes (2 minutes per slice).
Images from a control subject show that at early time points after administration 
[123I]CNS 1261 uptake was greatest in areas with high cerebral blood flow, such as the 
cortex and cerebellum (Figure 53). At later time points high levels of uptake were present 
in the occipital cortex. There was no accumulation of [123I]CNS 1261 in white matter at 
40 minutes. The initial distribution of [12^ I]MK801 in the brain also reflected cerebral 
blood flow with greatest radioactivity in the cerebellum and other cortical grey structures. 
However, there was a progressive loss of contrast between grey and white matter over 
the course of the experimental period and eventually no distinction could be made
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FIGURE 53 : [123I]CNS 1261 uptake and retention in a normal volunteer
Axial SPECT images show the distribution of radioactivity in the brain of a normal 
human control subject starting 2 minutes after the administration of [123I]CNS 1261 
with the final image in the series showing distribution 42 minutes after tracer injection. 
All images were captured at the level of the the occipital cortex. 'Hot' colours represent 
areas with high tracer uptake and 'cold' colours represent areas with low uptake. Early 
images show typical blood flow distribution with highest radioactivity observed within 
cortical areas. Late images show that the tracer does not accumulate in areas of white 
matter.
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between these tissues on the images. Quantitative data showed that radioactivity in grey 
matter decreased over the experimental period while radioactivity in white matter was 
minimally altered (Owens et al, 1997).
Plasma clearance of [123I]CNS 1261 was extremely rapid and was reminiscent of the 
situation in rat plasma (Figure 54). Brain clearance of the tracer was somewhat slower 
than expected from the plasma trace and indicates some form of trapping. This trapping 
has been attributed to plasma protein binding.
The in vivo uptake and retention of [125I]CNS 1261 following permanent proximal 
occlusion of the middle cerebral artery in the rat was similar to that previously 
described for [125I]MK801 (McCulloch et al, 1992). 120 minutes after injection, 
binding was significantly decreased in the dorsolateral caudate nucleus and insular 
cortex. Tracer uptake was markedly increased within the striatum, where uptake in the 
ipsilateral caudate nucleus was approximately 2-fold higher than that in the equivalent 
area of the contralateral hemisphere (Figure 55). These region are generally accepted to 
be areas of increased NMDA receptor activation.
Results of the clinical assessment of [123I]MK801 uptake in man showed relatively 
increased tracer retention at late time points (60-120 minutes) after tracer administration 
in cortical areas adjacent to the site of the haemorrhage in 2 of the 5 patients. This 
uptake was consistent with presence of activated NMDA receptors (Owens et al, 1997). 
While it may be possible to image NMDA receptor activation during an ischaemic 
episode in the living patient with [123I]MK801, the utility of this tracer is ultimately 
limited by its lipophilicity (and consequent high non-specific binding).
[123I]CNS 1261 SPECT images showed that 6 hours after onset of an ischaemic 
episode, the earliest time point examined in man, there was no evidence of increased 
uptake in peri-ischaemic areas where NMDA receptor activation is proposed to occur. 
The rate of washout in peri-ischaemic areas is similar to that observed in occipital 
cortex, an area removed from ischaemia (Figure 56). The overall uptake and washout in 
this patient did not look different from that in normal volunteers.
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FIGURE 55 : [12"I]CNS 1261 uptake is increased in ischaemic areas
125Illustrative autoradiogram of [ I]CNS 1261 uptake after permanent middle cerebral 
artery occlusion. The isotope was administered 15 minutes after occlusion and the 
animals sacrificed 120 minutes thereafter. The occluded hemisphere is on the left, 
areas of increased uptake are indicated by arrow.
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A number of factors may underlie the inability to observe increased [123I]CNS 1261 
retention in stroke patients. Both [125I]CNS 1261 and [125I]MK801 uptake was increased 
in ischaemic areas when administered 15 min. after middle cerebral artery occlusion in the 
rat. The uptake of [125I]MK801 was shown to diminish as the time from occlusion 
increased (McCulloch et al, 1992). In the most acute stroke patient recruited, [123I]CNS 
1261 was administered 6 hours after onset of the ischaemic ictus. Assuming that a similar 
situation of diminished uptake over time occurs in humans, six hours after onset may be 
too late to to capture NMDA receptor activation.
No increased tracer retention was observed in either of the stroke patients images at 18 or 
24 hours. Baron et al (1996) have produced clinical evidence of heterogeneity between 
stroke patients in that some lacked a peri-ischaemic area. It is possible that the patient 
imaged 6 hours after onset of stroke represents the group of patients with no penumbral 
zone of NMD A receptor activation. It must be noted that the timing of imaging in humans 
is extremely difficult. Within the brain of a stroke patient it is assumed that there are areas 
of normal grey matter, ischaemic grey and white matter. Images must be captured at a 
time when radioactivity in normal grey matter is low enough to see any superimposed 
increases or, tracer accumulation in white matter is not so high that the phenomenon is 
masked. The background level of radioactive uptake cannot be 'faded out' and each event 
captured by imaging is superimposed on this level. If background (non-specific) levels of 
radioactivity are high, significant events will not be observed.
The initial results of the clinical evaluation of [123I]CNS 1261 are encouraging. [123I]CNS 
1261 shows no accumulation in white matter and and it is suggested that this tracer will be 
less limited by lipophilicity than [123I]MK801. Further acute stroke patients recruited to 
this study may confirm the existence of areas of increased NMDA receptor activation 
following cerebral ischaemia.
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A proposed future strategy to further evaluate [123I]CNS 1261 is to recruit patients with 
chronic epilepsy, into the study. It is assumed that the mechanism underlying epilepsy 
and ischaemia are related and glutamate release during seizures will increase NMDA 
receptor activation. In summary, the use of [12^I]CNS 1261 in man with SPECT 
remains a potential strategy for defining the location of areas of NMDA receptor 
activation in pathological conditions where glutamate concentrations are elevated.
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APPENDIX 1
1. Effect of CNS 1261 on cortical spreading depression
1.1 Surgical preparation of animals
Animals were anaesthetised with urethane (1500mg/kg i.p.) since halothane is known to 
inhibit CSD (Saito et al, 1995). A tracheotomy was performed and the animals connected 
to a small animal respirator (Ugo Basile, Linton Instruments) and ventilated with a 
mixture of 30% O2 and 70% N2O. The femoral vessels were exposed unilaterally by 
blunt dissection. Polyethylene catheters were inserted into the left femoral artery and vein 
and secured with silk thread. Animals were turned prone and the head fixed in a Kopf 
stereotaxic frame. A craniotomy (5x3mm) was drilled over the right parietal cortex and 
the bone and dura removed without damage to the underlying pial vessels. Two glass 
electrodes (tip diameter 10mm) were pulled from borosilicate glass capillaries (O.D. = 
0.86mm, I.D. = 1.5mm, Clark Electromedical Instruments). The electrodes were filled 
with saline and positioned 1.5-2mm apart and 1mm deep into the cortex using a 
micromanipulator. All electrode manipulations were performed under low power 
magnification in order to avoid trauma to large pial vessels. Ag/AgCl wires were inserted 
into the electrodes to measure DC potential, the rostral electrode measured initiation and 
the caudal electrode propagation of CSD. In several preparations a second larger burr 
hole was drilled in the ipsilateral hemisphere and a laser doppler flow probe positioned 
touching the intact dura. Two saline-filled cannulae containing Ag/AgCl wire were 
inserted under the skin and served as reference electrodes. The preparation was allowed 
to stabilise for 15 minutes before any further manipulation were performed.
1.2 Induction of cortical spreading depression
CSD was electrically evoked using a bipolar stimulating electrode placed at 90° to the 
rostral recording electrode. The stimulating electrode was positioned so that it touched, 
but did not visibly depress the cortical surface. Electrocortical stimulation consisted of a
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train of 5ms pulses at 40Hz for 2s at 10 minute intervals. The threshold for evoking 
CSD was determined by increasing the current gradually until a response was triggered. 
On determining the stimulation threshold (generally 0.1-0.2mA), the current was then 
increased by 10%. The cortex was stimulated 3 times in order to establish that responses 
were reproducible at both electrodes.
1.3 Drug treatment
CNS 1261 (1 mg/kg) was administered intravenously following confirmation of 
reproducible responses. Responses were recorded for a further 120 minutes after 
administration
1.4 Data processing
All signals, including blood pressure, heart rate and DC potential were recorded using a 
Gras Model 7 polygraph and processed by an in-house DART computer using the 
program RATCSD. The rate of CSD propagation was calculated from the latency of the 
DC shift at the rostral and caudal electrodes and the distance between them.
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APPENDIX 2
TABLE 1
[125I]CNS 1261 uptake 5 minutes after intracortical injection of CSF or NMDA
VEHICLE (CSF) NMDA (27jimoles)
STRUCTURE ipsilateral contralateral ipsilateral contralateral
anterior cingulate cortex 0.74 ± 0.08 1.37 ± 0.08 0.98 ± 0.06 1.23 ± 0.24
genu 0.23 ± 0.01 0.35 ± 0.02 0.40 ± 0.01 0.47 ± 0.07
sensory motor cortex
layers I-ELI 0.63 ± 0.08 1.33 ± 0.07 1.65 ±0.70 1.8610.10
layer IV 0.82 ± 0.07 1.51 ±0.08 2.00 ± 0.87 1.89 ± 0.08
layers V-VI 0.92 ± 0.02 1.30 ± 0.03 2.03 ± 0.75 1.70 ± 0.05
caudate nucleus 1.18 ±0.02 1.22 ± 0.01 1.42 ±0.11 1.5610.13
corpus callosum 0.25 ± 0.03 0.40 ± 0.01 0.49 ± 0.23 0.50 ± 0.06
anterior thalamus 1.62 ± 0.03 1.61 ±0.11 2.04 ±0.11 2.06 ± 0.14
hippocampus CA1 0.62 ± 0.01 0.64 ± 0.01 0.77 ± 0.00 0.81 ±0.05
hippocampus CA3 0.61 ± 0.00 0.71 ± 0.01 0.80 ± 0.01 0.84 ± 0.05
lateral habenular nucleus 1.77 ± 0.23 1.72 ±0.15 2.07 ± 0.15 2.08 ± 0.04
mediodorsal thalamus 0.93 ± 0.04 1.01 ± 0.02 1.13 ±0.13 1.20 ± 0.33
ventrolateral thalamus 1.07 ± 0.05 1.13 ±0.10 1.48 ±0.19 1.38 ± 0.25
internal capsule 0.34 ± 0.01 0.36 ± 0.00 0.46 ± 0.02 0.44 ± 0.01
parietal cortex
layers 1-El 0.61 ± 0.01 1.27 ±0.11 1.12 ±0.21 1.45 ± 0.47
layer IV 0.75 ± 0.02 1.43 ±0.13 1.26 ± 0.02 1.69 ± 0.28
layers V-VI 0.82 ± 0.04 1.23 ±0.10 1.30 ± 0.03 1.51 ± 0.26
hypothalamus 0.68 ± 0.09 0.66 ± 0.09 0.94 ±0.11 0.93 ± 0.01
posterior cingulate cortex 1.48 ±0.16 1.59 ± 0.21 1.58 ±0.11 1.65 ± 0.30
hippocampus molecular layer 0.80 ± 0.03 0.85 ±0.12 0.87 ±0.12 0.99 ± 0.23
dentate gyrus 0.88 ± 0.04 1.03 ± 0.06 1.01 ± 0.09 1.0310.14
auditory cortex
layers I-EI 0.95 ± 0.28 1.38 ±0.15 0.96 ± 0.13 1.53 10.12
layer IV 1.18 ± 0.44 1.53 ± 0.07 1.18 ±0.39 1.7610.13
layers V-VT 0.71 ± 0.01 1.22 ± 0.04 1.10 ±0.21 1.55 1 0.23
substantia nigra pars reticulata 1.01 ± 0.04 0.91 ±0.11 1.20 ± 0.00 1.23 1  0.10
substantia nigra pars compacta 0.79 ± 0.04 0.71 ± 0.03 1.05 ± 0.06 1.1310.15
medial geniculate body 1.18 ±0.03 1.26 ± 0.01 1.4210.13 1.4810.15
auditory cortex
layers I-EI 0.70 ± 0.10 1.30 ±0.10 0.91 ±0.02 1.27 1  0.01
layer IV 0.73 ± 0.10 1.55 ± 0.24 0.8910.14 1.45 1  0.04
layer V-VI 0.74 ± 0.09 1.22 + 0.05 0.8610.18 1.29 1  0.08
entorhinal cortex 0.96 ± 0.14 1.19 ±0.14 1.03 10.38 1.1510.14
inferior colliculus 1.50 ± 0.06 1.47 ± 0.03 1.44 10.22 1.42 1  0.02
pons 0.77 ± 0.05 0.76 ± 0.04 0.74 10.16 0.77 10.13
cerebellar cortex 1.00 ± 0.00 1.00 ± 0.00 1.00 10.00 1.00 1  0.00
cerebellar white matter 0.38 ± 0.01 0.37 ± 0.02 0.3910.13 0.3710.11
superior olive 1.72 ± 0.23 1.76 ± 0.02 1.541 0.22 1.56 10.05
Data are presented as mean ± n=2. [125I]CNS 1261 uptake was measured
following injection of NMDA or vehicle (CSF) into the ipsilateral sensory-motor 
cortex. Uptake of [125I]CNS 1261 in individual regions of interest was expressed as 
a ratio relative to uptake within the cerebellum. Roman numerals indicate the cortical 
layer examined.
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TABLE 2
[125I]CNS 1261 uptake 60 m inutes after intracortical injection of CSF or NMDA
VEHICLE (CSF) NMDA (27|imoles)
STRUCTURE ipsilateral contralateral ipsilateral contralateral
anterior cingulate cortex 1.46 ± 0.07 1.59 ±0.09 1.69 ±0.16 1.80 ±0,14
genu 0.94 ± 0.06 1.14 ±0.14 0.96 ± 0.09 1.04 ± 0.07
sensory motor cortex
layers I-EI 1.22 ± 0.08 1.30 ± 0.01 1.28 ±0.14 1.49 ± 0.07
layer IV 1.30 ± 0.05 1.37 ± 0.07 1.43 ±0.13 1.40 ± 0.05
layers V-VI 1.35 ± 0.04 1.39 ± 0.07 1.48 ± 0.09 1.45 ± 0.03
caudate nucleus 1.26 ± 0.05 1.25 ± 0.09 1.41 + 0.05 1.39 ± 0.04
corpus callosum 1.06 ± 0.05 1.11 +0.07 1.07 ± 0.04 1.04 ± 0.05
anterior thalamus 1.53 ± 0.09 1.48 ± 0.07 1.65 ± 0.09 1.75 ±0.18
hippocampus CA1 1.69 ± 0.08 1.71 ±0.18 1.80 ± 0.25 1.77 ± 0.25
hippocampus CA3 1.76 ±0.14 1.79 ± 0.20 1.88 ± 0.21 1.84 ± 0.27
lateral habenular nucleus 1.32 ±0.14 1.21 ±0.15 1.17± 0.10 1.15 ±0.05
mediodorsal thalamus 1.48 ± 0.06 1.47 ±0.13 1.62 ±0.10 1.63 ±0.14
ventrolateral thalamus 1.35 ±0.10 1.32 ± 0.07 1.43 ± 0.05 1.42 ± 0.05
internal capsule 1.04 ± 0.05 1.02 ± 0.05 0.92 ± 0.10 0.91 ± 0.08
parietal cortex
layers I-EI 1.32 ±0.11 1.44 ± 0.03 1.28 ± 0.08 1.36 ±0.10
layer IV 1.34 ±0.10 1.50 ±0.10 1.36 ± 0.02 1.47 ± 0.06
layers V-VI 1.40 ± 0.07 1.52 ± 0.06 1.46 ± 0.07 1.48 ± 0.06
hypothalamus 1.16 ±0.03 1.11 ±0.04 1.14 ±0.10 1.13 + 0.11
posterior cingulate cortex 1.48 ± 0.06 1.42 ±0.11 1.45 ±0.18 1.43 ± 0.20
hippocampus molecular layer 1.95 ±0.19 2.02 ± 0.36 1.97 ± 0.29 2.09 ± 0.38
dentate gyrus 1.93 ± 0.23 1.52 ± 0.02 2.09 ± 0.32 2.15 ± 0.40
auditory cortex
layers I-EI 1.43 ± 0.05 1.59 ±0.12 1.48 ± 0.03 1.53 ± 0.05
layer IV 1.44 ± 0.03 1.51 ±0.12 1.50 ± 0.08 1.53 ±0.11
layers V-VI 1.52 ± 0.04 1.57 ±0.10 1.59 ±0.13 1.57 ± 0.09
substantia nigra pars compacta 1.28 ± 0.07 1.23 ± 0.08 1.17 ±0.03 1.17 ± 0.07
substantia nigra pars reticulata 1.09 ± 0.04 1.06 ± 0.02 0.99 ± 0.08 1.08 ± 0.04
medial geniculate body 1.45 ± 0.08 1.38 ± 0.04 1.49 ± 0.09 1.50 ±0.17
visual cortex
layers I-EI 1.41 ±0.19 1.66 ±0.14 1.72 ±0.16 1.71 ±0.16
layer IV 1.57 ± 0.06 1.59 ± 0.14 1.68 ±0.16 1.60 ± 0.12
layers V-VI 1.58 ± 0.04 1.63 ±0.14 1.65 ±0.17 1.70 ±0.14
entorhinal cortex 1.94 ±0.18 1.90 ± 0.22 2.15 ±0.41 2.03 ± 0.33
inferior colliculus 1.22 ± 0.05 1.16 ±0.01 1.25 ± 0.06 1.24 ± 0.07
pons 1.25 ± 0.06 1.20 ± 0.02 1.32 ±0.12 1.32 ±0.17
cerebellar cortex 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00
cerebellar white matter 0.88 ± 0.05 0.82 ± 0.05 0.86 ± 0.08 0.85 ± 0.08
superior olive 1.19 ±0.05 1.19 ±0.04 1.26 ±0.11 1.31 ±0.13
Data are presented as mean ± S.E.M., n=3-4. [l^IjCNS 1261 uptake was measured 
following injection of NMDA or vehicle (CSF) into the ipsilateral sensory-motor 
cortex. Uptake of [12^ I]CNS 1261 in individual regions of interest was expressed as 
a ratio relative to uptake within the cerebellum. Roman numerals indicate the cortical 
layer examined.
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TABLE 3
[125I]CNS 1261 uptake 120 minutes after intracortical injection of CSF or NMDA
VEHICLE (CSF) NMDA (27|imoles)
contralateral ipsilateral contralateralSTRUCTURE ipsilateral
anterior cingulate cortex 1.87 ± 0.29
genu 1.34 ± 0.22
sensory motor cortex
layers I-HI 1.60 ±0.31
layer IV 1.68 ± 0.44
layers V-VI 1.68 ± 0.36
caudate nucleus 1.48 ± 0.28
corpus callosum 1.58 ± 0.25
anterior thalamus 1.61 ± 0.08
hippocampus CA1 2.38 ± 0.43
hippocampus CA3 2.42 ± 0.45
lateral habenular nucleus 1.24 ±0.17
mediodorsal thalamus 1.64 ± 0.30
ventrolateral thalamus 1.41 ± 0.26
internal capsule 1.21 ± 0.32
parietal cortex
layers I-EI 1.38 ±0.16
layer IV 1.41 ± 0.21
layers V-VI 1.58 ± 0.23
hypothalamus 1.08 ±0.16
posterior cingulate cortex 1.46 ±0.31
hippocampus molecular layer 2.50 ± 0.52
dentate gyrus 2.49 ± 0.45
auditory cortex
layers I-HI 1.65 ±0.13
layer IV 1.61 ±0.18
layers V-VI 1.69 ± 0.32
substantia nigra pars compacta 1.29 ± 0.21
substantia nigra pars reticulata 1.07 ± 0.03
medial geniculate body 1.42 ±0.17
visual cortex
layers I-EI 1.55 ± 0.07
layer IV 1.41 ± 0.07
layers V-VI 1.50 ±0.16
entorhinal cortex 1.85 ±0.13
inferior colliculus 1.01 ±0.07
pons 1.18 ±0.08
cerebellar cortex 1.00 ± 0.00
cerebellar white matter 0.97 ± 0.04
superior olive 1.23 ± 0.04
1.90 ± 0.27 1.67 ± 0.12 1.82 ± 0.13
1.50 ± 0.26 1.22 ± 0.06 1.29 ± 0.03
1.76 ± 0.43 1.16 ± 0.08 1.34 ± 0.07
1.63 ± 0.35 1.16 ± 0.11 1.30 + 0.09
1.64 ± 0.39 1.10 ± 0.09 1.44 ± 0.08
1.51 ± 0.28 1.33 ± 0.10 1.35 ± 0.07
1.54 ± 0.25 1.24 ± 0.06 1.26 ± 0.10
1.74 ± 0.12 1.47 ± 0.16 1.48 ± 0.10
2.38 ± 0.39 2.13 ± 0.22 2.20 ± 0.17
2.61 ± 0.48 2.23 ± 0.27 2.28 ± 0.14
1.23 ± 0.16 1.19 ± 0.11 1.17 ± 0.08
1.71 ± 0.33 1.58 ± 0.28 1.62 ± 0.12
1.44 ± 0.29 1.36 ± 0.19 1.37 ± 0.05
1.17 ± 0.31 1.05 ± 0.10 1.10 ± 0.08
1.44 ± 0.22 1.42 ± 0.19 1.58 ± 0.17
1.49 ± 0.29 1.48 ± 0.16 1.52 ± 0.13
1.58 ± 0.23 1.50 ± 0.16 1.52 ± 0.14
1.10 ± 0.18 1.10 ± 0.12 1.13 ± 0.12
1.45 ± 0.28 1.14 ± 0.18 1.13 ± 0.18
2.81 ± 0.58 2.40 ± 0.26 2.39 + 0.13
2.50 ± 0.45 2.20 ± 0.24 2.22 ± 0.06
1.65 ± 0.13 1.49 ± 0.09 1.50 ± 0.06
1.64 ± 0.33 1.50 ± 0.13 1.45 ± 0.09
1.75 ± 0.30 1.59 ± 0.11 1.55 ± 0.09
1.25 ± 0.25 1.08 ± 0.04 1.10 ± 0.02
1.14 ± 0.14 0.99 ± 0.03 1.02 ± 0.01
1.43 ± 0.20 1.42 ± 0.11 1.44 ± 0.11
1.58 ± 0.22 1.78 ± 0.07 1.85 ± 0.10
1.55 ± 0.37 1.69 ± 0.08 1.75 ± 0.11
1.56 ± 0.38 1.74 ± 0.09 1.82 ± 0.11
1.71 ± 0.23 1.84 ± 0.09 1.92 ± 0.03
1.01 ± 0.13 1.36 ± 0.14 1.38 ± 0.15
1.24 ± 0.15 1.47 ± 0.14 1.47 ± 0.15
1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00
0.94 ± 0.08 0.97 ± 0.02 0.94 ± 0.05
1.22 ± 0.08 1.08 ± 0.01 1.14 ± 0.02
Data are presented as mean ± S.E.M., n=2-3. [125I]CNS 1261 uptake was measured 
following injection of NMDA or vehicle (CSF) into the ipsilateral sensoiy-motor 
cortex. Uptake of [125I]CNS 1261 in individual regions of interest was expressed as 
a ratio relative to uptake within the cerebellum. Roman numerals indicate the cortical 
layer examined.
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